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The ATP-binding cassette (ABC) family of efflux transporters are expressed on the 
blood-facing (apical) surface of blood-brain barrier (BBB) endothelia and include P-
glycoprotein (Pgp) and breast cancer resistance protein (BCRP). These neuro-
protective transporters restrict the movement of compounds from the blood to the brain, 
including many chemotherapeutics; hence make treatment of brain tumours difficult.  
To further understand the role of efflux transporters in brain cancer, an in vitro model of 
primary porcine brain endothelial cells (PBECs) was used to explore changes in 
transporter expression at the BBB in response to glioma challenge. The in vitro results 
were then compared with changes in ABC transporter expression found within human 
brain tissue of glioma patients.  
The activity and expression of Pgp and BCRP in PBECs were compared between 
PBECs in co-culture with glioma cells (glioma model) and PBECs in co-culture with 
normal astrocytes (normal model control), to identify any differences in ABC 
transporters. Further work was conducted to identify any signaling pathways involved in 
inducing ABC transporter changes during glioma challenge. For this purpose, PBECs 
were grown in media conditioned by either normal astrocytes or glioma cells, where the 
function of ABC transporters in response to modulators of Sonic and Wnt signaling was 
assessed. Finally, confocal microscopy was used to examine the expression of BCRP 
and Pgp in brain tissue of glioma patients. 
The results have implication for the delivery of chemotherapeutics to the brain during 
tumour challenges. 
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BSA     bovine serum albumin 
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C6CM    C6 conditioned medium 
cAMP     cyclic adenosine monophosphate 
Cav-1     caveolin-1 
Caveolin-1-P   phosphorylated caveolin-1 
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CO2      carbon dioxide 
COX-2     cyclooxygenase 2 
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Ct      cycle of threshold 
DAB      Digital Audio Broadcasting 
dH20      deionised water 
Dkk-1    dickkopf 1 
DMEM     Dulbecco's modiﬁed Eagle's medium 
DMSO     dimethyl sulfoxide 
ECs      endothelial cells 
EDTA     ethylenediaminetetra acetic acid 
ETA    endothelin receptor a 
ETB      endothelin receptor b 
FCS      fetal calf serum 
FGF      fibroblast growth factor 
Flk-1     VEGF receptor 2 
gamma-GTP     gamma-glutamyl transpeptidase 
GAPDH     glyceraldehyde 3-phosphate dehydrogenase 
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GR      glucocorticoid receptor 
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IL-6      interleukin - 6 
IR      insulin receptor 
JAMs     junctional adhesion molecules 
KCL    King‘s College London 
KO      knock out 
LDL     low density lipoprotein 
MBECs     mouse brain endothelial cells 
MEM    Essential Minimum Eagle's Medium 
MPP+     1-methyl-4-phenylpyridinium  
MRP      multidrug resistance protein 
MW      molecular weight 
NaCl     sodium chloride 
NEAAs     non-essential amino acids  
NMDA    n-methyl-D-aspartate 
NOS      nitric oxide signaling 
NsM    neural stem cell media 
NVU      neurovascular unit 
O2      oxygen 
OAT      organic anion transporter 
OCT      organic cation transporter 
PBECs    porcine brain endothelial cells 
PBECs-C6  PBECs grown on Transwells in co-culture with C6 glioma 
cells 
PBECS-G7   PBECs grown on Transwells in co-culture with G7 glioma 
cells 
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PBECs-G7.4  PBECs grown on Transwells in co-culture with G7 glioma 
cells for 4 days 
PBECs-hAs   PBECs grown on Transwells in co-culture with human 
astrocytes 
PBECs-M     PBECs grown on Transwells in mono-culture 
PBECs-P     PBECs grown in plates 
PBECs-rAs   PBECs grown on Transwells in co-culture with rat 
astrocytes 
PBS     phosphate buffered saline 
PBST      phosphate buffered saline with Tween 20 
PDGF     platelet-derived growth factor 
Pgp      P-glycoprotein 
PKA      protein kinase A 
PKCβ1     protein kinase C β1  
PPAR     peroxisome proliferator-activated receptors 
PVDF    polyvinylidene difluoride 
PXR      pregnane X receptor  
RBE4      rat brain endothelial cell line 
RBECs     rat brain endothelial cells 
RFU      relative fluorescence units 
RT-QPCR   reverse transcriptase quantitative polymerase chain 
reaction 
SDS      sodium dodecyl sulfate 
sfPBEC   serum-free PBEC medium 
SHH    sonic hedgehog 
SLCs     solute carrier family of transporters 
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Src kinase    Tyrosine-protein kinase CSK 
t 1/2     half time 
TCA     trichloroacetic acid 
TEER     transendothelial electrical resistance 
TEMED   tetramethylethylenediamine 
Tf    transferrin 
TfR      transferrin receptor 
TJ     tight junction 
TNF-α     tumour necrosis factor -α 
TRI     total RNA isolation 
Tyr14     tyrosine 14 
UCL    University College London 
Vd     volume of distribution 
VEGF     vascular endothelial growth factor 
ZO     zona occluden 
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1 General Introduction 
 
1.1 The blood-brain barrier: historical background / 
physiological function 
 
The existence of a physical barrier between the blood and brain parenchyma was first 
observed by Ehrlich, where peripherally injected water soluble dye did not stain the 
brain (Ehrlich, 1885).  Together with Ehrlich's work and his own work using toxins 
Lewandowsky (1900), later went on to conclude that ‗brain capillaries must hold back 
certain molecules‘ establishing the existence of a vascular blood-brain barrier (BBB). 
Since these early studies, much research over the last 130 year has demonstrated the 
importance and complexity of this BBB, to arrive at the understanding of today. 
It is now known that the BBB is composed of endothelial cells of brain microvessels 
that form the interface between the blood and the brain parenchyma. The hallmark 
features of the brain endothelial cells, which differentiate them from non-brain 
endothelial cells, are their extremely ―tight‖ tight-junctions (TJs), high expression of 
transporters (uptake and efflux) mediating and controlling transcellular transport, 
paucity of pinocytic vesicles but presence of specific receptor-mediated transcytosis, 
and low expression of adhesion molecules mediated leukocyte attachment and entry 
(Abbott, 2013). 
The BBB endothelium has no fenestrations, but extremely ―tight‖ TJs between 
neighbouring endothelial cells. This forms a physical barrier where TJs bring 
neighbouring endothelial cells into close contact, resulting in a very narrow intercellular 
gap (~5 Å) (Avdeef, 2011). Consequently, most molecules cannot fit through this gap 
and therefore cannot cross into the brain via this paracellular route (Abbott, 2013). 
Furthermore, TJ formation separates the apical and basolateral domains of the plasma 
membrane (the ‗fence‘ foundation of the TJ), so that the apical (luminal) blood-facing 
surface and the basal (abluminal) brain-facing surfaces can have distinct functions 
(Abbott, 2013). 
This polarity enables endothelial cells to correctly express uptake transporters, either 
on the apical and/or basal surfaces, to enable the uptake of necessary nutrients into 
the brain via passage through the endothelial cells themselves. Uptake of certain larger 
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molecules can occur via adsorptive-mediated or receptor-mediated 
endocytosis/transcytosis (AMT/RMT) (Abbott et al., 2010)  
The presence of enzymes (e.g. cytochrome P450s), within the membranes of the 
endothelial cells as well as extracellularly and intracellularly, forms a metabolic or 
enzymatic barrier to such transport systems (Kuhnline Sloan et al., 2012). Efflux 
transporters on the apical surface of cells form an additional barrier to transport, which 
function in opposition to uptake transporters, pumping potentially neurotoxic 
compounds away from the brain and back into the blood (Begley, 2004). Thus, the BBB 
is not only a physical barrier but also transport barrier, that allows the transport of 
nutrients (such as glucose) into the brain, while restricting the entry of toxic and 
potentially damaging compounds to the brain (Abbott et al., 2010). All these processes 
work together to allow the BBB to maintain brain homeostasis and the correct 
microenvironment for neuronal function in the central nervous system (CNS).  
The BBB does not exist in isolation, but is supported by other cells of the CNS to form 
a neurovascular unit (NVU), including astrocytes, pericytes, microglia and neurons 
(Abbott, 2013). These cells help in the development and maintenance of the BBB and 
are therefore crucial to its existence and dynamic nature. 
Here, the different properties of the BBB will be discussed, together with ways in which 
the BBB is affected in cancer and the implications of the BBB efflux transporters for the 
treatment of primary brain tumours (gliomas). 
 
1.2 The BBB: tight junctions and glycocalyx  
 
The BBB acts as a physical barrier to most polar molecules as well as macromolecules 
such as proteins. The physical barrier is created by tight junctions (TJs) between 
neighbouring endothelial cells in the brain. Very ―tight‖ TJs are a key feature of the 
BBB, whereas non-CNS endothelial cells have leakier cell:cell contacts (Coomber & 
Stewart, 1986). These TJs leave only a small gap, severely restricting the paracellular 
passage of ions and molecules from the blood to the brain (Avdeef, 2011).  
Both adherens junctions (AJs) and TJs are found at the BBB. AJs are formed by 
protein complexes between transmembrane cadherin glycoproteins at the intercellular 
cleft that are linked to alpha, beta, and gamma catenin in the cytoplasm, which in turn 
are linked to the cytoskeleton of the cell (Steinberg & McNutt, 1999, Petty & Lo, 2002, 
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Brown & Davis, 2002, Paolinelli et al., 2011)  (Figure 1.1). Thus the AJs provide 
structural support to the endothelial cells and enable the formation of TJs. 
The TJs are formed of a complex between occludin, claudins and junctional adhesion 
molecules (JAMs) (at the intercellular cleft) linked to the cytoplasm and cytoskeleton 
via zonula occludens (ZO) proteins and cingulin (Abbott et al., 2010, Liu et al., 2012) 
(Figure 1.1). Several proteins are involved in TJ interaction and a comprehensive list is 
given in Table 1.1.  
 
Figure 1.1 Brain capillaries under normal 
condition (Paolinelli et al., 2011) 
Cerebral endothelial cells form complex 
junctions sealing the paracellular route and 
blocking the passage of polar molecules.  
TJs: Tight junctions such as claudins and 
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Cell–cell adhesion membrane 
proteins 
Cadherins (VE- and N-cadherin) 
Claudins (1, 3, 5, 12) 
occludin JAMs, (A, B, C) 
ESAM, nectin 
Cytoskeletal proteins  
α-catenin, β-catenin, plakoglobin, 
p120, afadin or AF6, α-actinin, 
eplin 
ZO proteins, cingulin 
ZONAB, afadin or AF6 
The table reports the best characterised components of AJs and TJs only.  
AJs, adherens junctions; TJs, tight junctions; ZO, zonula occludens; ZONAB, zonula occludens -
1 associated nucleic-acid-binding protein; JAMs, junctional adhesion molecules; ESAM, 
endothelial cell-selective adhesion molecule.  
 
Studies have shown that claudin 3, 5  and 12 are expressed at the BBB, while claudin 
1 and 2 are not normally expressed in the parenchymal vessels of the CNS (Nitta et al., 
2003, Pfeiffer et al., 2011) . A loss in the expression of these claudins has been shown 
to have consequences for BBB integrity. For example a loss of claudin 5 has been 
shown to result in barrier breakdown and paracellular leakiness (Nitta et al., 2003). 
Similarly, disruption of occludin, ZO-1 and ZO-2 proteins also leads to barrier 
breakdown and increased BBB permeability (Beauchesne et al., 2009). This 
demonstrates the importance of TJs in establishing the low permeability of the BBB, 
where breakdown of TJs leads to leak of plasma constituents including serum proteins 
into the brain, resulting in disruption of CNS homoeostasis and consequently disruption 
in neuronal activity. 
Another physical barrier present at the BBB, has recently been highlighted, namely the 
glycocalyx. This is a polysaccharide matrix that exists on the surface of the endothelial 
cells, which has been shown to have important functions at the BBB. It is composed of 
a negatively charged network of proteoglycan, glycoproteins, and glycolipids and it can 
act as a filter, by binding positively charged molecules. Thus, the glycocalyx restricts 
access of positively charged molecules to the endothelial cell surface and therefore 
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2.1 Transport at the BBB 
 
Due to the physical barrier of the BBB, most molecules can only enter the brain from 
the blood by crossing the endothelial cell layer.  
There are several routes of entry for such molecules (Figure 1.2). Gases such as O2 
and CO2 can freely diffuse across the barrier by passive diffusion, as can many small 
hydrophobic molecules (Liu et al., 2004). Lipid-soluble molecules, can easily 
interdigitate between the phospholipids of the plasma membrane to reach the cell 
interior; entry into the brain has been shown to positively correlate with the degree of 
lipid solubility (Abbott et al., 2010).  
The thinness of the BBB endothelial cell facilitates non-polar molecule diffusion, where 
flattening and elongation of the BBB endothelial cells decreases the distance over 
which a molecule must diffuse to reach from one side to the endothelium to the other 
side (Abbott et al., 2010). However, as a general rule the ability of molecules to diffuse 
decreases with increased surface charge and increased size of the molecule, with 
molecules of polar surface areas (PSA) above 80Å2 and molecular weight (MW) greater 
that 450 Da showing restricted permeability (Abbott et al., 2010). Furthermore, 
positively charged molecules have the additional problem of binding to the glycocalyx 
before reaching the cell surface and therefore less readily cross the BBB (Abbott et al., 
2010, Li et al., 2010). 
For polar molecules, solute carriers (SLCs) can facilitate crossing of the BBB. Several 
members of the SLC family of transporters have been shown to be expressed at the 
BBB (Table 1.2), including GLUT1 for glucose transport, several amino acid and 
nucleoside/nucleotide transporters (e.g. LAT1), organic anion transporters (OATs) and 
organic cation transporters (OCTs) which allow negative and positive ionic compounds 
respectively into the brain (Kusuhara & Sugiyama, 2005, Abbott et al., 2010).  
 




Figure 1.2 Transport mechanisms across the BBB. Modified from Abbott et al., (2010).  
 (a) Solutes may passively diffuse through the cell membrane and cross the endothelium. A 
higher lipid solubility and several other physico-chemical factors favour this process (see text). 
(b) Carrier-mediated influx via solute carriers (SLCs) may be passive or primarily or secondarily 
active and can transport many essential polar molecules such as glucose, amino acids and 
nucleosides into the CNS. The solute carriers may be bi-directional, the direction of net 
transport being determined by the substrate concentration gradient (1), unidirectional either into 
or out of the cell (2/3), or involve an exchange of one substrate for another or be driven by an 
ion gradient (4). In this last case the direction of transport is also reversible, depending on 
electrochemical gradients. (c) RMT (receptor mediated transcytosis) requires receptor binding of 
ligand and can transport a variety of macromolecules such as peptides and proteins across the 
cerebral endothelium (transcytosis). AMT (adsorptive mediated t ranscytosis) appears to be 
induced in a non-specific manner by positively charged macromolecules and can also transport 
across the endothelium. Both RMT and AMT appear to be vesicular-based systems which carry 
their macromolecule content across the endothelial cells.  
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Table 1.2 Solute carriers at the BBB. (Abbott et al. 2010)  
 
Such transporters allow essential nutrients and amino acids to be transported into 
brain, where they are needed for the survival of the CNS cells. The polarity of 
transporters (either existing on the apical-luminal and/or basal-abluminal surface of the 
endothelia) is also key, since this determines the direction of flux into and out of the 
cell. For example GLUT1 needs to be expressed apically, in order to have access to 
the glucose in the circulation and also basally/abluminally to carry glucose into the 
brain. Basal/abluminal transporters are also necessary to allow the transport of 
intracellular molecules (those that have managed to pass across the luminal cell 
surface and enter the intracellular space) into the brain parenchyma.  
Finally for larger molecules transcytosis of molecules is also possible. This is facilitated 
by pathways such as clathrin-mediated endocytosis and caveolae-mediated 
endocytosis (Abbott et al., 2010).  
General Introduction   
22 
 
Clathrin-mediated endocytosis is a process where ligands bind to ―clathrin-coated pits‖ 
on the plasma membranes. This is followed by small vesicle assembly (approximately 
100 nm in diameter) and internalisation. Clathrin-coated pits can take up a variety of 
extracellular molecules, including low density lipoprotein (LDL), transferrin (Tf), growth 
factors and antibodies (McMahon & Boucrot, 2011, Xiao & Gan, 2013) 
Caveolae are smaller flask-shape pits (approximately 50 nm in diameter) (Xiao & Gan, 
2013). They express caveolin molecules (e.g. caveolin 1 and 2), which when 
phosphorylated, trigger vesicle internalisation (Fagerholm et al., 2009). 
In the BBB, molecule transport occurs via either adsorptive-mediated or receptor-
mediated processes.   
Adsorptive-mediated transport is a non-specific mode of transport, where positively 
charged ligands/molecules interact with the negative cell surface via electrostatic 
interaction. A vacuole is then formed around the molecule, which becomes internalised 
into the endothelial cell. This is a nonspecific process (i.e. not receptor-mediated) and 
is often via the clathrin-mediated mode (Xiao & Gan, 2013). 
Receptor-mediated endocytosis is a specific process for cells to take up specific small 
and large molecular ligands, including hormones, growth factors, enzymes, and plasma 
proteins. In this process, the ligand binds to a receptor on the cell surface (usually 
found with clathrin-coated pits or caveolae). Due to a finite number of receptors on the 
cell surface, receptor-mediated endocytosis is normally a saturable process (Xiao & 
Gan, 2013). For example, transferrin receptor (TfR) and insulin receptor (IR), allow 
receptor mediated endocytosis of transferrin and insulin respectively (Haqqani et al., 
2013). A list of transcytotic mechanisms at the BBB is given in Table 1.3. 
  




Table 1.3 Transcytosis mechanisms at the BBB (Abbott et al. 2010).
 
 
2.2 BBB metabolic barriers 
 
Along with uptake processes and transporters, the BBB endothelial cells form a 
metabolic barrier. The thin nature of the endothelial cell to some extent aids rapid 
transport of molecules; however this does not completely prevent molecules from 
becoming degraded within the cell. Any molecule that enters the cells via any of the 
above processes is still vulnerable to metabolism and enzymatic degradation. For 
example even glucose is degraded in part as it crosses the BBB (McAllister et al., 
2001).  
Enzymes can be found on the surface, the apical/luminal or basal/abluminal 
membranes or in the cytoplasm of endothelial cells.  Enzymes such as gamma-GTP 
(Gamma-glutamyl transpeptidase) and ALP (Alkaline phosphatase) have been shown 
to be present in the apical/luminal membrane (Betz & Goldstein, 1978, Fukushima et 
al., 1990), while cytochrome P450 (CYP) enzymes have been found intracellularly 
(Ghosh et al., 2010).  
The presence of such enzymes gives rise to a metabolic barrier in the BBB that can 
restrict and even prevent molecules crossing the BBB into the brain parenchyma.  
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2.3 BBB transport barrier: the ABC efflux transporters 
 
In addition to metabolic processes, transport across the BBB is restricted by the 
presence of efflux transporters. These transporters tend to be localised on the 
apical/luminal surface of the endothelium and can pick up molecules from within the 
membrane lipid bilayer (Nervi et al., 2010) and actively efflux them back into blood.  
Therefore, they too can retard molecules from crossing the BBB. 
The most studied efflux transporters of the BBB are p-glycoprotein (Pgp), the multidrug 
resistance associated proteins (MRPs) and the breast cancer resistance protein 
(BCRP). They are all members of the ATP-binding cassette (ABC) transporter 
superfamily, characterised by their ability to use the energy from ATP-hydrolysis to 
transport their substrates against a concentration gradient (Begley, 2004, Abbott et al., 
2010) 
 
2.3.1 P-glycoprotein (Pgp) 
 
Pgp was the first discovered ABC efflux transporter and has therefore been studied the 
most extensively. It is the ~180 kDa  protein-product of the MDR1 gene in higher 
mammals such as pigs and humans (and mdr1a and mdr1b genes in rodents), 
composed of two functional units each formed of six transmembrane α-helices with one 
cytoplasmic domain responsible for ATP hydrolysis (i.e. a typical ABC-transporter 
conformation) (Bosch & Croop, 1998, Locher, 2009). In addition, two distinct substrate 
binding sites have been identified the R-site and the H-site (named after the drug 
specificities of Rhodamine 123 and Hoechst 33342) as well as a third M-site 
(modulation site) for modulators of Pgp (Ferreira et al., 2013). Immunohistochemical 
studies and mRNA analysis have shown Pgp is  expressed in the brain of humans, 
rats, mice and pigs (Warren et al., 2009), where there is a consensus that it is 
predominantly expressed on the apical/luminal surface of BBB endothelia (Stewart et 
al., 1996, Beaulieu et al., 1997, Roberts et al., 2008) 
In vivo studies with single (mdr1a) and double (mdr1a/b) knockout (KO) mice have 
clearly shown that when Pgp is lacking there is an increase in BBB permeation of 
compounds such as quinidine and nelfinavir (Kusuhara et al., 1997, Salama et al., 
2005). Similarly, Pgp inhibitor studies have found that certain molecules can more 
effectively cross the BBB in the absence of Pgp activity (Ibrahim et al., 2000, Mittapalli 
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et al., 2013). Transfection experiments (with cloned full-length human and mouse Pgp 
cDNA) have demonstrated that the Pgp gene can confer, to otherwise sensitive cells, 
resistance against different cytotoxic agents, including alkaloids, anthracyclines (Gros 
et al., 1986, Greenberger et al., 1988). Taken together, all the above have 
demonstrated the role of Pgp in the BBB to be that of an efflux transporter, where the 
substrates it can transport include a variety of different pharmaceutics (Linnet & Ejsing, 
2008, Matsson et al., 2009). 
In terms of Pgp modulation, this can involve changes in expression or changes in 
activity. 
Changes in expression 
Activation of the pregnane-X-receptor (PXR), constitutive androstane receptor (CAR) 
and glucocorticoid receptor (GR) pathways have been shown to lead to increased Pgp 
expression at the BBB (Narang et al., 2008, Miller, 2010, Lemmen et al., 2013). 
Similarly, glutamate via the NMDA/COX-2 pathway has been shown to increase Pgp 
expression (Yousif et al., 2012). In addition, Lim et al. (2007) showed that activating the 
Wnt pathway increases Pgp mRNA, with the β-catenin pathway being implicated in this 
response.  
The role of pro-inflammatory cytokines in Pgp regulation is still unclear, with different 
cytokines having different effects. IL-1β was shown to have no effect on Pgp mRNA, 
while IL-6 decreased Pgp mRNA levels and TNF-α increased Pgp mRNA expression in  
hCMEC/D3  endothelial cells (Poller et al., 2010).  
Changes in activity 
Pgp activity has also been shown to be regulated via expression-independent 
pathways. For example, phosphorylation of Pgp by PKC (protein kinase C) has shown 
to increase (Chambers et al., 1990) and decrease (Miller et al., 1998) Pgp activity and 
it was suggested that different isomers of PKC could act to either increase or decrease 
Pgp activity (Sachs et al., 1999).  
Pgp decreases in activity were also shown to result in response to loss in luminal 
expression of Pgp, consistent with caveolae internalisation in a PCK-independent 
pathway (Hawkins et al., 2010). Ubiquination of Pgp has also been shown to play a role 
in Pgp activity regulation, with increased ubiquination resulting in decreased activity 
(Zhang et al., 2004). 




2.3.2 Breast cancer resistance protein (BCRP) 
 
BCRP is a 72 kDa protein, which unlike other efflux proteins (with two repeated 
halves), consists of a single nucleotide binding domain and a single membrane-
spanning domain i.e. it is a half-transporter (Doyle et al., 1998). BCRP has been 
suggested to be able to form heterodimers and homotetramers (Mao & Unadkat, 2005), 
although it is still debated whether such dimerisation is required for functional activity 
(Mitomo et al., 2003, Mo & Zhang, 2009, Ni et al., 2010). Cooray et al., showed the 
location of BCRP in human microvessels in 2002. BCRP has been shown to be 
luminally expressed in brain capillary endothelia of human (Zhang et al., 2003), porcine 
(Eisenblatter et al., 2003), rat (Hori et al., 2004) and mouse (Lee et al., 2007, Lee et al., 
2005). However, its role at the BBB is still not fully characterised.  Eisenblatter et al. 
(2003) suggested that the pig BCRP protein was able to actively transport the 
chemotherapeutic drug daunorubicin across a monolayer of primary cultured brain 
endothelial cells. Furthermore, Hori et al. (2004) showed that transfection of the BCRP 
gene into HEK293 cells resulted in decreased penetration of mitoxantrone into these 
cells. However, this study involved BCRP which was greatly over-expressed and so 
could not provide a true insight into the role of BCRP in vivo, since endogenous levels 
of BCRP are normally relatively lower (Lee et al., 2007). When BCRP was not hyper-
expressed (i.e. was expressed at normal physiological levels), no mitoxantrone 
transport could be detected by Lee et al. (2007), suggesting that BCRP is not a major 
efflux protein at the BBB. However, Cisternino et al. (2004) using an in situ brain 
perfusion technique, showed that brain efflux of prazosin and mitoxantrone was 
inhibited by GF120918 (a Pgp and BCRP inhibitor)  in both wild-type and mdr1a KO 
mice. Interestingly, in the mdr1a KO mice BCRP was also shown to be up-regulated 
greater than 3-fold, suggesting an adaptive response exists between efflux proteins 
(i.e. where BCRP expression is increased to perhaps compensate for the absence of 
Pgp) (Cisternino et al., 2004).  
It should be mentioned that the relative expression levels of BCRP in rodent and 
human brain endothelia do not correlate well, with the protein expression of human 
BCRP measured to be 1.85 fold greater than that of mice (Uchida et al., 2011). This 
suggests that there is a need to use alternative models to murine when addressing the 
relevance of BCRP in vivo. 
General Introduction   
27 
 
Less is known about regulation of BCRP than Pgp. As for Pgp, BCRP expression has 
been shown to be increased in response to activation of PXR, CAR and GR receptors 
(Zhang et al., 2004, Narang et al., 2008, Lemmen et al., 2013), as well as to activation 
of the glutamate NMDA/COX-2 pathway and Wnt/β-catenin pathways (Lim et al., 2007, 
Yousif et al., 2012). 
Differential regulation of BCRP versus Pgp has also been shown in response to 
cytokines, where TNF-α (which increased Pgp expression) was shown to decrease 
BCRP expression by Poller et al. (2010).  
However, no pathways independent of Pgp regulation have been identified for BCRP 
nor have any expression-independent pathways and so further research on BCRP is 
still required. 
  
2.3.3 Multidrug resistance associated proteins (MRPs) 
 
Nine members of the MRP family have so far been discovered (MRP1-9); however, not 
all have been detected within brain capillary endothelia. Nies et al. (2004) found MRP1, 
MRP4 and MRP5 to be luminally localised on brain endothelial cells in human brain 
samples, but there was no positive staining for MRP 2, 3 or 6. However, this remains 
controversial since Potschka et al. (2003) and Soontornmalai et al. (2006) reported the 
presence of functional MRP2 at the BBB of rats and mice, respectively. In addition, 
more recent studies have additionally shown the expression of MRP8 and 9 mRNA in 
human brain microvessels or human brain endothelial cells (Dauchy et al., 2008, 
Dauchy et al., 2009). By contrast, one study in mice using liquid chromatography-
tandem mass spectroscopy proteomics showed MRP4 to be the only MRP detected at 
the BBB (Kamiie et al., 2008). The degree to which these differences can be attributed 
to differential expression between species is still unknown. 
Functionally, MRP1, MRP2 and MRP3 have all been shown to have preferential 
substrates among conjugated lipophilic compounds (e.g. steroids conjugated with 
glutathione, glucuronate or sulphate), with MRP6 also being able to transport 
glutathione conjugates (Nies et al., 2004). MRP4 and MRP5 substrates include cyclic 
nucleotides such as cGMP (Jedlitschky et al., 2000, Chen et al., 2001). However, their 
function at the BBB remains just as elusive as their expression profiles. Although 
Sugiyama et al. (2003) showed that MRP1 may play a role in the efflux of estradiol 
glucuronide from the BBB, since mrp1 KO mice showed less efflux of this compound 
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than their wild-type counterparts, other mrp1 KO mice studies showed little alteration in 
the net substrate transport in KO mice compared with wild-type (Sun et al., 2001, 
Cisternino et al., 2003). 
 
2.4 The neurovascular unit (NVU)  
 
It is important to note that the BBB endothelial cells do not exist in isolation, but are 
part of a neurovascular unit (NVU) of supporting cells that aid the development and 
maintenance of the BBB. These include astrocytes, pericytes, microglia and neurons 
(Figure 1.3). 
 
Figure 1.3 The BBB and the neurovascular unit.  Chen and Liu (2012) based on Abbott et al. 
(2006). 
Schematic representation of the blood–brain barrier (BBB) and other components of a 




The importance of astrocytes to the BBB has been hypothesised since 1967, where 
astrocytes were suggested to be involved in controlling the exit of materials from the 
brain capillaries (Davson & Oldendorf, 1967). 
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Astrocytes have since been shown important in glucose transport at the BBB, inducing 
the expression of GLUT1 on the luminal surface of endothelial cells (McAllister et al., 
2001). Astrocytes were shown to  induce more complex TJs (shown in electron 
microscope studies) (Dehouck et al., 1990, Wolburg et al., 2009), with high 
transendothelial electrical resistance (TEER) (measure of resistance to ion transport 
across the BBB)  and low inulin (small paracellular molecule) permeability, as well as 
maintaining the transport of essential amino acids such as leucine (Dehouck et al., 
1990, Kido et al., 2002).  
In vivo, chemical induction of astrocyte loss using a gliotoxin was shown to result in TJ 
breakdown and increased BBB leakiness which could be reversed by regrowth of 
astrocytes (Willis et al., 2004), showing astrocytes to be important both in vitro and in 
vivo. 
Astrocytes were shown to maintain Gamma-glutamyl transpeptidase (gamma-GTPase) 
enzyme activity in isolated microvessels places in culture, which is normally lost when 
microvessels are cultured alone (Kido et al., 2002). Furthermore, astrocytes were 
shown able to induce gamma-GTPase activity after it had been lost in culture (Dehouck 
et al., 1990). The presence of astrocytes has also been shown to increase the mRNA 
expression of efflux transporters such as Pgp in endothelial cells as well as increased 
levels of efflux activity (Kido et al., 2002, Berezowski et al., 2004) and  toxic depletion 
of astrocytes in vivo was also shown to result in decreased Pgp expression at the BBB 
(Willis et al., 2007) . 
Astrocytes have been shown to induce the expression of antioxidant proteins 
(manganese superoxide dismutase and heme oxygenase-1) in endothelial cells, 
thereby conferring protection against oxidative stress and free-radical induced damage 
(Schroeter et al., 1999, Schroeter et al., 2001, Son et al., 2005). 
Interestingly, astrocytes have been shown capable of inducing BBB markers (such as 
the transferrin receptor, Pgp, GLUT1 and gamma-GTPase activity as well as inducing 
close cell: cell interactions reminiscent of TJs (with decreased barrier permeability to 
inulin) in non-BBB endothelial cells such as human umbilical vein endothelial cells 
(Janzer & Raff, 1987, Tout et al., 1993, Hayashi et al., 1997) 
Studies have shown that some of the same inductive properties could be achieved 
through the use of astrocyte-conditioned medium (such as decreased paracellular 
permeability and alkaline phosphatase activity, increased TEER and improved f-actin 
and e-cadherin distributions) (Rubin et al., 1991, Sobue et al., 1999)  This 
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demonstrates that some astrocyte induction of the BBB phenotype involves the 
secretion of soluble factors by the astrocytes. 
All this together shows that astrocytes play an important role in establishing and 




Recently studies have revealed the importance of pericytes in establishing and 
maintaining BBB phenotype. 
Daneman et al. (2010) showed that the BBB is formed during embryogenesis in the 
absence of astrocytes (which only begin to be expressed postnatally), whereas 
pericytes are recruited to vessels over a week before astrocytes are generated. This 
indicates that pericytes may play a role in BBB development. Prenatal capillaries 
showed the presence of TJ protein, GLUT1 and Pgp. Interestingly, Pgp expression was 
present but only at low levels, with increases in expression occurring postnatally (which 
correlated with astrocyte expression, implicating astrocytes in the expression of efflux 
transporters).  
By examining pericytes-deficient mice, BBB permeability was shown to inversely 
correlate with pericyte number (i.e. increased BBB permeability correlating with 
decreased pericyte number). Although the expression of TJ proteins did not appear 
affected in this study (occludin, Claudin 5 and ZO-1), structural abnormalities were 
clear in the endothelial junctions (e.g. the length of junctions were random, with altered 
parallel and perpendicular junctions), showing that pericytes are important in TJ 
formation. Transcytosis was also shown to increase with decreased pericyte numbers. 
The results indicated that pericytes do not induce BBB-specific gene expression but 
inhibit expression of molecules that increase vascular permeability, i.e. pericytes down 
regulate the expression of ‗default‘ not brain endothelial characteristics, while 
astrocytes upregulate the specific BBB features.  
In postnatal mice (2-8 months), Armulik et al. (2010) used mice with different 
deficiencies of pericytes (26-72% normal levels) and showed that increased blood 
vessel diameter and decreased vessel density correlated with decreased  pericytes 
density. So pericytes were demonstrated to be important for angiogenesis in the brain.  
VE-cadherin, ZO-1 and Claudin-5 protein levels where not altered in pericytes-deficient 
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mice, but increased width of TJs was noted under the electron microscope (EM), as 
well as increased density of transcytotic vesicles (in agreement with the embryonic 
study above).  
Microarray studies examined the expression of transporters, with GLUT1 unaffected 
but transferrin receptor showing decreased levels, with the decrease correlated with 
reduced pericyte density. This implicates pericytes in aspects of transporter expression 
and BBB uptake function (Armulik et al., 2010). 
Similarly, Bell et al. (2010) used mice of increasing age (1,6-8,14-16 months) with 
different levels of pericyte deficiency to show that loss of pericytes at the capillaries, 
resulted in increased permeability of the BBB to macromolecules (e.g. serum proteins) 
indicative of deregulation of transcytotic pathways. This showed that BBB dysfunction 
of transcytosis can occur as a result of pericyte deficiency. Also, a decrease in ZO-1 
and claudin 5 as well as decreased collagen IV and laminin correlated with increased 
age of the pericyte-deficient mice showing that a lack of pericytes also results in TJ and 
basal lamina dysfunction. This suggests that although initially a lack pericytes may not 
affect TJ protein expression, chronic lack of pericytes does eventually lead to TJ 
protein loss. 
In summary, pericytes are important in BBB development and maintenance of the BBB. 
They are important in angiogenesis and in establishing capillary diameter (capillaries 
can act to constrict capillaries) (Winkler et al., 2011) and therefore blood flow regulation 
of the brain. In addition they are important in the establishment of the basal lamina, 
secreting many molecules involved in the creation and remodelling of the basal lamina, 
and therefore are key players in the maintenance of the BBB and CNS 
microenvironment  (Winkler et al., 2011). 
 
2.4.3 Neurons  
 
In addition to astrocytes and pericytes, neurons have also been shown to modulate the 
BBB. Duport et al. (1998) co-cultured endothelial cells with brain slices containing intact 
neural networks, which resulted in increased TJ expression and decreased BBB 
permeability. Similarly, Savettieri et al. (2000), showed that co-culture of endothelial 
cells with neurons increased the expression of occludin at the endothelium, indicating 
that neurons increased TJ protein expression. 




2.4.4 Interactions between cells of the NVU 
 
It is important to note that interactions between the cells of the NVU are also important 
in the modulation of the BBB. For example, the increase in BBB occludin in the 
presence of neurons has been shown to be enhanced/speeded up when astrocytes are 
also present (Schiera et al., 2003). 
Similarly, one study showed that addition of astrocytes to pericyte-endothelial cultures 
resulted in reorganisation of the 2D structure into a 3D structure, resulting in the 
formation of capillary-like structures and increased expression of the BBB marker 
GLUT1. This shows that both cell types are required for BBB formation (Ramsauer et 
al., 2002).  
In the same study, it was shown that astrocytes induce morphological changes in the 
pericytes, which then allows the pericytes to stabilise the capillary-like structures, 
conferring resistance against apoptosis (Ramsauer et al., 2002). Similarly, Armulik et 
al. (2010) showed that pericyte-deficient mice had altered astrocytes, with altered 
polarisation of astrocyte end-feet shown by changes in Aquaporin4 (marker of 
astrocyte polarisation) expression at the astrocyte end-feet in the deficient mice.  
This demonstrates that the cells of the NVU work together and cross-communicate  to 
form, maintain and modulate the BBB. Consequently, deregulation of the NVU cells, 
such as in brain cancer, can have a severe impact on the BBB. 
 
2.5 Cancer and the CNS 
 
Brain cancers make up 2-3% of total cancers, however survival rates are lower than for 
non-CNS with medium survival without treatment being only 1-2 months, while 
treatment through surgery and radiation only increases this to 6 months after surgery 
(Martinez et al., 2013).  
Although metastatic brain tumours do occur, this is uncommon, with only 10-20% of all 
systemic malignancies eventually metastasising to the brain (Gerstner & Fine, 2007). 
This is largely due to the barrier nature of the BBB, where metastasising cells in the 
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blood stream must attach and invade the BBB before they can reach the brain (Arshad 
et al., 2010, Martinez et al., 2013).  
Most CNS cancers arise from CNS cells themselves, giving rise to primary tumours. 
The most common primary tumours are gliomas (tumours originating from glial cell) 
accounting for over 30% of all brain tumours and 80% of malignant tumours (Agnihotri 
et al., 2013). Gliomas can further be subcatagorised depending on their cell of origin (if 
known), e.g. gliomas arising from astrocytes are astrocytomas, and oligodendrogliomas 
arise from oligodendrocytes.  
Cancer stem cells can also arise from neural stem cells and like their non-cancerous 
counterparts are capable of giving rise into a variety of different cell types resulting in 
mixed tumour cell populations (Wen & Kesari, 2008). 
Irrespective of origin, the common feature of all tumours is aberrant growth and 
proliferation of the tumour cells. However, such growth requires a good supply of 
nutrients and O2. Small tumours (<1-2mm) can survive by passive diffusion of nutrients/ 
O2 from the existing BBB. However, as the tumour grows beyond 2mm it outgrows its 
supply of nutrients and O2 (Jain et al., 2012). This leads to the development of a 
hypoxic environment within the tumour and surrounding tissue. This triggers the 
expression of Hypoxia-inducible factor 1-α (HIF-1α) which in turn promotes angiogenic 
pathways, such as the VEGF (Vascular endothelial growth factor) pathway (Figure 1.4) 
(Jain et al., 2012). Non-VEGF pathways also exist that help promote angiogenesis 
(growth factors, FGF (Fibroblast growth factors), PDGF (Platelet-derived growth 
factor)). Such angiogenic factors and pathways lead to the tumour developing its own 
blood vessels and thus gaining its own nutrient supply. However, these blood vessels 
are quite immature and leaky (Gerstner & Fine, 2007, Jain et al., 2012) and are often 
referred to as the blood-tumour barrier (BTB), to indicate differences from the normal 
BBB. 




Figure 1.4 Tumour growth in angiogenesis in Glioma (Jain et al., 2012)  
Tumour angiogenesis involves a multitude of controlled signaling cascades and structural 
changes 
 
As the tumour continues to grow the tissue becomes hypervascularised to meet the 
nutrient /O2 demands of the tumour's ever-increasing size. Thus one of the hallmarks of 
high grade tumours is the hypervascularisation, where the degree of 
vascularisation/endothelial proliferation helps categorise the tumours (Grier & 
Batchelor, 2006).  
Together with the extent of endothelial proliferation, tumours are graded by four other 
histopathological characteristics associated with anaplasia, according to the WHO 
grading system. These are cellular density, nuclear atypia, mitosis and necrosis. 
Grades are given from I to IV, with IV being the most aggressive type of tumour. Grade 
I tumours are benign/non-malignant/non-cancerous tumours, that are slow-growing and 
resemble normal cells (Grier & Batchelor, 2006). Grade II tumours have 
some/moderate increase in cellular density with occasional nuclear atypia, with 
rare/absent mitotic activity and an absence of necrosis and endothelial proliferation. 
Grade III tumours have defined increases in cellular density with distinct nuclear atypia 
and marked mitotic activity, with an absence of necrosis and endothelial proliferation. 
Finally Grade IV tumours (e.g. glioblastomas) have all the features of Grade III tumours 
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together with high cellular density, necrosis and endothelial proliferation (Marquet et al., 
2007). 
Survival times often correlate with tumour grades, with poor survival times for patients 
with high grade tumours (Agnihotri et al., 2013). This is because tumour growth can 
result in direct alterations to the brain and the brain microenvironment (e.g. through 
necrosis and hypoxia as detailed above), but also due to indirect effects. One crucial 
indirect effect is the alteration of the BBB by tumours, which leads to BBB dysfunction; 
a dysfunctional BBB can no longer maintain brain homeostasis leading to altered CNS 
microenvironment and changes in CNS activity (Deeken & Loscher, 2007).  
 
2.6 Changes in the BBB in cancer challenge  
 
2.6.1 The BBB and BTB in cancer 
 
Several studies have examined the vasculature in and around tumours to assess the 
level of BTB and BBB breakdown.  
In a study by Schlageter et al. (1999) several rat tumour models were used to identify 
differences between normal and tumour vessels. Tumour microvessels showed a 
tendency towards increased diameter and circumference with increases in intervessel 
distance from ~20 µm (normal) to > 50 µm (tumour). Tumour vessels also had 
increased capillary wall thickness and the presence of fenestrations, whereas normal 
vessels showed no fenestrations. There was also an increase in the number of 
interendothelial junctions and gaps.  
Concerning transporters in tumour vessels, Guerin et al. (1992) using the rat 9L glioma 
model showed that GLUT1 coverage of vessels decreased from 100% (in normal) to 
74% in tumour vessels (malignant glioblastoma). Hence decrease in GLUT1 positive 
density also occurs in tumour vessels, further distinguishing them from normal vessels. 
Madden et al. (2004) harvested non-neoplastic and tumour-associated endothelial cells 
and conducted transcriptome analysis to identify differences in gene expression 
between the different endothelial cells.  The results showed several genes to be 
induced (e.g. Endothelin receptor type B, HSPG2/Perlecan, RDC-1) or suppressed (1 
NR4A1, Annexin A3 ANXA3, MT1A, HSP70, Syntaxin 7) in tumour vasculature when 
compared with non-neoplastic vessels (Table 1.4 and Table 1.5). This differential gene 
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expression between normal BBB and tumour BTB vessels, may be indicative of 
different BBB functional activity. 
Table 1.4 Genes induced in tumour vasculature (Madden et al., 2004) 
  
Table 1.5 Genes suppressed in tumour vasculature (Madden et al., 2004)
 
 
In a study by Shibata (1989), electron microscope imaging was used to compare glial, 
non-glial and metastatic brain vasculature from human brain tumours.  
In glial tumours, capillaries had thickened walls and irregular cell junctions (that were 
short or elongate), with surface infolding of endothelial cells as well as increased 
numbers of pinocytic vesicles. There was also irregularity in basal lamina and the 
presence of a large extravascular space. However, although such changes were 
pronounced in malignant gliomas (high grade tumours), only slight changes were noted 
in benign astrocytomas (low grade tumours), which had normal capillary width, TJs, 
basal lamina, perivascular space and only moderate surface infolding and increase in 
pinocytic vesicles (Shibata, 1989).  
Similarly, Larsson et al. (1990), used gadolinium-DTPA (a molecule normally BBB 
impermeable) to assess BBB permeability and showed that in low grade tumours the 
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BBB is largely intact. Grade II astrocytomas showed no or little gadolinium-DTPA 
permeability, with more permeability in Grade III astrocytoma, and Grade IV 
glioblastomas showing the highest permeability. This showed that BBB dysfunction 
correlates with tumour grade. 
Interestingly these observations are in agreement with Schlageter et al. (1999), who 
showed that the increase in vessel size was greater in larger tumours than in smaller 
tumours.  
Furthermore, Shibata 1989 showed that vessel alterations were more pronounced in 
the tumour centre than in the periphery of the tumour and even less so in the 
surrounding brain which appeared normal in most cases (Shibata, 1989). This 
demonstrated that blood vessels within a tumour (i.e. the BTB) are not only 
heterogeneous, but that they are more normal with increased distance from the tumour 
core. Consequently, the BBB surrounding tissue furthest from the tumour core is left 
intact is most cases. However, the fact that the surrounding brain was affected in some 
cases (Schlageter et al., 1999), does show that the tumour can influence the 
surrounding parenchyma although any effects should diminish with increased distance 
from the tumour.  
The grade and proximity to tumour core are not the only factors that can affect the 
blood vessels. The origin of the tumour and its microenvironment have been shown to 
be important in the development of the tumour blood vessels (Hobbs et al., 1998, 
Regina et al., 2001).   
Although there are many features in common among glial, non-glial and metastatic 
tumours, there are also clear differences. 
In the Shibata (1989) study, non-glial tumour vessels showed increased surface 
infolding, increased vesicles and many fenestrations, with discontinuous TJs and 
irregular basal lamina. In metastatic tumours, endothelial cells were shown to be 
proliferating and had marked infolding with increased number of pinocytic vesicles and 
a high degree of fenestrations. However, tumours of glial origin showed no endothelial 
fenestration, irrespective of grade. This links tumour origin to tumour vasculature, with 
the vasculature of non-glial tumours more like the vasculature found in the tissue of 
origin (Regina et al., 2001). 
The tissue/cell of origin is not the only determinant in the development of tumour 
vasculature. Hobbs et al. (1998), showed that the microenvironment of the tumours is 
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important to vascularisation. In this study, mice were implanted with the same tumour 
type but in different locations; the results showed that cranial tumours grew twice as 
fast as subcutaneous tumours. Furthermore the cranial tumour vasculature had smaller 
transvascular gaps between endothelial cells. This suggests that the cranial 
microenvironment favours tumour growth and also alters the phenotype to become 
more like of that of the CNS vasculature.  
Factors such as tumour grade, origin and microenvironment result in the high 
heterogeneity of tumour vasculature and therefore make targeting brain tumours 
difficult, since it is unclear whether the BTB and the surrounding BBB are intact. 
Chemotherapy is becoming increasingly important in glioma treatment since traditional 
brain tumour treatments (involving radiotherapy and/or surgery), do not guarantee 
complete removal of cancerous cells, often resulting in reoccurrence (Wen & Kesari, 
2008). However, if the BTB and BBB are intact, this becomes a problem for 
chemotherapeutic treatment of brain tumours since many chemotherapeutics cannot 
cross the BBB under normal circumstances, largely due to the presence of ABC efflux 
transporter (see Section 1.5.). Although in later stages of cancer the BTB and 
surrounding BBB are more permeable to drugs, there are other problems by this stage 
such as oedema and high levels of necrosis (Dinda et al., 1993). Furthermore, cancer 
stem cells may also exist within tumours, which have been shown to confer resistance 
of malignant tumours to chemotherapy, making treatment of such tumours even more 
difficult (Wen & Kesari, 2008, Agarwal et al., 2011).  
It should also be mentioned that in CNS-cancer (including late stage cancer) not all 
cancer cells are always in the form of tumours, as some of the cancer cells may have 
migrated away from the site of origin (Agarwal et al., 2011). Therefore, even if every 
cancer cell of the original tumour is surgically removed or irradiated, the undetected 
and untreated invasive cancer cells are left behind which can grow into a new tumour 
(Agarwal et al., 2011).  
These invasive cells fall into the ‗small tumour‘ category (<2mm) and so do not require 
their own nutrients/O2 supply and therefore do not have their own BTB (Agarwal et al., 
2011, Jain et al., 2012). This means they are situated within an area with intact BBB 
that is not readily permeable to chemotherapeutics (see Figure 1.5) (Agarwal et al., 
2011). 
It is clear that considerable research is needed to enhance the effectiveness of CNS 
chemotherapeutics. 




Figure 1.5 Multiple mechanisms and barriers that limit drug delivery to glioma (Agarwal et al., 
2011) 
The blood–brain barrier (BBB) and the blood–tumour-cell barrier (BTB) form barriers that a 
systemically administered drug must cross to reach the tumour. The centre of the figure shows 
the invasion of glioma cells from the tumour core into the normal brain parenchyma. Above this, 
parts a and b show how the integrity of the BBB affects drug delivery in these different locations 
(a) The BBB is often disrupted at the site of the tumour, with the lack of TJs allowing for easy 
diffusion of drugs and small molecules into the tumour. However, this is also the part of the 
tumour that gets removed after surgery. (b) The BBB is intact in areas centimeters  away from 
the tumour core. Drug delivery across this barrier is restricted by the presence of TJs between 
endothelial cells and more importantly by drug efflux transporters that pump drugs back into the 
blood. The amount of drug that is able to cross this barrier and reach the brain is usually a 
fraction of what reaches the tumour core. Nests of tumour cells in such locations protected by 
the intact BBB eventually give rise to the recurrent tumour after surgery.  
 
2.6.2 Efflux transporters at the BBB in CNS cancer 
 
As mentioned previously, one of the major reasons that chemotherapeutics cannot 
cross the BBB is the presence of BBB ABC efflux transporters, where many 
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chemotherapeutics have been shown to be substrates for one and usually more than 
one efflux transporter (Matsson et al., 2009). 
In spite of this, relatively little research has been focused on understanding the efflux 
transporters of the BBB during cancer challenge. Although some studies have 
examined alterations in the ABCs during cancer challenge, there are many 
discrepancies between studies.  
As with the morphological changes in the BBB (detailed previously) the expression of 
the efflux transporters in the vasculature has also been shown to be dependent on the 
tumour origin (Deeken & Loscher, 2007). 
Metastatic tumours in the brain 
In one histological study examining 137 metastatic tumour samples (breast, lung and 
prostate carcinomas) none of the tumour capillaries of these samples were found to be 
positive for Pgp expression. Conversely, 86% of the glioma tumour vessels showed 
positive Pgp staining, while normal brain vessels showed 100% Pgp positive staining 
(Toth et al., 1996). However, other studies showed different results. Regina et al. 
(2001) showed that in lung carcinoma brain metastases, the capillaries did possess 
Pgp, but that this was only 40% of the level of normal brain vessels. Similarly, 
melanoma metastases tumour vasculature possessed diminished Pgp level, with only 
5% that of normal brain vessels.   
Regina et al. (2001), suggested that the Pgp levels were linked to the tissue of origin, 
with Pgp levels of the original tissue influencing levels of Pgp expressed in the newly 
formed blood vessels. This may explain why glial tumours maintain BBB phenotypes 
(i.e. the same level of Pgp as normal brain vasculature) in some cases (Toth et al., 
1996). 
Non-glial tumours in the brain 
Non-metastatic, primary non-glial tumours (e.g. meningiomas originating from the 
meninges) have also been compared with glial tumours, showing similar results to the 
metastatic tumours. 
In an immunohistological study on microvessels of 22 primary CNS lymphoma and 30 
glioma samples, decreases in both Pgp and BCRP were detected in 63% and 93% of 
the lymphoma areas tested, respectively, with BCRP undetectable in 50% of subjects. 
Conversely, most gliomas were found to express Pgp and BCRP at similar levels as 
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normal brain vessels although decreases in Pgp and BCRP were noted in higher grade 
tumours, especially in proliferating endothelia and around necrotic foci (Sakata et al., 
2011). Interestingly, the decrease in the transporter expression of lymphoma vessels 
was more prominent in areas of dense and perivascular tumour cell infiltration 
compared to sparse areas of infiltration. This suggests that alterations to efflux 
transporter expression are more pronounced nearer the tumour core, similar to other 
morphological changes that occur during cancer challenge at the BBB (see section 
1.8.1). 
For MRPs, no MRP1-positive vessels were detected in either lymphoma or glioma 
vessels (Sakata et al., 2011). This agrees with a study by Cooray et al. (2002) 
examining the vasculature in normal tissue, tumours of glial origin and tumour 
meningiomas, finding no MRP1, 3 or 5 detected in any of the tumour types tested. 
However, Cooray et al. (2002) did find BCRP to be present luminally in all cases. 
However, the levels of expression were not quantified here so cannot be compared to 
those of Sakata et al. (2011). 
When intracranial ependymal tumours and spinal tumours were examined by Ginguene 
et al. (2010), Pgp and BCRP were both shown to be present luminally on tumour 
vessels. In both tumour types, the tumour microvessels showed heterogeneous Pgp 
labelling (weak and strong), while BCRP showed consistently strong labelling 
(Ginguene et al., 2010). This is in keeping with the results of Regina et al. (2001) in 
metastatic tumours, which together suggest that Pgp levels in the vasculature of 
tumours from metastatic and non-glial origins tend to have weaker/more 
heterogeneous Pgp expression than normal brain or glial tumours. By contrast BCRP 
expression appears to remain strong irrespective of tumour type (Ginguene et al., 
2010). 
Although metastatic and non-glial brain tumours appears to have lower levels of Pgp, 
Allen et al. (2000) showed that even low levels of Pgp and MRPs can still significantly 
deter drug passage. Hence, although levels of Pgp in some tumours may be low, they 
may still pose a problem for chemotherapy delivery. 
Chemotherapeutic challenges would also exist (perhaps to an even greater extent) for 
glial tumours with fully expressed ABC transporters in their vessels. However, some 
studies suggest that even glial tumours are susceptible to changes in ABC transporters 
(e.g. loss in Pgp). 
 




Concerning Pgp expression in the microvessels of gliomas, Toth et al. (1996) found 
that Pgp expression was lower in glioma than in normal vasculature (86% in tumour 
compared with 100% Pgp in normal brain). Interestingly, there was no difference in the 
relative staining intensity of Pgp in endothelial cells of normal brain versus tumour 
periphery, however the most central regions of tumours were unreactive for Pgp. 
Conversely, Toth et al. (1996) did show that the areas surrounding the brain tumours 
maintained an intact BBB in terms of Pgp expression. This shows that like other 
morphological features of the BTB/BBB (see section 1.8.1), the degree of Pgp 
expression varies with distance from the tumour core (inversely correlated). 
Furthermore, Toth et al. (1996), showed that in Grade I and II tumours Pgp staining 
was just as strong as normal brain, while Grade IV glioblastoma vessels showed more 
heterogeneous staining, with both weak and strong Pgp staining observed and with 4 
of the 18 samples tested being completely negative.  
Sawada et al. (1999) also showed a trend towards decreased Pgp expression in 
tumour microvasculature with tumour grade, finding weaker Pgp staining in new tumour 
blood vessels compared to normal cerebral blood vessels (although Pgp was shown to 
retain luminally expression).  An inverse correlation between Pgp expression and the 
proliferation of endothelial cells was noted, with proliferating cells shown to be 
functionally immature (Sawada et al., 1999). This suggests that in proliferating cells 
Pgp expression is reduced. 
By contrast, some studies have shown increased levels of Pgp with tumour grade.  
Nabors et al. (1991), showed Pgp-positive tumour vessels only in high grade tumours 
and not in low grade tumours. Tews et al. (2000), showed Pgp in tumour glioblastoma 
vessels with strong Pgp expression in both non-neoplastic and tumour tissue (i.e. no 
diminution in Pgp expression in high grade tumours).   
Concerning expression of the other ABC transporters, Zhang et al. (2003) compared 
non-malignant tumours to glioblastoma to determine the relative mRNA expression 
levels of BCRP, MRP1 and Pgp (using laser capture microscopy to isolate tumours 
vessels for QPCR). The vessels were shown to have similar levels of BCRP and PGP 
mRNA, but the highest levels of mRNA were found to be for MRP1 (8 fold greater than 
the other two transporters). The results also showed significantly higher BCRP mRNA 
in glioblastoma vessels compared to non-malignant vessels, while MRP1 decreased in 
glioblastoma. 
General Introduction   
43 
 
Calatozzolo et al. (2005), showed that in endothelial cells of gliomas MRP1, 3 and 5 
and Pgp were expressed both at the mRNA and protein levels, with the highest mRNA 
levels found to be for MRP1. 
By contrast, Tews et al. (2000) found no MRP1 in tumour glioblastoma vessels and no 
MRP1 was detected by the Sakata et al. (2011) study in glioma vessels. 
The differences reported may be due to lack of correlation between mRNA and protein 
expression, where mRNA translation into protein may be prevented, resulting in little 
low or no protein expression. 
Bronger et al. (2005) used PCR and immunostaining methods in combination to show 
the presence of MRP4 and MRP5 expression at both mRNA and protein level in glioma 
vasculature. However, no MRP2 and MRP3 could be detected in tumour vasculature at 
either the protein or mRNA level. Interestingly, although MRP6 mRNA could be 
detected, no detectable MRP 6 protein was observed. This shows that discrepancies 
between mRNA and protein levels of the MRP proteins can occur. 
Bronger et al. (2005) showed MRP4 and MRP5 proteins to be luminally expressed with 
the proteins showing positive staining in 87% and 86% of the tumour capillaries tested, 
respectively. Staining was weak/low, but consistent expression was observed across 
Grade II to Grade IV glioma. So unlike some Pgp studies, MRP4 and MRP5 expression 
in tumour endothelial does not appear to correlate with tumour grade. However this is 
only one study and is therefore not conclusive.  
Interestingly, the capillaries that failed to stain in the Bronger et al. (2005) study were 
shown to be proliferating, linking the proliferative state of the blood vessels to poor 
expression of MRPs. This agrees with the earlier observations concerning Pgp, 
indicating that proliferation in endothelial cells of tumour microvessels results in 
decreased expression of multiple efflux transporters.  
The appearance of MRPs is interesting, since there is still controversy as to whether 
these are expressed in normal tissue. Regina et al. (1998), suggested that in normal 
brain, astrocytes act to suppress MRP1. However, MRP1 expression has been shown 
present in normal brain endothelial microvessels as has MRP4 (See section on MRPs). 
Concerning BCRP, Bronger et al. (2005) showed that BCRP is expressed at both the 
mRNA and the protein levels (luminally) in tumour vessels. 
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Sakata et al. (2011) found BCRP to behave like Pgp, where in low grade gliomas all 
samples showed strong BCRP and Pgp staining of capillaries (stronger than normal 
brain), while in high grade gliomas (28 samples) only 77% showed strong BCRP and 
Pgp staining, with the rest showing weaker staining relative to normal brain. This 
suggests that both Pgp and BCRP may first increase in low grade tumours (showing 
stronger expression than normal brain vessels), but then decrease in higher grade 
tumours (showing weaker expression than normal brain vessels). 
In summary, the data concerning efflux transporter expression is inconclusive with 
differences in protein expression being shown by different studies. Furthermore there is 
a lack of correlation between mRNA levels and protein expression, not only between 
different studies, but within the same study, that also complicates the matter. In 
addition, there are no studies comparing protein expression with the transporter 
function and so no indication as to whether increases/decreases in protein levels 
actually lead to altered ABC transporter activity.  
Some clear patterns concerning tumour vasculature are beginning to emerge (e.g. link 
between ABC transporter expression and the proliferative state of capillaries), but more 
research is needed. Furthermore, the surrounding tumour tissue (with an 
established/mature BBB) is rarely investigated, so there is no real knowledge of how 
the established BBB efflux transporters are affected by tumours. Clearly more work 
needs to be done to investigate this.  
 
2.7 Aims and Objectives  
 
The aim of the project was to better understand how the BBB reacts to the presence of 
glioma cells. It was aimed to identify any differences in ABC transporter 
activity/expression in normal BBB and glioma BBB as well as identifying possible 
factors responsible for any differences. 
Towards this aim the following objectives were defined: 
a) To identify and characterise an appropriate model for the ‗normal‘ BBB that 
could be used as a reference control for a glioma BBB model consisting of 
endothelial cells co-cultured with glioma cells. 
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b) To compare the ABC transporter activity/expression in endothelial cells co-
cultured with glioma cells with the normal reference control, to determine any 
changes in ABC transporters induced by the glioma cells. 
c) To assess possible glioma factors involved in altering ABC transporter 
activity/expression within endothelial cells. 
d) To determine any changes in ABC transporter expression in human brains in 
response glioma challenge using confocal microscopy on human tissue from 
control and glioma brains. 
e) To correlate in vitro results concerning ABC transporter changes with the 
expression changes in human brains to identify any common effects on ABC 
transporters in the BBB as a results of glioma challenge.  
s




3 Materials and Methods 
All chemicals were purchased from Sigma unless otherwise stated.  
 
3.1 Coating plastics for cell culture 
 
For cell culture involving porcine brain endothelial cells (PBECs), plastics required pre-
coating with fibrous proteins. Plastics were coated with rat tail collagen (0.33 mg.ml -1, 
isolated in accordance with Strom and Michalopoulos (1982)). For T-75 flasks, 4ml of 
collagen was used and the collagen was left on the flasks for 2 hours at room 
temperature. The collagen was then removed and the flasks were washed twice with 
equal volumes (i.e. 4 ml) of Hanks‘ Balanced Salt Solution (HBSS). Then 4 ml of 7.5 
µg.ml-1 fibronectin was added to the flask and the flask was incubated for 2 hours at 
room temperature. The flasks were then washed with HBSS (as above), before the 
addition of porcine brain capillaries (see section 2.4). 
Transwell inserts (polycarbonate, 0.45 µm pore, Corning) were similarly coated using 
500µl of collagen for each 12-Well Transwell and 1.5 ml for each 6-Well Transwell (for 
2 hours), followed by 500µl of fibronectin for each 12-Well Transwell and 1.5 ml for 
each 6-Well Transwell (for 2 hours). 
For 96 and 24 well plates, these were coated with collagen only using 200µl and 500µl 
of collagen per well, respectively, with the collagen left on the plates for 2 hours at  
room temperature. 
For rat astrocyte cell culture, plastics were coated with 10 µg.ml
-1
 poly-L-Lysine for 1 
hour at 37˚C, 5% CO2 in air, using the same volumes as for the collagen. The coating 
was then removed and the plastics allowed to dry before the addition of cells. 
For human astrocyte cell culture, plastics were coated with 15 µg.ml-1 poly-L-Lysine , 
using the same volumes as for the collagen. Coating occurred for 24 hours at 37˚C, 5% 
CO2 in air, followed by washing twice with dH20 before the addition of cells. 
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3.2 Isolation of porcine brain microvessels 
 
To obtain PBECs, the culture begins with 3 porcine brains (from Cheale Meats Ltd 
abattoir, immediately dispatched after euthanisation), and generates 6 cryovials (3 vials 
of PBEC 60s and 3 vials of PBEC 150s) (see terminology below). One vial yields 10 -
15 12-well Transwell inserts (1x105 cells per Transwell). 
 
PBECs isolation was in accordance with Patabendige et al. (2013). The brains were 
removed from the skulls, cut into hemispheres and placed on ice in Iscove‘s Dulbecco's 
Modiﬁed Eagle's medium (DMEM) medium with 100 µg∙ml-1 penicillin and 100 U∙ml-1 
streptomycin. From each hemisphere only the cortex was used for PBEC isolation, with 
the rest of the brain matter discarded (i.e. the cerebellum, diencephalon and brain stem 
were removed). The meninges and white matter were removed from the cortices using 
surgical instruments, to give clean cortices. The clean cortices from all 3 brains were 
pooled together and then passed through a 50 ml syringe into a solution of Eagle's 
Minimum Essential Medium (MEM), with 25 mM hydroxyethyl piperazine-
ethanesulfonic acid (HEPES) containing 10% fetal calf serum (FCS), 100 µg∙ml-1 
penicillin and 100 U∙ml-1 streptomycin. The cortical matter was then homogenised 30 
times (15 times with a loose pestle followed by 15 times with a tight pestle) (Dounce 40 
ml Homogeniser). The homogenate was divided into 3 sections (1 section per porcine 
brain used) and was filtered through nylon meshes. Each section was filtered through 
its own set of 2 meshes. 
Firstly, a 150 µm mesh was used, with the microvessel fragments, large capillaries of 
sizes greater than 150 µm becoming trapped on the mesh, while capillary fragments 
smaller than 150 µm pass through the mesh and into the filtrate. Secondly, the filtrate 
was re-filtered through a 60 µm mesh, where the enriched capillary fragments greater 
than 60 µm (but smaller 150 µm since they had already been filtered through the 150 
µm mesh) were retained on the 60 µm mesh. The capillaries on the 150 µm mesh were 
then used to generate PBEC ‗150s‘, while the capillaries on the 60 µm were used to 
generate PBEC ‗60s‘ and were therefore kept separate from this point onwards. 
In total, 3 meshes of 60 µm and 3 meshes of 150 µm were generated, one of each kind 
from each section filtered. The meshes containing the capillaries were then incubated 
with a digest mix (composed of M199 medium containing 10% FCS, 100 µg∙ml-1 
penicillin, 100 U∙ml-1 streptomycin, 210 U∙ml-1 collagenase type III (VWR International), 
90 U∙ml-1 Trypsin (VWR International), 115 U∙ml-1 DNase I (VWR International) for 1 
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hour at 37˚C, 5% CO2 in air. All 3 meshes of 150s were digested together separate 
from the 60s meshes and vice versa. 
The digest mixes containing the digested capillaries of either 150s or 60s, were then 
centrifuged at 105 x g for 5 minutes at 4˚C. The pellets containing the capillaries were 
then washed twice, by firstly resuspending the capillary pellet in MEM medium and 
then by centrifugation at 105 x g for 5 minutes at 4˚C. The washed pellets were then 
each resuspended in 3 ml freezing medium (10% dimethyl sulfoxide (DMSO) in FCS), 
and aliquoted into cryovials as 1 ml aliquot of PBECs. The 3 PBEC 150s and 3 PBECs 
60s cryovials were then placed at -80˚C in a Mr. Frosty container for 24 hours and then 
moved to liquid nitrogen for long-term storage. 
 
3.3 Primary rat astrocyte isolation  
 
To obtain primary rat astrocytes, the culture begins with 6-10 rat pups (postnatal 0-2 
days, Sprague-Dawley) and produces 6-12 cryovials (~800,000 cells/vial, passage 1 
(p1)) 
 
Rat cortical astrocytes were prepared according to Rist et al. (1997). 
Animals were killed by neck dislocation and decapitated.  The skin of the head was 
incised longitudinally using a scalpel and the bone was then cut and removed. The 
brain was eased out of the skull and placed in Dissection Buffer (HBSS without Ca+, 
Mg
+, with 10 mM HEPES, 100 U∙ml-1 penicillin and 100 g∙ml-1 streptomycin).  The 
cortex was isolated and the remaining brain matter was removed. The meninges were 
removed and the brains placed back into Dissection Buffer (~12.5 ml) and cut into 
pieces using a scalpel. This cortical matter was then mixed with 1.25 mg∙ml-1 trypsin in 
a 50:50 ratio, and was digested for 30 minutes at 37oC.  After digestion, 10 ml of Rat 
Astrocyte Medium A was added (DMEM containing 4.5 g∙L-1 glucose and 2 mM L-
alanyl glutamate (Glutamax), 10% fetal calf serum, 100 U∙ml-1 penicillin, 100 g∙ml-1 
streptomycin). The suspension was centrifuged at 360 x g and the pellet was 
suspended in 5 ml of medium and triturated with a fine–bore polished pipette. The 
suspension was centrifuged as before and the supernatant was filtered using a 73.5 
m mesh tissue sieve and the filtrate was plated into flasks (pre-coated with poly-L-
lysine).  
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Cells were isolated by Siti Yusof (BBB group Kings College London, 2008/9). 
Medium was changed one day after the preparation and then every three days until 
cells were confluent (~7 days).  On day 14–16 after plating, the medium was changed 
to Rat Astrocyte Medium A containing 10 M cytosine arabinoside (to eliminate dividing 
cells).  At this stage, the astrocytes were confluent, and the contaminating cells, which 
are not contact-inhibited, are susceptible to cytosine arabinoside. The flasks were 
shaken at 37oC for 24 hours to dislodge contaminating cell types and the medium was 
changed to remove the dislodged cells. This procedure was repeated for five days in 
total. The cells were then allowed to reach confluence. The cells were then trypsinised 
by washing the cells twice with HBSS without Ca2+ or Mg2+, before incubation with X1 
Trypsin/EDTA for 1-3 minutes at 37°C, 5% CO2
 . The trypsin was then quenched with 
medium and the cells were centrifuged at 360 X g for 5 minutes and the spent medium/ 
trypsin was discarded. The cells were resuspended in Freezing Medium and aliquoted 
into 1 ml aliquots (of ~800,000 cells). The cells were placed at -80˚C in a Mr. Frosty 
container for 24 hours and then moved to liquid nitrogen for long-term storage. 
 
3.4 Cell Culture 
 
Cells were kept at 37˚C, 5% CO2 in air unless stated otherwise. 
 
3.4.1 Culture of primary porcine brain endothelial cells (PBECs) 
 
Porcine brain microvessels were defrosted and grown in collagen and fibronectin 
coated T-75 flasks, in PBEC Medium (DMEM containing 1 g.L-1, 100 µg∙ml-1 penicillin, 
100U∙ml-1 streptomycin, 125 μg∙ml-1 heparin,  2 mM L-glutamine and 10% Bovine 
Plasma Derived Serum (BPDS) (First Link UK)) and 4 µg∙ml-1 of puromycin. Puromycin 
is a toxin that is also a substrate of P-glycoprotein (Pgp) and so selectively eliminates 
any cells that do not express Pgp at sufficiently high levels to exclude the puromycin 
(such as pericytes, which are the major contaminant of the preparation), without 
affecting the endothelial cells which do express Pgp at sufficiently high levels. 
The microvessels were kept at 37°C, 5% CO2 and endothelial cells were seen to grow 
out of the microvessels. These porcine brain endothelial cells (PBECs) were passaged 
when ~ 50% confluent (usually within 3 days). If the cells did not reach 50% confluence 
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within 3 days, the cells were fed on Day 3 with fresh PBEC Medium (without 
puromycin, since contaminants would have already been eliminated by this stage), and 
allowed to grow further at  37°C, 5% CO2 until 50% confluence was reached (in 
another 2-3 days). 
The cells were then washed twice with HBSS without Ca2+ or Mg2+, before being 
incubated with X1 Trypsin/EDTA for 8-15 minutes at 37°C, 5% CO2
 which allowed the 
cells to become detached from the flask.  The trypsin was quenched with PBEC 
medium and the cells were centrifuged at 360 X g for 5 minutes, and the spent 
medium/trypsin was discarded. The cells were resuspended and seeded into the 
plates/Transwells at a density of 100,000 cells/cm2.  
PBECs were passaged to either 96-Well or 24-Well plates pre-coated with collagen or 
onto 12-Well or 6-Well polycarbonate Transwells (0.45 µm pore, Corning) that had 
been pre-coated with collagen and fibronectin. 
 
PBECs in plates 
For PBECs in plates (PBECs-P), PBEC-60s were left at 37°C, 5% CO2 for 2-3 days to 
reach confluence. The cells were either immediately assayed after confluence was 
reached or fed with fresh medium and left at 37°C, 5% CO2 for another 1-3 days until 
the cells were used. 
 
PBECs in mono-culture or in co-culture with human astrocytes or G7 glioma 
cells 
For mono-cultured PBECs (PBECs-M), PBECs in co-culture with human astrocytes 
(PBECs-hAS) and PBECs in co-culture with G7 glioma cells (PBECs-G7), PBECs-60s 
were passaged into PBEC Medium and placed in Transwell inserts pre-coated with 
collagen/fibronectin. The Transwell inserts were then placed above an empty well 
containing PBEC Medium and grown to confluence, which occurred in 3 days. 
For PBECs-M, on the fourth day after passaging the medium was changed to PBEC 
Serum Free Medium (DMEM containing 1 g∙L-1 glucose, 100 µg∙ml-1 penicillin, 100 
U∙ml-1 streptomycin, 125 μg∙ml-1 heparin, 2 mM L-glutamine, 550 nM hydrocortisone) 
containing 250 µM CPT-cAMP and 17.5 µM RO-20-1724 (CalbioChem) both apically 
and basally, and 24 hours later the cells were assayed (see assay sections). 
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For PBECs-hAS and PBECs-G7, on day 4 after passaging the medium on the apical 
chamber was changed to PBEC Serum Free Medium containing 250 µM cAMP and 
17.5 µM RO-20-1724 and the Transwell insert was placed above a well containing 
either human or G7 Cells at ~50% confluence in Neural Stem Cell Medium composed 
of DMEM/F-12 Medium (1:1 mix) with 365 mg∙L-1 L-glutamine and additionally 
containing 29 mM Glucose, X1 non-essential amino acids (NEAAs) (PAA, GE 
healthcare), X1 Penicillin/Streptomycin (PAA, GE healthcare, 10 mM HEPES, 0.012% 
BSA, 0.1% β-mercaptoethanol, X0.5 B27 supplement (PAA, GE healthcare) and X0.5 
N2 supplement (PAA, GE healthcare), 1 µg∙ml-1 laminin, 10 ng∙ml-1 Mouse EGF and 10 
ng∙ml-1 basic human FGF.  The TEER was monitored once a day for 48 hours and after 
48 hours the PBECs were ready to be assayed. 
Alternatively, for PBECs-G7, PBECs-60s were passaged to a Transwell insert (in 
PBECs medium) which was immediately placed above ~50% confluent G7 cells (in 
Neural Stem Cell Medium). After 4 hours the PBECs were moved to a new well of 
~50% confluent G7 cells (in Neural Stem Cell Medium), then moved again every 12 
hours for a total of 4 days. On the fourth day after passaging, the medium on the 
PBECs was changed to PBEC Serum Free Medium with 250 µM CPT-cAMP and 17.5 
µM RO-20-1724, and the cells were left in co-culture with G7s (in Neural Stem Cell 
Medium) for a further 24 hours before use. 
 
PBECs in co-culture with normal rat astrocytes or C6 glioma cells 
For PBECs in co-culture with primary rat astrocytes (PBECs-rAS) or C6 glioma cells 
(PBECs-C6), PBEC-60s were passaged into PBEC Medium and placed in Transwells 
and immediately placed above confluent normal rat astrocytes or C6 glioma cells in Rat 
Astrocyte Medium B (DMEM containing 4.5 g∙L-1 glucose, 10% fetal calf serum, 100 
U∙ml-1 penicillin, 100 g∙ml-1 streptomycin). The cells were grown in co-culture for 3 
days, and then on the fourth day after passaging, the medium was changed to PBEC 
Serum Free Medium, both apically and basally, for 24 hours. The PBECs were then 
ready for use. 
 
PBECs in conditioned medium 
For PBECs grown in conditioned medium, the PBECs-150s were passaged into 50% 
Conditioned Medium (consisting on a 1:1 mix of PBEC Medium and Conditioned 
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Medium) and seeded into plates coated with collagen. The medium was changed in 2 
days to fresh 50% Conditioned Medium with or without a drug treatment. The cells 
were then left for 2 days before being assayed. For further details regarding 
conditioned medium (i.e. type and composition) see section 2.4.6. 
 
3.4.2 Primary rat astrocyte cell culture  
 
Primary rat astrocytes were grown in Rat Astrocyte Medium B (DMEM containing 4.5 
g∙L-1 glucose, 10% fetal calf serum, 100 U∙ml-1 penicillin and 100 g∙ml-1 streptomycin) 
with medium changed every 3 days. 
For PBEC co-culture experiments, primary rat astrocytes were defrosted 4 days before 
co-culturing with PBECs. The astrocytes (p1) were defrosted in Astrocyte Medium B 
and seeded into 12-Well or 6-Well plates (pre-coated with poly-L-lysine) at a seeding 
density of 1.75 x 104 cells/cm2.  The medium was changed 3 hours after defrosting (to 
remove DMSO from within the freezing medium of the cells) and again 3 days after 
confluence, (1 day before the start of co-culture).  
Twenty-four hours later, PBECs were placed in co-culture with the confluent astrocytes, 
by placing a Transwell insert containing the PBECs above the well in which the 
astrocytes were grown.  
On the fourth day of co-culture, the medium on both the PBECs and astrocytes was 
changed to PBEC Serum Free Medium (DMEM containing 1 g∙L-1 glucose, 100 µg∙ml-1 
penicillin, 100 U∙ml-1 streptomycin, 125 μg∙ml-1 heparin,  2 mM L-glutamine, 550 nM 
hydrocortisone) containing 250 µM CPT-cAMP and 17.5 µM RO-20-1724 
(CalbioChem). The PBECs were ready for use 24 hours later and the astrocytes were 
discarded. 
 
3.4.3 Human astrocyte cell culture 
 
Human astrocytes were purchased from Science Cell Research Laboratories at (p1) 
and grown in Human Astrocyte Medium (Science Cell Research Laboratories) until 
passage 3. 
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For PBEC co-culture, human astrocytes (p3) were defrosted into  Human Astrocyte 
Medium and seeded directly into plates (coated with poly-l-lysine) at a density of 3.2 x 
104/cm2. The next day the medium was changed to Neural Stem Cell Medium, 24 
hours later (2 days before the start of the co-culture).  
Two days later confluent PBECs were placed above the human astrocytes, when 
human astrocytes were ~50% confluent. The co-culture was maintained for 48 hours 
and then the PBECs were removed for further experiments and the astrocytes were 
discarded. 
 
3.4.4 C6 glioma cell culture 
 
C6 were received as a gift from the late Irving Fritz (Babraham Institute, Cambridge). 
For PBEC co-culture experiments, C6 glioma cells (p129-133) were defrosted 3 days 
before co-culturing with PBECs. The C6s were defrosted into Rat Astrocyte Medium B 
and seeded into plates at a density of 2.20 x 104 cells/cm2. The medium was changed 1 
hour after defrosting and then again 2 days later when the C6s were confluent (1 day 
before co-culturing with PBECs began).  
The PBECs were then placed above the C6s 24 hours later to begin the co-culturing 
process. 
Two days after the start of co-culture the media on the PBECs and C6 was changed to 
fresh media in all cases except for some RNA studies, see Results sections.  
On the fourth day of co-culture the medium on both the PBECs and C6s was changed 
to PBEC Serum Free Medium, containing CPT-cAMP and Ro-20-1724. The PBECs 
were ready for use 24 hours later and the C6s were discarded. 
 
3.4.5 Primary G7 glioma cell culture 
 
Human primary cell lines used in this study were obtained from Steven Pollard (UCL) in 
accordance to UK regulations and following approval from the local and ethical review 
board (Lothian Regulatory Ethics Committee; Ref LREC/2002/6/15). Tissue was 
donated using written informed consent from patients or next of kin for tumour biopsies 
and foetal tissue, respectively. 




G7 cells (p26-29) were obtained from the Cancer Institute (UCL). G7s are glioma cells 
isolated from a glioblastoma multiform patients and have tested positive for stem cell 
markers. G7 cells were obtained directly on plates at ~30% confluence in Neural Stem 
Cell Medium. The medium was changed 24 hours later to fresh Neural Stem Cell 
Medium (2 days before the start of the PBEC co-culture).  
Two days later confluent PBECs (in PBEC Serum-Free Medium with 250 µM CPT-
cAMP and 17.5 µM RO-20-1724) were placed above the G7 glioblastoma cells, which 
were at ~50% confluence. The co-culture was maintained for 48 hours and then the 
PBECs were removed for further experiments and the G7 were discarded. 
Alternatively, non-confluent PBECs (in PBEC Medium) were placed above ~50% 
confluent G7s for 4 hours. The PBECs were then moved to new G7s (~50% 
confluence) and then moved again every 12 hours for a total of 3 days. On the fourth 
day the medium on the PBECs was changed to PBEC Serum Free Medium with 250 
µM CPT-cAMP and 17.5 µM RO-20-1724 and the PBECs were placed above new G7s 
for a final 24 hours.     
 
3.4.6 Collection of conditioned medium 
 
For collection/production of primary rat astrocyte-conditioned medium, cells were 
defrosted into Rat Astrocyte Medium B and placed in a T-75 flask (pre-coated with 
poly-L-lysine) at a density of 800,000 cells per flask. The medium was changed 3 hours 
later and then every 3 days until cells were confluent (~7-9 days).  
When the astrocytes became confluent, 10 ml of fresh medium was placed on the cells 
and left for 48 hours. Two different media were used, Rat Astrocyte Medium B or 
Serum Free PBEC medium. 
The medium was collected 48 hours later and stored at -80˚C as Rat Astrocyte 
Conditioned Medium. Fresh medium was then placed on the cells and the collection 
process was repeated. 
For collection/production of C6 glioma conditioned medium, cells were defrosted into 
Rat Astrocyte Medium B and placed in a T-75 flask at a density of 1,000,000 cells per 
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flask. The medium was changed 1 hour later and then every 2 days until cells were 
confluent (~4-5 days). 
When the C6s were confluent, the cells were treated the same as the astrocytes 
(detailed above) to produce C6-conditioned medium. 
Conditioned Neural Stem Cell Media from normal glial cells (Cb660s) and glioma cells 
(G7s, G15s and G26s), were obtained from the Institute of Cancer Research (UCL) 
(with all cells positive for stem cell markers). The media consisted of Neural Stem Cell 
Medium that had been placed on cells (at 40-60% confluence) for 48 hours before 
being collected.  
 
3.5 Treatment of PBECs with reagents 
 
PBECs in 50% conditioned medium were treated with one or more of the following 
drugs for 48 hours.  
To target the Wnt Pathway, human Dickkopf-related protein 1 (Dkk-1) a Wnt receptor 
inhibitor was used at a final concentration of 0.1 mg∙ml-1 (Aviscera Bioscience). To 
promote the pathway, BIO (a GSK-3β inhibitor) was used at a final concentration of 1 
µM. 
To target the Sonic Hedgehog Pathway, SHH (recombinant human) was used at a final 
concentration of 1 µg∙ml-1 (Source Bioscience), while cyclopamine (SMO receptor 
inhibitor) was used at 30 µM to inhibit the pathway. 
A summary of the drugs used is given in Table 2.1. 
 
Table 3.1. Drug treatments  
Drug Conc. Target Action Ref 
BIO 1  µM GSK3β Agonist Lim  et al. (2008) 
Dickkopf 0.1 mg∙ml
-1
 Frizzled Receptor Antagonist Lim et al. (2008) 
SHH 1 µg∙ml
-1
 Sonic Receptor Agonist Chen et al. (2012) (used 0.1 mg∙ml
-1
) 
Cyclopamine 30 µM SMO receptor Antagonist Yauch et al. (2008) 
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The drug treatment was given on the day the medium on the PBECs was changed and 
all drug treatments were administered with either DMSO, dH20 or PBS vehicle (where 
the final concentration of vehicle was ≤1%) in the final medium. 
 
3.6 Monitoring trans-endothelial electrical resistance (TEER) 
 
The resistance (Ω) of the PBECs that had been grown on Transwells was measured 
using an STX100 probe and EVOM volt-ohmmeter, where a jig was used to dock the 
chopsticks during the measurement in order to ensure that the chopstick was inserted 
at the same point and distance from filter for all Transwells. The resistance of a blank 
Transwell filter (without any cells) was also measured, and this was subtracted from the 
resistance of the PBECs on the Transwells. TEER was then expressed as Ω∙cm2. 
 
3.7 Viability assay 
 
To determine the viability of cells, an MTT viability assay was used. 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)  is a yellow organic 
heterocyclic compound that can be reduced enzymatically to an insoluble purple salt. 
The assay is based on the reduction of MTT to an insoluble purple tetrazolium salt by 
dehydrogenases (mainly mitochondrial succinate dehydrogenase) in live cells, where a 
colour change (yellow to purple) is measured in terms of absorbance. 
All cells were washed with PBS prior to the addition of (100 μl) 1 mg∙ml-1 MTT in 
DMEM without phenol red (Invitrogen 1188028), and incubated at 37˚C in 5% CO2 for 4 
hours. The medium was then removed and the crystals that had formed were dissolved 
in 100 μl isopropanol for 10 minutes. The plate was then shaken and read at 560 nm 
using Labsystems Multiscan Ascent plate reader and viability was measured as the 
levels of absorbance. 
 
3.8 Activity assays 
 
Activity assays were used to determine the uptake and efflux activity of PBECs as 
detailed below. 
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3.8.1 Uptake assay  
 
An uptake assay was used to assess the uptake of 3H-1-methyl-4-phenylpyridinium 
(3H-MPP+) by PBECs. MPP+ is a common substrate for Pgp, BCRP and the MRPs 
(Unpublished work by the BBB group 2008).  
Unless stated otherwise steps were conducted at 37˚ C. 
Confluent PBECs in 96-well plates were incubated with 200 µl 3H-MPP+ Buffer 
consisting of 27.55 KBq∙ml-1 of 3H-MPP+ (Perkin Elmer) in Assay Buffer (25 mM 
HEPES, 0.1% BSA in HBSS, pH 7.35) and 14C-sucrose 5.55 KBq∙ml-1 (Movarek 
Biosciences) for either 30 minutes, 1 hour or 4 hours. 14C-sucrose was used as an 
extracellular space marker, since it is not taken up by the PBECs. After the incubation 
time, the 3H-MPP+ buffer was removed and the cells were washed with PBS (4°C).   
To determine the amount of 3H-MPP+ taken up, the cells were then lysed for 1 hour in 
Assay Lysis Buffer (1% Triton X-100 in dH20). From the lysate 100 µl was mixed with 
3.5 ml of Scintillation Fluid (Ultima Gold, Perkin Elmer)  and counted for 3H and 14C 
signals using 1219 RackBeta Liquid Scintillation counter (LKB Wallac), while another 
100 µl of the lysate was removed for BCA Analysis (see Section 2.9.1).  
Alternatively, to determined the viability of the cells after exposure, after washing cells 






 efflux assay – 24 well plate  
 
The efflux of 3H-MPP+ from the PBECs was then assessed using a 3H-MPP+ Efflux 
Assay in a 24-Well plate format. Since MPP+ is a common substrate for Pgp, BCRP 
and MRPs, it was used as a tool to assay the activity of these efflux transporters. The 
assay involves an initial loading stage (where 3H-MPP+ is taken up by the PBECs) and 
a secondary efflux stage (where efflux of 3H-MPP+ from inside the PBECs and into an 
extracellular buffer is directly measured). In the presence of  an ABC transporter 
inhibitor the  efflux of 3H-MPP+ should be lower than in the absence of the inhibitor (if 
the ABC transporter is present and acting to efflux the 3H-MPP+). Therefore, the 
inhibitable level of 3H-MPP+ efflux is a measure of ABC transporter activity. 
Unless stated otherwise steps were conducted at 37˚ C. 
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Confluent PBECs in 24 well plates were preloaded with 3H-MPP+ by incubating the 
cells for 60 minutes  with  Assay Buffer A (25 mM HEPES in HBSS, pH 7.35, 0.1% 
BSA) containing 3H-MPP+ (27.75 KBq∙ml-1) and 14C-sucrose (5.55 KBq∙ml-1). 14C-
sucrose was used as an extracellular space marker in this assay, since it does not 
enter the cells. 
 
After the hour, the buffer was removed and the cells were washed with PBS (4°C). 
Non-radioactive Assay Buffer A with vehicle control (DMSO or methanol) or with ABC 
transporter inhibitors was then added to the loaded cells.  
 
The ABC transporter inhibitors used were haloperidol and verapamil (Pgp inhibitor/ 
substrate) (Matsson et al., 2009), Ko143 and prazosin (BCRP inhibitor/substrate) 
(Matsson et al., 2009) and MK571 (inhibitor to all MRP transporters) (Weksler et al., 
2005, Poller et al., 2008, Matsson et al., 2009, Cioni et al., 2012). 
  
The cells were incubated in the buffer for between 30 seconds and 35 minutes. The 
buffer was then removed and kept as the Extracellular Efflux Sample. The cells were 
then lysed with 1% Triton-X-100 for 45 minutes and the lysate was collected as the 
Intracellular Retention Sample. 
 
The Extracellular Efflux Sample and Intracellular Retention Sample were then mixed 
with 3.5 ml Ultima Gold Scintillation Fluid (Perkin Elmer) and counted for the amount of 




3.8.3 3H-MPP+ efflux assay – 12- well Transwells  
 
The 3H-MPP+ Efflux Assay was also conducted in a Transwell format, to assess 
polarised efflux activity of the ABC Transporters. The assay in this format varies from 
the 24-well format, so details are given separately. 
Unless stated otherwise steps were conducted at 37˚ C. 
Confluent PBECs on Transwells were first loaded with 3H-MPP+ by incubating the cells 
for 60 minutes  with  Assay Buffer A containing 3H-MPP+ (27.75 KBq∙ml-1) only, with the 
buffer added to both the apical (0.5 ml in the Transwell) and basal (1 ml surrounding 
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the Transwell) chambers. After the incubation both chambers were washed with PBS 
(4˚C) and the cells were then incubated with Assay Buffer A containing 0.185 KBq∙ml-1 
14C-sucrose in the apical chamber (0.5 ml) and Assay Buffer A without any radioactivity 
in the basal chamber (1 ml), for 30 seconds to 35 minutes. In this assay 14C-sucrose 
was used as a paracellular transport marker to assess the integrity of the PBEC 
monolayer. Since 14C-sucrose cannot cross the cells directly, any 14C-sucrose transport 
from the apical chamber to the basal chamber must occur via the paracellular route.  
After the incubation time, the Apical buffer was removed and kept as the Apical Efflux 
Sample and the Basal Buffer was removed and kept as the Basal Efflux Sample. The 
cells were then lysed in 1% Triton-X-100 (0.5 ml apically and 1 ml basally) for 45 
minutes and the lysate (apical and basal lysates pooled) was collected as the 
Intracellular Retention Sample  
 
All samples were mixed with 3.5 ml of Scintillation Fluid and counted for amount of 3H 
and 14C within each samples using a 1219 RackBeta Liquid Scintillation counter (LKB 
Wallac). 
 
3.8.4 Hoechst 33342 uptake assay 
 
The Hoechst 33342 Assay was used to determine the efflux activity of PBECs grown in 
96-well plates. 
Hoechst is a nucleotide-binding dye that upon binding to DNA becomes fluorescent. It 
enters cells by diffusion across the cell surface membrane (Zhang et al., 1999). 
However, Hoechst is a substrate for the ABC efflux transporters, Pgp (Shapiro et al., 
1997, Tang et al., 2004) and BCRP (von Wedel-Parlow et al., 2009). Therefore, the 
uptake of Hoechst is retarded by the presence of ABC transporters with the level of 
retardation in uptake being proportional to the efflux activity of the transporters. 
Inhibition of an efflux transporter should result in less dye being actively effluxed (than 
in the absence of inhibitor) and therefore more of the dye can reach and bind to DNA 
within the cells.  
 
Unless stated otherwise steps were conducted at 37˚ C 
PBECs grown in 96 well plates were incubated for 1 hour with a Preincubation Buffer 
consisting of 25 mM HEPES, in HBSS, pH 7.35, 0.1% BSA with vehicle control 
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(DMSO) or with inhibitor (0.2 µM Ko143 or 60 µM Haloperidol).  The Preincubation 
Buffer was removed and the cells were incubated with Hoechst Assay Buffer (25 mM 
HEPES, in HBSS, pH 7.35, 0.1% BSA with 10 µM Hoechst 33342).  
 
The Hoechst Assay buffer was left on the cells for 1 hour, the cells were then washed 
with PBS (4˚C) and the cells were analysed with a Bio-Tek Synergy HT plate reader at 
360 nm excitation and 460 nm emission wavelengths to give Relative Fluorescence 
Units (RFUs) per well. 
 
The method was adapted from von Wedel-Parlow et al, 2009, where all conditions 
apart from the inhibitors used were maintained as published previously. 
 
The cells were then lysed for 45 minutes with 1% Triton-X-100 and the protein content 
of the lysate was measured in µg with a BCA assay (see section 2.9.1).  
 
Results were then expressed as RFUs/µg protein in a well. 
 
 
3.9 Expression studies 
 
3.9.1 BCA Assay  
 
The Pierce protein assay was used to quantify proteins. The assay is based on the 
reduction of Cu2+ to Cu1+ by protein (in an alkaline environment), where Cu1+ reacts 
with bicinchoninic acid (BCA) in a colourimetric reaction that can be measured in terms 
of absorbance. The BCA assay was conducted according to the Pierce Kit instructions 
to measure total cellular protein levels. Protein samples (e.g. 100 µl of cell lysate) were 
incubated at 37°C for 30 minutes with equal volumes of Pierce Reagent Mix (a mixture 
of Reagents A and B in a 50:1 ratio, respectively), before absorbance readings were 
measured at 540 nm in Labsystems Multiscan Ascent plate reader.  
BSA protein standards of known concentrations were measured alongside protein 
samples, to construct a calibration curve of absorbance against protein concentration, 
from which the absorbance measured with a sample of unknown protein concentration, 
could be used to determine the protein concentration within the sample. 
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3.9.2 mRNA expression 
 
RNA was isolated at different stages of the PBEC culturing process for analysis.  The 
cell culture process involves the growing endothelial cells out from capillaries isolated 
from pig brain (See Section 2.4). Therefore the RNA from capillaries was initially 
isolated at cell culture day 0 (Day 0 Samples). The capillaries were grown for 3 days in 
puromycin, with RNA isolated after these 3 days (Day 3 Samples). Puromycin was then 
removed from the medium and 3 days later the cells were passaged to the Transwells 
with RNA isolated on the Day of Passaging. 
The PBECs were passaged and grown in 6 well Transwells either alone (i.e. in mono-
culture) or in co-culture with normal rat astrocytes.  Once on the Transwell, the PBECs 
were grown to confluence which occurred in 3 days, and RNA was isolated from the 
confluent PBECs (3 Days Co-culture Samples). In addition, the confluent PBECs were 
incubated for 24 hours in PBEC serum-free medium containing 250 µM CPT-cAMP and 
17.5 µM RO-20-1724 and RNA was isolated after these 24 hours (4 Days in Co-culture 
Sample).  
RNA isolation was conducted using TRI (Total RNA Isolation) Reagent® (Sigma). The 
PBECs were lysed for 5 minutes in 450 µl – 1000 µl of TRI. BCP (1-bromo-3-
chloropropane) was then added; 100 µl per 1 ml of TRI solution, and the solution was 
mixed and then incubated at room temperature for 15 minutes. The mixture was then 
centrifuged at 12000 x g for 15 minutes (4˚C). The aqueous phase of the mixture 
(containing the RNA) was then removed to a fresh tube for further processing. The 
interphase and organic phases were then processed separately for Protein Isolation 
(see section 2.9.3) 
Isopropanol was added to the aqueous phase, 500 µl for 1 ml TRI solution initially 
used, and vortexed for 10 second. The mixture was incubated at room temperature for 
10 minutes and then centrifuged at 12000 x g for 8-15 minutes (4˚C) until a white 
precipitate of RNA was formed. The RNA pellet was washed with 75% ethanol (1 ml 
per 1 ml of TRI solution) and centrifuged at 7500 x g for 5 minutes (4˚C). The ethanol 
was discarded and the pellet was air-dried for 3-5 minutes. The pellet was 
resuspended in dH20 and the RNA was stored at -80˚C. 
The RNA isolated was purified using the miniElute Clean Up kit (Qiagen) with the 
RNase-free DNase Set. RNA samples (45 µg or less) were each combined with 10 µl 
RDR buffer, 2.5 µl DNase I stock and made up to 100 µl with dH2O. The mixture was 
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incubated at room temperature for 10 minutes, then mixed with 350 µl of RLT buffer 
and 250 µl ethanol. The mixture was placed on a miniElute column and centrifuged for 
15 seconds using Heraeus Biofuge Pico centrifuge (max speed). 500 µl RPE buffer 
was then added to the column and the column was re-centrifuged for 15 second. Then 
500 µl 80% ethanol was added to the column and the column was centrifuged for 2 
minutes. The column was then left to dry (for 5 minutes) and 14µl -100µl of dH20 was 
used to elute the RNA from within the column.  
The RNA was quality checked using the Aligen RNA 6000 Pico Kit. To a Pico 
Microchip, 1 µl of RNA was added per well (for a total of 9 wells/ 9 samples per chip) 
containing the RNA ladder. The chip was then analysed with the Bioanalyzer 2100 and 
Software Version 2.6 and RNA purity measurements given a number of 1-10 (10 being 
the purest). RNA sample of ≥ 7 were considered of good quality for PCR work.  
A 2 step RT-QPCR reaction was conducted on purified and high quality RNA. Step 1, 
the RNA was converted to cDNA, Step 2, QCPR analysis was conducted on the cDNA. 
To convert the RNA into cDNA the TaqMan® Reverse Transcription Reagents were 
used (Life Technologies). 
Each RNA sample underwent the DNase Reaction, where per 10 µl reaction, 100 ng 
RNA was combined with 1 µl X10 Reaction buffer, 2.2 µl 25 mM MgCl2, 2 µl 
deoxyNTPs, 0.5 µl Random Hexamers, 0.2 µl RNase Inhibitor 0.25 µl MultiScript 
DNase enzyme and volumes were made up to 10 µl using dH20. For each sample, a 
negative reaction was also run, where no MultiScript was used. 
The reaction mix was then thermo cycled using a robocycler (25˚C for 10 minutes, 
48˚C for 30 minutes, 95˚C for 5 minutes then held at 4˚C). 
The cDNA was then used in the second step for the PCR reaction. For the PCR 
reactions, a Pooled Standard Sample was created as a positive control, by pooling 
~20% of the cDNA from each sample.  The cDNA samples were then diluted in a 1 in 4 
ratio with dH20 for the next step. 
For the PCR reaction, 4 µl (~10ng) of the diluted cDNA was combined with 1 µl 
TaqMan Probes per 20 µl reaction and 10 µl TaqMan® Fast Universal PCR Master Mix 
(2✕), No AmpErase® UNG to give a final concentration of X1 (5 µl water was used to 
make up the solution to the final volume). The following probes were used 
Ss03373435_m1 (MDR1) (for Pgp), Ss03393456_u1 (ABCG2) (for BCRP), 
Ss03376563_uH (ACTB) (for β-actin), Ss03373286_u1 (GAPDH) (for GAPDH), with all 
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probes obtained from Life Technologies (details of probes can be found in the  
Appendix, Section 9.4, however exact probe sequences were not disclosed by the 
company). 
Reactions were run on MicroAmp Fast 96-Well Plates, 0.1 ml, in duplicates or 
triplicates per plate, for all samples except the negative control (where no MultiScript 
had been added) which was a single well per sample on the plate. Alternatively, 
reactions were scaled down to 10 µl and run on 394 well plates (MicroAmp) by Matt 
Arno (Genomics Center, KCL) with all reactions in quadruplicate.  
A standard curve and blank controls (of water) were also run in duplicates per plate. 
The standard curve was made from the serial dilution of the Pooled Standard Sample 
(mentioned above). 
All reactions were then run on the 7900HT Fast Real-Time PCR System and software 
using default setting of 20 seconds at 95˚C, then 40 cycles of 1 second 95˚C and 20 
seconds 60˚C. The cycle of threshold (Ct) values were then analysed (see calculations 
section 2.10.5). 
 
3.9.3 Isolation of protein from PBECs and western blotting  
(see Appendix for results) 
 
Organic/interphase samples obtained from section 2.9.2 were processed to isolate the 
total cellular protein. Per 1 ml of TRI solution used in the initial isolation, 300 µl of 100% 
ethanol was added and the samples were mixed by inversion and incubated at room 
temperature for 3 minutes. The samples were then centrifuged at 2000 x g for 5 
minutes (4˚C) and the supernatant (containing the protein) was then further processed. 
Acetone was added to the supernatant to precipitate the protein (X3 volumes of 
acetone were added to X1 the volume of the supernatant) and the samples were 
incubated at room temperature for 10 minutes. The samples were centrifuged and the 
supernatant discarded. The protein pellet was washed with 1 ml of Protein Wash 1 
(300 mM guanidine hydrochloride in 95% ethanol, with 2.5% glycerol). The samples 
were centrifuged after incubation with the protein wash for 10 minutes at room 
temperature. Centrifugation was at 8000 X g for 5 minute (4˚C). The protein was 
washed twice more with Protein wash 1 then once with Protein Wash 2 (100% ethanol 
containing 2.5% glycerol). The pellets were resuspended in 1% Triton-X-100, 6 M urea 
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containing EDTA-free protease inhibitor cocktail (Rouche) and protein samples were 
stored at -80˚C. 
Isolated Protein then underwent SDS-PAGE. For SDS-PAGE, polyacrilamide gels were 
made to 0.75 mm thickness. The resolving portion of the gel was made using 8% 
Acrylamide/Bis (BioRad), 375 mM Tris-HCl pH 8.8, 0.1% SDS, 0.1% APS, 0.06% 
TEMED (GE Healthcare). The stacking portion of the gel was made with 4% 
Acrylamide/Bis (BioRad),  375 mM Tris-HCl pH 6.8, 0.1% SDS, 0.05% APS, 0.1% 
TEMED).  
The protein samples (7.5 µg – 100 µg) were prepared, by mixing protein with X5 
Sample Dye (62.5 mM Tris-HCl pH6.8, 10% Glycerol, 2% SDS, 5% β-mercaptoethanol, 
0.025% bromophenol Blue) so that the final concentration of the dye was X1. The 
samples were then heated at 95˚C for 10 minutes, centrifuged (pulse spun for 10 
seconds) and allowed to cool at room temperature for 1 minutes. The cooled samples 
were loaded onto the gel with 5 µl SeeBluePlus2 (Invitrogen) ladder and/or 5 µl 
MagicMark (Invitrogen) ladder and ran at 120 Volts for 1 hour in Tris-Glycine Running 
Buffer (240 mM Tris, 190 mM Glycine, 0.1% SDS, pH 8.3) 
The gel was transferred onto a PVDF membrane (Millipore, 0.45 µm pore) using the 
Novex Semi Dry Western Blotting System (Invitrogen). A sandwich was made 
composed of one 2.5 mm Filter Paper (Invitrogen) soaked in Transfer Buffer (25 mM 
Tris, 190 mM glycine, 10% methanol, pH 8.5 or 10 mM NaHCO3, 3 mM NaCO3, 20% 
methanol pH 9.9) , followed by the PVDF membrane (that had been soaked in 100% 
methanol for 5 minutes), then the SDS-gel, then a final 2.5mm filter paper soaked in 
Transfer Buffer (25 mM Tris, 190 mM glycine, 10% methanol, pH 8.5 or 10 mM 
NaHCO3, 3 mM NaCO3, 0.1% SDS, pH 9.9). The sandwich was then transferred for 30-
75 minutes at 20 Volts.   
The PVDF membrane was then placed in Blocking Buffer (20mM Tris-HCl, 137mM 
NaCl, 0.1% Tween 20 (Fisher Scientific) and 5% milk powder (Marvel), pH 7.6) for 1 
hour at 4˚C. The membrane was then incubated with primary antibodies in Antibody 
Diluent Buffer (0.5% BSA in PBS, pH 7.4) overnight at 4˚C.  
The antibodies used include BXP-21 (mouse IgG2A, 1:200 dilution) (Calbiochem), 
C219 (mouse IgG2A, 0.25 µg∙ml-1 dilution) (Calbiochem) and C11 (goat IgG, 1:1000 
dilution) (Santa Cruz). 
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The membrane was then washed in PBST (PBS+0.1% Tween 20) 3 times (15 minutes 
each wash) and the washed membrane was incubated with secondary antibodies in 
Antibody Diluent Buffer overnight at 4˚C.  
The secondary antibodies used include Goat, anti-mouse IgG2A HRP (1:1000 dilution) 
(GeneTex) and Donkey, Anti-goat IgG HRP (1:1000 dilution) (Alpha Diagnostics). 
The membrane was washed 3 times with PBST as before and then washed with a final 
30 minute wash in PBS. 
The membrane was then incubated in a 50:50 solution of West Dura Pico Kit (Pierce) 
for 1 minute and visualised using Syngene Imager and software.  
 
3.9.4 Confocal microscopy 
 
Wax embedded slides of normal brain tissue, Grade I and Grade II astrocytomas 
obtained from US Biomax or Biochain or were either a gift from Dr. Marios 
Papadopoulous (St. George‘s Hospital).  
Slides were dewaxed and prepared for staining as follows: Slides were placed in 100% 
xylene for 5 minutes and repeated with fresh xylene. This was followed by 3 minutes in 
100% ethanol that was repeated with fresh ethanol.  The slides were then placed for 3 
minutes in 70% ethanol and then under running water for 2 minutes.  The slides were 
then incubated in 3% H2O2 for 15 minutes and then placed in running water for 10 
minutes. The slides were then incubated with 1% Antigen Unmasking Solution (Vector 
Laboratories) in dH20 and microwaved (full power for 15 minutes). The slides were left 
to cool for 20 minutes at room temperature and then underwent staining.  
The primary antibodies used included BXP-21 (anti-BCRP, mouse IgG2A), JSB-1 (anti-
Pgp, mouse IgG1) (GeneTex GTX23366), anti-von Willebrand factor (VWF) (Rabbit 
IgG1) (Millipore AB7356) and anti-CD34 (Rabbit IgG1) (GeneTex GTX61737). Antibody 
dilutions were made using Antibody Diluent (Dako) (1:200 BXP-21, 1:40, 1:200 JSB-1, 
1:100 anti VWF or 1:100 anti-CD34) and dilutions were added to slides. Slides were 
then placed at 4˚C overnight, then washed 3 times (5 minutes a wash) with X1 PBST 
(made from X10 stock from Dako) 
Alexa Fluor secondary antibodies were used (Invitrogen) and diluted in Antibody 
Diluent. Red-Alexa Fluor-546 (against mouse IgG2A – BCRP, 1:80 dilution), Green –
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Alexa Fluor-488 (against mouse IgG1-Pgp 1:100 dilution) and Far Red-Cy5 (against 
Rabbit IgG1- VWF or CD34, 1:50 dilution). The secondary antibodies were added to 
the slides and left to incubate for 3 hours at room temperature in the dark. The slides 
where then washed 3 times in 1X PBST (5 minutes each wash) and then rinsed with 
dH20. VECTASHIELD DAPI mounting medium (Vector Laboratories) was then added 
and coverslips were placed onto the slides. 
Images were taken with either the Leica SP8vis microscope (UCL Confocal Imaging 
Unit) taking 290 µm² images in z-stacks (0.5 micron step size) using an 40X objective 
(oil immersion) or Nikon Diaphot DTM Microscope (Paul Fraser, KCL) single images 
using 40X objective (water immersion).  
With the Leica SP8vis, sequential imaging was conducted first assessing DAPI and 
BCRP, then assessing Pgp and VWF or CD34, so as to avoid bleed through.  




3.10.1 Uptake of 3H-MPP+ into PBECs in plates 
 
The uptake of 3H-MPP+ into PBECs grown in 96-well plates was calculated as the 
Volume of Distribution (Vd). This is the volume that the 3H-MPP+ would occupy (within 
the cells) if it reached the same concentration in the cell as in the medium.  
All samples were corrected for background radioactivity (in blank samples) before 
calculations, with blank/background radioactivity measured as the DPMs in the non-
radioactive assay buffer (for efflux samples) or 1 % Triton-X 100 lysis buffer (for 
intracellular retention samples).  
Equation 1 was used to determine the Vd of 3H-MPP+ within cells, correcting for the Vd 
of the extracellular marker 14C sucrose. Here 14C-Sucrose was used as a marker for 
extracellular space, since it does not enter the cells and therefore any 14C-Sucrose 
detected would only be present in the extracellular space at the end of the experiment. 
The corrected Vd was then divided by the protein content of a well (i.e. the total protein 
in a well measured using a BCA assay).  
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Equation 1: Volume of distribution (Vd) 
 
 
NB.  All samples were taken from the same well.  
 








 detected intracellularly (within the lysate of a well) at the end 
of the experiment  
14
C I = The total dpms of 
14
C-Sucrose detected in the same lysate sample as 
3
H I  
3






 at the beginning of the experiment
 
14




C-Sucrose at the beginning of the experiment 
 
Tot Prot = Total protein in mg (in the well from which 
3
H I was measured) 
 
3.10.2 Calculations for 3H-MPP+ efflux assay in 24 Well plate format 
 
To calculate the Total 3H-MPP+ Loaded into PBECs during a 3H-MPP+ Efflux Assay 
using either 24-Well plate format or Transwell format, firstly samples were corrected for 
14C-sucrose. 
For the 24-Well format, 14C-Sucrose was used as an extracellular space marker; the 
extracellular efflux samples and intracellular retention samples (lysates) were corrected 
for 14C-sucrose using Equation 2. 
 









 detected within the sample 
14
C S = The total dpms of 
14
C-Sucrose detected within the sample  
3




added at the beginning of the experiment (in the Loading 
Buffer) 
14
C To = The total dpms of 
14
C-Sucrose added at the beginning of the experiment (in the 
Loading Buffer) 
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The Total 3H-MPP+ Loaded for 24-Well Efflux assay was then calculated as the sum of 
the corrected 3H-MPP+ in the Extracellular efflux Sample and the corrected 3H-MPP+ in 
the Intracellular sample (lysate) per well (Equation 3).  
 




 Loaded   
 
 








 loaded into PBECs per well.  
Corrected 
3




 in the Extracellular Efflux Sample after correction for 
14
C-
sucrose (with Eq 2.)  
Corrected
 3




 detected Intracellularly (within the lysate) after correction for 
14
C-
sucrose (with Eq.2).  
 
The Total 3H-MPP+ Loaded was then used to calculate the percentage of 3H-MPP+ 
effluxed, as shown in Equation 4. 
 









 loaded into PBECs per well (calculated using Eq 3).  
Corrected 
3




 in the Extracellular Efflux Sample after correction for 
14
C-
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WORKED EXAMPLE (From haloperidol dose-response curve) 
NB. All samples have been corrected for blank 
Extracellular Efflux sample = 2118 3H dpms, 3 14C dpms 
Intracellular lysate sample = 2046 
3
H dpms, 0 
14
C dpms 
Initial amount of 3H added (3H To) = 1465200 dpms 
Initial amount of 14C added (14C To) = 144400 dpms 
 
Step 1. Correction for 14C-Sucrose 
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3.10.3 Calculation for PBECs on Transwells 
 
In the Transwell experiments 14C-sucrose was used as a paracellular permeation 
marker. Since it does not enter endothelial cells, the only way for 14C-sucrose to cross 
from the Apical Chamber to the Basal Chamber of the Transwells is via the paracellular 
route. Therefore its flux can be used as a measure of the paracellular flux/ leakiness of 
a monolayer. The apparent permeability (Papp) of 14C-sucrose (i.e. the leakiness of the 
monolayer) was calculated in some cases using Equation 5 (Avdeef, 2011).  
 
Equation 5 : Apparent Permeability (Papp) 
Papp (cm.s
-1
) = dQ/(dT x A X Co) 
dQ = transported amount (dpms in Basal Chamber)  
dT = time (seconds) 
A = surface area of filter (in cm)  




For calculations concerning the efflux of 3H-MPP+, the Intracellular Retention Samples 
obtained from the 3H-MPP+ Assay in the Transwell format were corrected for 14C-
Sucrose using Equations 6 and 7. Firstly the percentage of 14C-sucrose in the 
Intracellular Retention Samples was calculated using Equation 6. Secondly, this was 
then used to correct the 3H-MPP+ Intracellular Retention Sample against 14C-sucrose 
using Equation 7.  
The total 3H-MPP+ Loaded was then calculated as the sum of the 3H-MPP+ measured 
in the Apical plus Basal Efflux Samples, together with the 14C-Sucrose corrected 
Intracellular Retention Sample (as shown in Equation 8).  
For the efflux percentage calculations, the Apical and Basal Samples were expressed 
as a percentage of the Total 3H-MPP+ Loaded in the PBECs (Equation 4). 
To convert the Total 3H-MPP+ Loaded into mol, Total 3H-MPP+ Loaded was expressed 
as a percentage of the 3H-MPP+ dpm in the Loading Buffer where 1.5 ml of 3H-MPP+ 
Loading Buffer was added per Transwell at a concentration of 9 nM 3H-MPP+ i.e. a total 
of 13.5 pmol was added per Transwell.  
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Equation 6:  
14
C-Sucrose in Intracellular Retention Sample 
 
NB. All samples were collected from the same Transwell  
 
14
C I = The total 
14
C dpms in the Intracellular Rentention Sample (i.e. in the Lysate Sample)  
14
C B = The total 
14
C dpms in the Basal Chamber (i.e. in the Basal Efflux Sample)  
14
C A = The total 
14
C dpms in the Apical Chamber (i.e. in the Apical Efflux Sample)  
 
Equation 7: Correction for 
14
C-sucrose in Intracellular Retention Sample  
 















H I= The total 
3
H dpms in the Intracellular Retention Sample (i.e. in the lysae sample)  
% 14C = the percentage of 14C-sucrose within the lysate sample (measured using Eq.6) 
 




 Loaded per Transwell  
 
 








dpms in the Basal Efflux Sample  
 
3
H A= The total 
3
H dpms in the Apical Chamber (i.e. in the Apical Efflux Sample)  
Corr  
3




dpms in the Intracellular Retention Sample after correction for 
14
C-Sucrose (calculated using Eq 7). 
 
  




WORKED EXAMPLE (Mono-culture, 35 minute efflux, no inhibitor) 
Basal Efflux Sample = 5444 3H dpms, 2191 14C dpms 
Apical Efflux Sample = 2516 3H dpms, 4022 14C dpms 
Intracellular Sample (Lysate) = 3352 3H dpms, 92 14C dpms 
Initial 14C = 6644 dpms (total dpms) 
Initial 3H = 5,355,000 dpms (total dpms) = 13.5 pmol 
 
 









       = 1.45 % 
=3303 dpms 





















= 2516 + 5444 + 3303 
= 11263 dpms 
 
• % Efflux calculations   II.   fmol loaded calculations  
= 22.3 % 
 
= 48.3 % 
Where 0.210% of 13.5 pmol (total mol in         
loading buffer) is 0.0284 pmol  
                                   OR  
                                   28.4 fmol 
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3.10.4 Calculation of inhibitable Hoechst 33342 uptake 
 
To calculate the inhibitable Hoechst 33342 Uptake, was a 2 Step Process. 
 
Step 1:  Calculating the Inhibitable Uptake (Inh U) 
 
InhU = Inh – no Inh 
 
Inh = Uptake in the presence of inhibitor (RFU/µg protein)  
No Inh = Uptake in the absence of inhibitor (RFU/µg protein)  
 





Baseline= Uptake in the absence of any drug treatment and in the absence of any 
inhibitor (RFU/µg protein) 
 
 
3.10.5 Calculations for mRNA levels 
 
To calculate the fold change of the Gene of interest was a 3 step process. 
 
Step 1: First the ΔCt for a gene of interest (GOI) was calculated as follows from the 
cycle of threshold (Ct) values of the PCR reaction: 
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ΔCt GOI  = CtGOI – CtRef G 
CTRef G = The CT of the reference gene (in the Same Sample)  
 
Step 2: The ΔΔCt of the GOI was then calculated using the ΔCt as follows: 
ΔΔCtGOI = ΔCtGOI – ΔCtRef S 
 ΔCTRef S = The ΔCt of reference sample (i.e. mono-culture sample)  
 
Step 3: The fold change of the GOI was then was calculated as follows: 
n-fold change  = 2- ΔΔCt  
 
3.10.6 Calculation from confocal imaging 
 
In an image, CD34-positive pixels were initially isolated (Image Hopper Software), 
where only CD34-positive vessels less than 7 µm width were analysed (size 
determined using ImageJ Software). The intensity of Pgp or BCRP signal in the CD34-
positive pixels was then measured across all images in a z-stack. The data were then 
pooled and expressed as a histogram using Image Hopper Software. The area under 
the curve (AUC) was calculated and divided by the number of pixels analysed to give 




All statistics was conducted using Graph Pad Prism 5 Software. 
For comparisons of 2 data sets, t-tests were conducted (e.g. between no inhibitor 
(vehicle control) and inhibitor data sets).  
For comparisons of 3 or more data sets, 1-way ANOVA analysis was conducted. If the 
ANOVA analysis showed p<0.05 significance the data sets were then compared using 
post-hoc tests. For comparisons of 3 data sets a Newman-Keuls Multiple Comparison 
Test was then used. However, the Newman-Keuls Multiple Comparison Test is not 
appropriate for comparisons of more than 3 data sets (Graph Pad Prism Guidelines), 
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therefore for comparison of 4 or more data sets the Tukey's Multiple Comparison Test 
was used. 
 




4 In vitro BBB Models  
 
4.1  Results  
In this chapter, cell culture systems were modified to allow study of efflux transporter 
activity in normal BBB endothelial cells and assessed to determine their suitability for 
later use during co-culture with glioma cells. Primary porcine brain endothelial cells 
(PBECs) were used as an in vitro cell model of the blood-brain barrier (BBB). These 
cells have been shown to have high transendothelial electrical resistance (TEER) 
(Cohen-Kashi Malina et al., 2009, Patabendige et al., 2013a, Patabendige et al., 
2013b) and a similar expression pattern of efflux transporters to the human BBB, thus 
making them a good BBB model (Warren et al., 2009). To study the ABC transport 
activity within PBECs, 3H-MPP+ was used. MPP+ was previously shown to be a  
substrate for Pgp, with MPP+ flux across Caco-2 cells increasing in the apical to basal 
direction and decreasing in the basal to apical direction in the presence of the Pgp 
inhibitor Cyclosporin A (Bleasby et al., 2000). In a different study, MPP+ uptake into 
MDCK cells was increased by the Pgp/BCRP inhibitor PMEO-DAPy (Mandikova et al., 
2013). Matsson et al., (2009) also showed that MPP+ can inhibit MRP2 substrate 
transport (ATP-dependent transport of estradiol-17β-glucuronide), indicating that MPP+ 
is either an inhibitor or competitive substrate of MRP2. This together with unpublished 
data by the BBB group at KCL (Patabendige, 2008) indicates that MPP+ is a common 
substrate of the main ABC transporters (i.e. Pgp, BCRP and MRPs). Using MPP+ as a 
substrate, a 3H-MPP+ efflux assay was developed that directly measures efflux from 
endothelial cells and polarised efflux from both the apical and basal surfaces can be 
assessed separately.  
4.1.1 Viability of PBECs after 3H-MPP+ incubation 
 
To determine whether 3H-MPP+ is toxic to PBECs, their viability was measured (using 
an MTT assay) after the cells had been exposed to 3H-MPP+ for up to 4 hours. No 
differences were seen in PBEC viability between those exposed to 3H-MPP+ and those 
not exposed (control conditions) (Figure 3.1). 
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The viability of the PBECs was measured using 
an MTT assay after the cells had been incubated 


















) alone (control) 
for up to 4 hours.  
The results are expressed as % control, with 
control results represented by the dotted line.   
Values are mean ± SEM of n=11-16 wells from 3 
different  plates  using 3 different batches of 
PBECs.  





4.1.2 Uptake of 3H-MPP+ into PBECs 
 
3H-MPP+ uptake was measured for up to 4 hours and the results showed an increase in 
the volume of distribution (Vd) of 3H-MPP+ between 30 minutes and 1 hour, but no 
further increase between 1 hour and 4 hours (Figure 3.2). This indicates that uptake of 
3H-MPP+ reaches steady-state/saturation within 1 hour and for further work, 1 hour 













 uptake by PBECs 
 












) for 30 minutes, 1 hour or 4 hours, 
with
14
C-sucrose as a marker for extracellular 
space. The cells were then washed and 







C-sucrose and the other half of 
used for protein content measurement using 
a BCA assay. 
Results are expressed as volume of 
distribution (Vd) in µl.mg
-1




Values are mean ± SEM of n=10-13 wells from 3 different plates using 3 different batches of 
PBECs. 
*p<0.05 significant difference between indicated conditions using 1-way ANOVA and Newman-
Keuls Multiple Comparison post test. 
 
4.1.3 Rate of 3H-MPP+ efflux by PBECs in plates 
 
PBECs in 24 well plates were loaded with 3H-MPP+ and then efflux from the loaded 
cells was measured between 30 seconds and 35 minutes.  
3H-MPP+ efflux is shown plotted against time in Figure 3.3, where efflux was shown to 
increase with time. There appeared to be more than 1 component to the rate of 3H-
MPP+ efflux, with the line plotted deviating from linear by 35 minutes of efflux.  The 
efflux half times t1/2s were calculated as 37 minutes (all data points) The initial rate 
could not have been release of non-specific binding since a thorough wash process 
was conducted prior to the efflux stage of the experiment and in addition, efflux was 
corrected for 14C-sucrose (extracellular space marker). In addition, non-specific binding 
analysis was conducted previously, which showed that no significant level of non-
specific binding of 3H-MPP+ occurred to the PBECs cell surface (see Appendix 9.1.2).  

























 efflux from PBECs in plates 










. The loaded cells were then incubated with efflux buffer 
for the times shown. The buffer was then collected, the cells  were lysed, and the buffer and 












 initially loaded into the cells (A). Results of non-linear regression analysis are shown in 
table.   
To calculate the efflux rate constant (K) the intracellular retention data were plotted on an Ln 
scale (B); the rate of efflux (over the 35 minutes) is shown by the solid line.  
A 
B 
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All data points collected are shown on the graph, where there are n=3 measurements for each 






 efflux from PBECs on Transwells 
 
To assess whether 3H-MPP+ efflux from PBECs is polarised, the 3H-MPP+ efflux assay 
was conducted on PBECs grown on Transwells. 
3H-MPP+ efflux from PBECs in mono-culture (PBECs-M) or in co-culture with rat 
astrocytes (PBECs-rAS) was assessed over time. Efflux into both the apical and basal 
chambers of the Transwells were measured between 30 seconds and 35 minutes, 
together with the intracellular retention of 3H-MPP+. 
The results (Figure 3.4) show  decreased intracellular 3H-MPP+ with time that begins to 
plateau within the first 12 minutes for the PBECs-M and PBECs-rAS (Figure 3.4 AIII 
and BIII). However, when the efflux to the apical and basal chambers were analysed 
separately, the results showed that for both the PBECs-M and PBECs-rAS, the apical 
efflux continued to increase after 12 minutes, whereas basal-directed efflux reached a 
plateau at 12 minutes (Figure 3.4 AI-AII and BI-BII). The apical linear correlation 
suggests an active process, while the plateau at the basal surface suggests an 
equilibrative process.  
The results showed faster efflux in the PBECs-rAS than PBECs-M, and the half time for 
total efflux were calculated as 55 minutes and 32 minutes for PBECs-M and PBECs-
rAS respectively (Figure 3.4 AIV and BIV). This was not due to greater 3H-MPP+ 
uptake, since the data was corrected for potential differences in uptake by being 
expressed as a percentage of the total 3H-MPP+ loaded per well. Therefore, increases 
in overall efflux rate may indicate increased efflux transporter activity in the PBECs-
rAS.  
 




Figure 3.4 Polarised efflux of 3H-MPP+ over time  
 
PBECs were grown on Transwell filters in either in mono-culture (PBECs-M, A) or in co-culture 
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. The loaded cells were then incubated with efflux buffer 
in both the apical and basal chambers of the Transwells for the times shown. The buffers were 




. The cell 




with correction for 
14
C-





 effluxed apically or basally, or retained intracellularly was then expressed as a 




 initially loaded into the cells. 
I)  Intracellular retention, II) Apical efflux, III) basal-directed efflux,  IV) Ln Intracellular retention 




 efflux (over 35 minutes) (shown 
by the solid line in IV). 
The graphs show all the data point collected from a total of 4 experiments together.  
 
To estimate the rates of efflux at the apical and basal surfaces, the efflux constant 
obtained from the percentage efflux in 35 minutes was divided by the estimated 
intracellular retention at 17.5 minutes (halfway through the 35 minutes) (extrapolared 
from the lines drawn in Figure 3.4 IV). The resulting rate constants are given in Table 
3.1, which show that there is no differences in the basal rates of 3H-MPP+ efflux 
between PBECs-M and PBECs-rAS, but a greater apical efflux rate of PBECs-rAS 
together with a greater overall rate (measured from the intracellular retention data). 
This suggests  that the greater rate of efflux in PBECs-rAS is as a result of greater 
apical efflux with no difference in basal efflux. 
This implies that the basal astrocytes are having an effect on the apical surface, but not 
on the basal surface. 
 
Table 3.1 Rates of efflux 
  Efflux rate constant K (min-1) 
  
Loss of total 
intracellular pool Apical Basal 
PBECs-M 0.013 ± 0.004 0.003± 0.001 0.010 ± 0.003 
PBECs-rAS 0.022 ± 0.003 * 0.011 ± 0.001 *** 0.011 ± 0.003 
*p <0.05, *** p<0.001 difference in 1-tailed unpaired t-test between PBECs-M and PBECs-rAS 
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To study the contribution of different efflux transporters to 3H-MPP+ efflux, efflux was 
assessed at a single time, using PBECs-M, PBECs-rAS and PBECs-hAS (PBECs 
grown in co-culture with human astrocytes).  
Before the start of the assay, the integrity of the PBECs‘ tight junctions (TJs) was  
assessed using transendothelial electrical resistance (TEER) measurements (Figure 
3.5), which showed a barrier was in place under all conditions with average TEER of ~ 
200Ω.cm2 or greater.  
 
Figure 3.5 TEER measurements of 
PBECs  
PBECs were grown on Transwells either 
alone in mono-culture (PBECs-M) or in 
non-contact co-culture with primary rat  
astrocytes (PBECs-rAS) or human 
astrocytes (PBECs-hAS).  
The chart shows the TEER 
measurements for the different cultures. 
For PBECs-M and PBECs-rAS, the cells  
were kept in serum-free medium for 1 day 
with TEER measured after this day. For 
the PBECs-hAS, the cells were kept in 
serum-free medium for 2 days prior to the 
assay and TEER measured on the 2nd 
day.   
* p<0.05, *** p<0.001 differences between indicated conditions using 1 -way ANOVA, Values are 
mean ± SEM of n=10-34 wells from 3-5 different plates.  
 
For the assay, the efflux time of 35 minutes was used since previous results indicated 
this to be the approximate apical t1/2 of 
3H-MPP+ efflux for PBECs-M (apical t1/2, total 
rate) (Table 3.1). 
Significant differences in 3H-MPP+ efflux were seen between the different PBEC 
conditions, with the greatest overall efflux shown by PBECs-rAS followed by the 
PBECs-M and finally by the PBECs-hAS (Figure 3.6C). There was a significant 
difference in apical efflux, with PBECs-rAS showing greater efflux than the other 2 
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models (Figure 3.6A). At the basal face PBECs-hAS showed lower basal-directed 
efflux than the other 2 models (Figure 3.6B).  
This indicates that basal astrocytes may exert effects on PBEC efflux capacity at both 
the apical and basal surfaces. 
 
 Figure 3.6 Efflux of 3H-MPP+ by PBECs on Transwells 
PBECs were grown on Transwells in mono-culture (PBECs-M) or co-culture with either rat 
astrocytes (PBECs-rAS) for a total of 4 days or in co-culture with human astrocytes (PBECs-




 efflux assays. 




. The loaded cells were then incubated with efflux buffer 
in both the apical and basal chambers of the Transwells for 35 minutes. The buffers were then 
collected separately and the cells were lysed. The buffers and lysate (intracellular sample) were 




 with correction for 
14















remaining int racellularly (from lysate analysis).
 
 
A) Apical efflux, B) basal -directed efflux, C) overall efflux  (the sum of the apical and basal 
efflux), D) intracellular retention.  
A B 
C D 
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Values are mean ± SEM of n=4-6 wells from 3-6 experiments using 3-4 different batches of 
PBECs. 
*p<0.05 **p<0.01, ***p<0.001 difference in 1 way ANOVA analysis and Newman -Keuls Multiple 
Comparison post test  
 
Differences in 3H-MPP+ loading between the different PBEC systems were assessed 
(Figure 3.7) with significant differences measured: The PBECs-rAS showed greater 
loading than the PBECs-hAS. 
 





PBECs were grown on Transwells in 
mono-culture (PBECs-M) or co-culture 
with either rat astrocytes (PBECs-rAS) 
for a total of 4 days or in co-culture with 
human astrocytes (PBECs-hAS) for 2 
days.  










loaded into the cells was analysed by 





with correction for 
14
C-sucrose and 
expressed as fmol/Transwell.  
Values are the mean ± SEM of n=10-34 
wells from 3-4 different plates.  
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Differences in TJ integrity were also shown, where both of the co-culture systems had 
greater TEERs, indicative of ―tighter‖ TJs, than the PBECs-M (Figure 3.5). This 
demonstrates that in addition to differences in uptake and efflux characteristics 
(above), the different PBEC models also differ at the tight-junction level.  
 
4.1.5 Effect of ABC transporter inhibitors on 3H-MPP+ efflux 
 
To determine whether 3H-MPP+ efflux was due to the activity of ABC transporters, ABC 
transporter inhibitors were added during the efflux phase of the assay.  
Haloperidol (specific non-competitive inhibitor) and verapamil (non-specific competitive 
substrate) were used to assess Pgp activity, while Ko143 (specific non-competitive 
inhibitor) and prazosin (non-specific competitive substrate) were used to assess BCRP 
activity (Weksler et al., 2005, Poller et al., 2008, Matsson et al., 2009, Cioni et al., 
2012).  
The efflux results (Figure 3.8) showed decreased efflux with increasing concentrations 
of inhibition. IC50 values were calculated as follows: haloperidol 52.48 ± 0.23 µM; 
verapamil 23.99 ± 0.04 µM, Ko143 0.21 ± 0.26 µM; and prazosin 37.77 ± 0.16 µM 
(Figure 3.8) (Raw inhibition data is shown in the Appendix Section 9.2). This 
demonstrated that efflux was at least in part due to the action of both Pgp and BCRP.  

















In vitro BBB Models   
88 
 




. The loaded cells were then 
incubated with efflux buffer with or without ABC inhibitors (0 – 300 µM) for 35 minutes. The 
inhibitors used were the Pgp inhibitors haloperidol (A I) and verapamil (A II), and the BCRP 
inhibitors Ko143 (A III) and prazosin (A IV).   
















 initially loaded into 
the cells. 
The data were normalised to the minimum and maximum efflux per inhibitor across all the 
concentrations tested, with the minimum efflux becoming 0% and the maximum efflux becoming 
100%.  
The values are shown as mean ± SEM of 3-5 wells where possible, or as single point when less 
than 3 wells were tested at the same concentration. Values are pooled from 3-5 plates.  
 
The dose-response data were also analysed by Lineweaver-Burk plots. The 
Lineweaver-Burk plots for all the inhibitors gave good linear correlation (r² > 0.7 for 
Ko143 (p<0.0001), r² > 0.8 for prazosin (p=0.0003), and r² > 0.9 for haloperidol 
(p<0.0001) and verapamil (p<0.0001) (Figure 3.9A), suggesting that, over the 
concentration ranges tested, the inhibitors were acting on a single binding site (i.e. a 
single transporter) or that inhibitors may be acting on multiple sites with the same 
affinity.  
Eadie-Hofstee plots were constructed in addition to Lineweaver-Burk plots. The Eadie-
Hofstee plots showed linear relationships for all inhibitors at the higher inhibitor 
concentrations tested, however at the lowest concentrations, where efflux inhibition 
was not seen  (see 3.8), the plot deviated from linear. The inhibitors used here have 
been previously assessed by Matsson et al., (2009) in a study examining the effects of 
ABC transporter inhibitors known to act on multiple transporters. Matsson et al., (2009) 
showed that prazosin had IC50s of 36 µM for BCRP and 240 µM for Pgp, with a low 
concentration of Prazosin having no significant effect on Pgp or MRP2 activity 
(Prazosin did not inhibit MRP2 at any concentration). Similarly, Haloperidol (Pgp IC50 
= 39 µM) did not result in inhibition of BCRP or MRP2 activity until concentrations 
reached greater than 100µM.  Ko143 (BCRP IC50 = 0.2 µM), did not affect Pgp or 
MRP2 activity even at concentrations greater than 1 µM, when BRCP inhibition was 
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maximal (Matsson et al., 2009). This demonstrates that at certain concentrations 
inhibitors may be transporter specific.  
In the current study, the Km values measured using the Lineweaver-Burk plots were 
similar to the IC50 values of the dose-response curves for haloperidol and Ko143 (58.9 
µM for Haloperidol and 0.12 µM for Ko143), but the competitive substrates verapamil 
and prazosin showed Km of approximately twice the IC50 values calculated (63.6 µM 
for prazosin and 66.4 µM for verapamil), which may be a reflection of substrate 
specificity.  Based on these results and similar results within the literature it was 
concluded that the best concentrations to use were as follows: 60 µM haloperidol, 50 
µM verapamil (Fricker et al., 2002), 0.2 µM Ko143 and 35 µM prazosin (Matsson et al., 
2009).  
  






















Figure 3.9 Kinetic analysis of dose-response data of ABC Inhibitors  





 efflux are shown in A I - IV.  







































To investigate the polarisation of transporters, 3H-MPP+ efflux was separately assessed 
apically and basally with ABC transporter inhibitors, using PBECs grown on Transwells 
(PBECs-M, PBECs-rAS and PBECs-hAS).  
In addition to haloperidol and verapamil (to assess Pgp activity), Ko143 and prazosin 
(to assess BCRP activity), the MK571 inhibitor, a non-specific inhibitor for the MRP 
family of efflux transporters, was used at a concentration of 10 µM to assess MRP 
activity (Weksler et al., 2005, Poller et al., 2008, Matsson et al., 2009, Cioni et al., 
2012). Due to the scarce availability of human astrocytes, only Ko143 was tested on 
the PBECs-hAS. 
For the PBECs-M and PBECs-rAS, the results showed inhibitable efflux (i.e. decreased 
efflux in the presence of inhibitors)  by one or both Pgp inhibitors (haloperidol and 
verapamil) and the BCRP inhibitor prazosin on the apical surface but not on the basal 
surface, (Figure 3.10). Similarly, for the PBECs-hAS, the Ko143 inhibitor only inhibited 
efflux on the apical surface and not on the basal surface, suggesting that BCRP-
dependent efflux was only present apically. In addition, the inhibitions in apical efflux 
agreed with increases in the percentage of 3H-MPP+ retained intracellularly for the 
PBECs in co-culture (Figure 3.10 CII and CIII), with significant intracellu lar retention 
increases, in the presence of inhibitors, seen for the PBECs-rAS (by haloperidol, 
verapamil, Ko143 and prazosin) and the PBECs-hAS (by Ko143).  




Figure 3.10 Polarised ABC Transporter Activity in PBECs 
PBECs were grown on Transwells in mono-culture (PBEC-M, I) or in non-contact co-culture with 




 efflux assays.  




. The loaded cells were then incubated with efflux buffer 
containing ABC inhibitors in both the apical and basal chambers of the Transwells for 35 
minutes. The inhibitors used were the Pgp inhibitors haloperidol (60 µM) and verapamil (50 µM), 
the BCRP inhibitors Ko143 (0.2 µM) and prazosin (35 µM) and the non-specific MRP family 
inhibitor MK571 (10 µM). 
The buffers were then collected and the cells were lysed. The buffers and the lysate were 
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remaining int racellularly (from lysate analysis).
 
 
A) Apical efflux, B) basal -directed efflux, C) int racellular retention.  
Values are mean ± SEM of n=3-6 wells from 3-6 experiments using 3-4 different batches of 
PBECs. 
* P<0.05, ** P<0.01, *** P<0.001 significantly different from vehicle control using an unpaired t -
test. 
 
Since inhibitors were able to show complementary effects on apical efflux and 
intracellular retention, the results indicate that the polarised co-cultured PBECs are 
appropriate tools for measuring ABC transporter activity. However, there was no effect 
of MK571 inhibitor (10 µM) (Figure 3.10), indicating that no detectable MRP activity 
was present using this model and method. 
To compare the levels of Pgp and BCRP activity between the different systems, the 
percentage inhibition was assessed for the inhibitors (Table 3.2), with greater inhibition 
being indicative of greater transporter activity. 
 

















APICAL  Haloperidol Verapamil Ko143 Prazosin  MK571 
PBECs-M  NSD 21.1±2.5 NSD 17.6±3.3 NSD 
PBECs-





   




 efflux in the vehicle control, 
expressed as a percentage of efflux in vehicle efflux.  
*p<0.05 difference in a 1-tailed unpaired t-test between PBECs -M and PBECs-rAS.  
NSD = no significant difference. 
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The results (Table 2) showed greater apical haloperidol-inhibitable efflux in PBECs-rAS 
than in PBECs-M. Significant apical Ko143-dependent efflux was shown in PBECs-hAS 
but not the other two conditions. This suggests differences in Pgp and BCRP activity 
exist between the different PBEC culture formats used. 
 
4.1.6 mRNA expression of the ABC transporters 
 
To analyse the mRNA expression of Pgp and BCRP transporter in PBECs, β-actin and 
GAPDH were first assessed to determine whether they could be used as reference 
genes (i.e. if they were good indicators for general gene expression). β-actin is an 
important component of the cell cytoskeleton and is essential for cell survival. Similarly, 
GAPDH is a component of glycolysis, an essential process in cell function. Since both 
genes are essential to cell survival they are constitutively expressed and have been 
used as reference genes in previous studies on endothelial cells (Yin et al., 2010, 
Dwyer et al., 2012), with GAPDH regularly used as a reference gene in PBEC studies 
(Warren et al., 2009, Lemmen et al., 2013) 
RNA was isolated at different stages of the PBEC culturing process and was analysed 
by RT-PCR.  The PCR Ct values for both β-actin and GAPDH showed variation across 
the samples (Figure 3.11). There were significant increases in Ct values after 
passaging, with greater increases the longer the cells were in culture. A higher Ct 
indicates lower levels of RNA since more PCR cycles of amplification are required to 
reach the cycle of threshold (Ct). Therefore the results suggest that both β-actin and 
GAPDH mRNA levels decrease after passaging, with greater decreases in later stages 
of the cell culture process. However, there was a good correlation between the β-actin 
and GAPDH Cts (R
2
=0.9917, p<0.0001) (Figure 3.12), suggesting that both these 
―house-keeping‖ gene were altered in approximately the same proportions, indicating 
common changes in gene expression. Hence, these genes appear to be good 
measures of generalised gene expression and were used as reference genes in further 
work. However, it should be noted that despite the good correlation, GAPDH Ct values 
were consistently lower than those of β-actin, indicating higher expression of GAPDH 
than β-actin. 




Figure 3.11 β-actin and GAPDH Ct (cycle of threshold) values from RT -QPCR experiments 
The results show the Ct values for β-actin (A) and GAPDH (B) RNA from RT-QPCR 
experiments conducted on RNA collected from PBECs at different stages of the cell culture 
process.  
Day 0 represents the primary isolated porcine capillaries. The PBECs were grown out  from the 
capillaries for up to 6 days (the first 3 days in puromycin containing medium). RNA was isolated 
after the 3 days of puromycin treatment (Day 3) and on day 6 when the cells were passaged to 
Transwells (Day 6).  
Once on Transwells, the PBECs were either grown alone (i.e. in mono-culture, Mono) or in co-
culture with primary rat astrocytes (rAS). The PBECs, in either mono -culture or in co-culture with 
the rAS, were grown on the Transwells for 3 days in serum-containing medium after which RNA 
was isolated (3 Days in Mono or 3 Days in rAS). Alternatively, the PBECs, in either mono-
culture or in co-culture with the rAS, were grown on the Transwells for 3 days in serum-
containing medium, followed by 24 hours in serum -free medium containing 550 nM 
hydrocortisone, 250 µM CPT-cAMP and 17.5 µM Ro-20-1724, before RNA isolation (4 Days in 
Mono or 4 Days in rAS). 
The Ct values obtained per condition are expressed as box and whisker plots, showing the 
range of Ct obtained per sample type. Values were obtained from 3 samples per condition, 
where PCR was conducted on triplicates per plate and n=3 plates were run.  
** p<0.01, ***p<0.001 significance in unpaired 2 tailed t-test. 
 
A                B 
In vitro BBB Models   
96 
 
Figure 3.12 Correlation of β-actin and 
GAPDH 
The graph shows the correlation of 
Ct values of β-actin and GAPDH 
RNA from RT-QPCT experiments 
conducted on RNA collected from 
PBECs at different stages of the cell 
culture process. 
Each point shows the average Ct of a 
single sample; PCR experiments 
were conducted in triplicates of a 





To assess the expression of Pgp and BCRP, the RNA samples collected previously 
underwent RT-QPCR with either Pgp or BCRP primers, with resulting Ct values 
normalised against the reference genes (β-actin and GAPDH) (Pgp and BCRP Ct 
values obtained from the different samples are shown in the Appendix Section 9.4) .  
The results indicate that the Pgp and BCRP mRNA levels in the capillaries (Day 0) 
were significantly greater than after the cells had been in culture (Figure 3.13). This is 
consistent with other work showing transporter expression decreases in primary cell  
culture (Torok et al., 2003). 
The mRNA levels of Pgp and BCRP in the cells after 3 days in puromycin (Day 3) and 
on the Day of Passaging were not significantly different, indicating that the removal of 
puromycin from the medium did not change the expression of efflux transporters 
(Figure 3.13). However, changes in mRNA levels were seen after the PBECs were 
passaged to Transwells. Firstly, Pgp mRNA levels were significantly increased by 2.7 
or 3.3 fold (depending on the reference gene used) after 3 days on the Transwells, 
when PBECs had reached confluence (Figure 3.13).  
For mRNA levels after 4 days on Transwells, the results were inconclusive, with 
normalisation against β-actin showing no change in Pgp mRNA levels from the Day of 
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Passaging, but normalisation against GAPDH showing increased mRNA levels (3.5 
fold compared to the Day of Passaging, similar increases to those shown after 3 days 
on the Transwells) (Figure 3.13). 
No changes in BCRP mRNA were shown after 3 days on Transwells, however 
significant increases in BCRP levels were noted after 4 days on Transwells (3.5 fold or 
5.3 fold, depending on the reference gene used) (Figure 3.13). 
This implied that mRNA changes for Pgp occurred within 3 days, while BCRP changes 
in mRNA required the fourth day of growth, at which time the fold change in BCRP 
mRNA was greater than that of Pgp. This may be indicative of different transcriptional 
times required by the two different ABC genes or differential effects of using serum-free 
medium for 24 hours.  
No significant differences between PBECs in mono-culture and in co-culture with rat 
astrocytes were detected suggesting equal levels of Pgp and BCRP mRNA 
transcription within these systems (Figure 3.14 and Figure 3.15). Therefore, any 
differences in activity (shown previously) are likely to be due to post-transcriptional 
events of the gene-expression process. 




Figure 3.13 mRNA levels of Pgp and BCRP throughout the cell culture process  
Total RNA was isolated from PBECs grown on Transwell filters in mono culture. The RNA 
underwent RT Q-PCR using Pgp (A) or BCRP (B) primers.  
Ct values obtained per gene per sample were normalised against either β -actin (light bars, I) or 
GAPDH (dark bars, II) Ct values obtained for the sample (to gi ve the ΔCt) then further 
normalised against the average ΔCt at Day 6 to give the ΔΔCt, which was then used to 
calculate the fold change 2
- ΔΔCt 
shown above.  
Day 0 represents the primary isolated porcine capillaries. The PBECs were grown out  from the 
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after the 3 days of puromycin treatment (Day 3) and on day 6 when the cells were passaged to 
Transwells (Day 6).  
Once on Transwells, the PBECs were grown alone (i.e.  in mono-culture) for 3 days in serum-
containing medium after which RNA was isolated (3 Days in Mono). Alternatively, the PBECs, 
were grown on the Transwells for 3 days in serum-containing medium, followed by 24 hours in 
serum-free medium containing 550 nM hydrocortisone, 250 µM CPT-cAMP and 17.5 µM Ro-20-
1724, before RNA isolation (4 Days in Mono) 
Values are mean ± SEM of n=3 samples per condition, where PCR was conducted on triplicates 
per plate and n=3 plates were run.  
** p<0.01, ***p<0.001 difference in unpaired 2 tailed t-test to Day 6 
  




Figure 3.14 Pgp and BCRP mRNA levels of 
PBECs after 3 days on Transwells 
Total RNA was isolated from PBECs grown 
on Transwell filters either in mono culture 
(Mono) or co-culture with normal rat  
astrocytes (AS) for a total of 3 days in 
serum-containing medium. The RNA 
underwent RT Q-PCR using Pgp (A) or 
BCRP (B) primers. 
Ct values obtained per gene per sample 
were normalised against either β-actin (light  
bars, I) or GAPDH (dark bars, II) Ct values 
obtained for the sample (to give the ΔCt) 
then further normalised against the average 
ΔCt of the mono-cultured cells to give the 




Values are mean ± SEM of n=3 samples 
per condition, where PCR was conducted in 
triplicates per plate and n=3 plates were 
run.  
























Figure 3.15 Pgp and BCRP mRNA 
levels of PBECs after 4 days on 
Transwells  
Total RNA was isolated from PBECs 
grown on Transwell filters either in 
mono culture (Mono) or co-culture with 
normal rat astrocytes (AS) for a total of 
4 days (3 days in serum-containing 
medium and a further day in serum-
free medium with 550 nM 
hydrocortisone, 250 µM CPT-cAMP 
and 17.5 µM Ro-20-1724).  
The RNA underwent RT Q-PCR using 
Pgp (A) or BCRP (B) primers. 
Ct values obtained per gene per 
sample were normalised against either 
β-actin (light bars, I) or GAPDH (dark  
bars, II) Ct values obtained for the 
sample (to give the ΔCt) then further 
normalised against the average ΔCt of 
the mono-cultured cells to give the 
ΔΔCt, which was then used to calculate the fold change 2
- ΔΔCt 
shown right.  
Values are mean ± SEM of n=3 samples per condition, where PCR was conducted in triplicates 
per plate and n=3 plates were run.  



























Initial studies were conducted to find a suitable BBB model that would enable 
comparisons between BBB efflux transporter activities in different culture conditions, for 
later use with a glioma cell co-culture.  
Focus was initially placed on the ―normal‖ conditions as detailed in this chapter. 
The primary porcine brain endothelial cells (PBECs) used have been shown to 
maintain the characteristics of the BBB in vivo, with ―tight‖ TJ formation (measured by 
high transendothelial electrical resistance and low paracellular substrate transport 
(Cohen-Kashi Malina et al., 2009, Patabendige et al., 2013a, Patabendige et al., 
2013b). In addition, PBECs have been shown to have a similar expression pattern of 
ABC transporters to the human BBB (Warren et al., 2009), which is of particular 
importance when addressing the aim of studying the ABC efflux transporters (in normal 
and glioma conditions). Together this indicated that PBECs would be a good model for 
the study. 
To optimise the PBEC model to better suit the aim of the overall study, different culture 
conditions were considered: PBECs grown on Transwells and in non-contact co-culture 
with astrocytes. Transwells allow separate apical and basal surface analysis  that is 
more representative of the in vivo BBB, and several studies have shown that co-culture 
of endothelial cells with rat astrocytes helps to induce and maintain features of the in 
vivo BBB. Furthermore, human astrocytes were used to assess the suitability of a 
humanised model. 
In addition, the 
3
H-MPP efflux assay was developed to assess the activity of ABC efflux 
transporters within the different PBEC conditions.  
 
4.2.1 Differences in 3H-MPP+ Loading 
 
Significant differences in the amount of 3H-MPP+ loaded between PBECs-rAs and 
PBECs-hAS were shown in the study, indicating different influences of these astrocytes 
on the uptake of 3H-MPP+ by these models (Figure 3.7).  
Uptake of 3H-MPP+ has been previously studied in brain endothelium. Early studies by 
Martel et al. (2001), showed uptake of 3H-MPP+ into RBE4s (immortalised rat 
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endothelial cell line) to be  Na+- independent, energy dependent and pH dependent. 
The study further showed uptake of 3H-MPP+ was not affected by OAT inhibitors but 
was inhibited by OCT inhibitors, inhibiting either OCT1 or OCT2, both of which had 





 uptake into primary rat brain endothelial cells (RBECs), 
although the study of OCT2 and OCT3 effects were not possible since the RBECs 
were not shown to express these transporters. Together the studies implicate the OCT 




 at the BBB. 
Lin et al. (2010), showed that OCT1 and OCT2 are expressed mainly apically in human 
and rat microvessels. This apical expression agreed with the earlier Martel et al. (2001) 
study that found that only 3H-MPP+ transport in the apical to basal direction was subject 
to inhibition by OCT inhibitors. Together this shows that uptake of 3H-MPP+ occurs via 
OCT transporters on the apical surface of the BBB. 
In addition, unpublished work by the BBB group at King's College London (2008) has 
shown the activity of OCT transporters in PBECs, where MPP+ uptake in PBECs was 
inhibited by OCT1/2 inhibitors.  
Taken together, this suggests the differences in loading between PBECs-rAS and 
PBECs-hAS noted here (Figure 3.7) indicate different levels in the activity/expression 
of these uptake transporters within the different systems. 
It should be noted that any differences in loading will not affect efflux, as results were 
expressed as a percentage of the total 3H-MPP+ loaded. In addition, during the course 
of the experiment the concentration of extracellular 3H-MPP+ is much lower than the 
intracellular concentration, so the concentration gradient favors efflux, even if loading is 
lower in the PBECs-hAS.   
Also, experiments have shown that the OCT uptake transporters do not significantly 
contribute to efflux, with inhibition of OCTs by amantadine (OCT1/2 inhibitor) during the 
course of a 3H-MPP+efflux assay yielding no difference in 3H-MPP+ efflux compared 
with  control (See Appendix Section 9.3). Therefore, OCT uptake transporters do not 
play a significant role in efflux of 3H-MPP+ in this model.  
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4.2.2 Differences in 3H-MPP+ efflux 
 
Differences between the different PBEC culture systems were shown when examining 
the efflux of 3H-MPP+. 
Firstly, differences in the initial rates of 3H-MPP+ efflux from PBECs-P and PBECs-M 
were seen, with slower efflux when cells were on Transwells (i.e. PBECs-M). The 
different rates of efflux could be due to differences in exposed surfaces, where the 
polarisation effect (i.e. creation of both apical and basal surfaces) caused by the use of 
Transwells decreased the rate of overall efflux. However, it should be noted that the 
efflux rate of the PBECs-rAS was similar to the efflux rate shown by the PBECs-P. This 
indicates that the PBECs-P are also a good model for the study of apical efflux.  
Differences in the media used could also have contributed to the differences in efflux 
between PBECs-P and PBECs-M, with the latter having the medium changed to 
serum-free medium with hydrocortisone, CPT-cAMP and Ro-20-1724 supplements for 
the last 24 hours of culture. The use of hydrocortisone, CPT-cAMP and Ro-20-1724 
correlated with increases in the mRNA expression levels of BCRP here (Figure 3.13) 
and are also implicated in Pgp and MRP mRNA changes by Perriere et al. (2007). 
Therefore, medium differences may have affected the efflux, contributing to the slight 
differences seen, i.e. PBECs-M had slower initial t1/2 than the PBECs-P. 
Differences in the use of hydrocortisone, CPT-cAMP and Ro-20-1724 could not explain 
differences in efflux noted between the PBECs-M and the PBECs-rAS, since both 
cultures were exposed to hydrocortisone, CPT-cAMP and Ro-20-1724. In spite this, 
differences were noted.  Higher TEER, indicative of tighter TJs in the PBECs-rAS were 
seen (Figure 3.5). This is in agreement with a number of studies showing that co-
culturing endothelial cells with astrocytes improves tight junction formation, increasing 
TEER and decreasing paracellular permeability (Gaillard et al., 2001, Tan et al., 2001, 
Helms et al., 2010, Patabendige et al., 2013a). 
Comparing co-cultured and mono-cultured PBECs, the PBECs-rAS were shown to 
have higher rates of 3H-MPP+ efflux than PBECs-M (Figure 3.4). Furthermore, efflux 
from the apical surface was greater in PBEC-rAS in single-time point experiments 
(Figure 3.6), with no differences in basal efflux. Together this indicates that the factors 
regulating efflux may be greater in the co-culture system.  
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The transporters at least partially responsible for the efflux of 3H-MPP+ were shown 
here to be Pgp and BCRP (Figure 3.10). Results showed more conclusive Pgp and 
BCRP activity in the astrocyte co-culture compared to monoculture, with ABC 
transporter inhibition of efflux correlating with increased intracellular retention of 3H-
MPP
+
  (Figure 3.10 and Table 3.2). Although MPP
+ 
is positively charged, it has a 
logD7.4 of 0.5, similar to other known ABC transporter substrates (e.g. Taurocholate 
logD7.4 of 0.1, Quercetin logD7.4 of 1.0, Bromosulfalein logD7.4 of 0.4 and doxorubicin 
logD7.4 of 0.2 (Matsson et al., 2009). Furthermore, Bleasby et al., (2000), suggested the 
possibility that MPP+ was sufficiently lipophilic to passively diffuse across cell 
membranes. Further, Tsinman et al, 2011 showed that bases can traverse porcine 
plasma membranes effectively, with results correlating well with rodent in situ brain 
perfusions, demonstrating that basic compounds (such as MPP+) can cross lipid 
membranes despite their positive charge. Together this suggests that MPP+ is 
sufficiently lipophilic to interact with the ABC-efflux transporter active sites located 
within the hydrophobic transmembrane regions of the ABC transporters (Nervi et al, 
2010).  
Several studies have shown that co-culturing endothelial cells with rat astrocytes leads 
to up-regulation of Pgp mRNA, protein and activity. Gaillard et al. (2000), compared 
primary bovine brain endothelial cells (BBECs) in mono-culture with 50% astrocyte-
conditioned medium, with BBECs in contact co-culture with rat astrocytes, showing that 
in co-culture Pgp protein expression increased together with increased Pgp activity 
(vinblastine exclusion assay and daunorubicin transport). Similarly, Dohgu et al. (2004) 
using a mouse BBB model, compared mono-cultured endothelial cells and astrocyte 
contact co-cultured endothelial cells and showed increased Pgp activity in the astrocyte 
co-culture system from Rhodamine123 (Rho123) accumulation assay. Xue et al. (2013) 
also showed increased Pgp protein expression when endothelial cells were in contact 
co-culture with astrocytes when compared to endothelial cells in mono-culture.  
Many earlier findings on the effects of astrocytes have come from contact co-culture 
(above), however the results here are using a non-contact co-culture system, since it 
allows for straight forward comparisons of mono-cultured cells with co-cultured cells. It 
is not possible to rigorously compare transport through two layers of cells (contact-co-
culture) with transport through one layer of cells (mono-culture or non-contact co-
culture), since the underlying cell layer of astrocytes could itself alter the flux of 
substrates, especially since astrocytes have been shown to express low levels of Pgp  
and BCRP (Ballerini et al., 2002, Hirrlinger et al., 2005). In addition, since the overall 
aim of the project involves the assessment and therefore use of glioma cells, and since 
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gliomas have been reported to express extremely high levels ABC efflux transporters 
(Sharom, 2008, Decleves et al., 2008), the use of glioma in a contact-co-culture would 
likely alter the transport flux of a substrate. For such reasons focus was placed on non-
contact co-culture models in the current study.  
The results obtained in the current study differ from the studies reported above in some 
respects. In the current study, the non-contact co-culture model did not show any 
significant differences in mRNA levels between the PBECs-M and the PBECs-rAS. 
However, the activity results were more conclusive in both the co-culture models than 
in the mono-culture model. PBECs-M showed no significant changes in intracellular 
retention of 3H-MPP+ upon addition of inhibitors, despite significant inhibition of apical 
efflux, while PBECs-rAS did (Figure 3.10). This, together with the observed increased 
efflux rates (Figure 3.4) and greater apical efflux but no difference in basal efflux 
(Figure 3.6) suggests greater activity of ABC transporters in the co-cultured model, 
despite no increase in mRNA levels being detected (Figure 3.13 and Figure 3.14). 
Therefore the results indicate that Pgp and BCRP activity can be increased by non-
contact co-culture with astrocytes independently of increases in mRNA levels of the 
ABC transporters. Whether this is via post-transcriptional effects or other factors, e.g. 
greater tight-junction integrity in the PBECs-rAS leading to more polarised transporter 
expression is unclear. However, since this is a non-contact model, it does suggests 
that any effects are a result of diffusible factors, secreted by the astrocytes or by the 
PBECs themselves as a response to the presence of astrocytes. 
Increases in Pgp activity have also been shown in other non-contact co-culture models 
Cohen-Kashi Malina et al. (2009) compared PBECs in mono-culture, contact co-culture 
and non-contact co-culture, and although significant increases in Pgp activity could 
only be seen when comparing the contact co-culture with mono-culture, the non-
contact co-cultured PBECs showed Pgp activity level similar to that of the contact co-
culture model.  
Both protein and mRNA levels were assessed in Lim et al. (2007), where RBECs in 
mono-culture and in non-contact co-culture with astrocytes were compared. The results 
showed increased mdr1a mRNA and Pgp protein levels as well as a higher ratio of Pgp 
activity (although activity was not significant), showing that similar effects on Pgp 
transporter mRNA levels can be achieved using contact and non-contact co-culture. 
However, it should be noted that in this study, co-culture with astrocytes occurred over 
9 days, compared to the current study where co-culture with the rat astrocytes was for 
4 days. This suggests that in the short term (up to 4 days) ABC transporter activity is 
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regulated post-transcriptionally via diffusible factors, however in the long term (9 days) 
the diffusible factors may induce mRNA changes as well.  
In the study by Perriere et al. (2007), where ABC transporter mRNAs from RBECs in 
mono-culture were compared with mRNAs from RBECs in optimised non-contact 
astrocyte co-culture, the co-culture conditions showed increased mdr1a mRNA (not 
significant), increased BCRP mRNA and decreased mdr1b, showing that BCRP mRNA 
levels can also be elevated in non-contact co-culture. However, in the Perriere et al. 
(2007) study a simple mono-culture model was compared to a highly optimised co-
culture model, where medium differences may have played a role. In the optimised 
model, hydrocortisone, CPT-cAMP and Ro-20-1724 were used together with the 
addition of astrocytes, which was compared to a mono-culture without hydrocortisone, 
CPT-cAMP and Ro-20-1724. In the current study, the use of hydrocortisone, CPT-
cAMP and Ro-20-1724 correlated with the mRNA increases in BCRP (Figure 3.13, Day 
4). Therefore, increases in mRNA levels shown by Perriere et al. (2007), may be due to 
the addition of hydrocortisone, CPT-cAMP and Ro-20-1724 and not solely due to the 
presence of astrocytes. 
Considering MRP activity, in-house evidence suggested that 3H-MPP+ is effluxed via 
MRPs (BBB Group King's College London, 2008, Unpublished). However, no 
inhibitable MRP activity was detected in the current study. This may indicate that the 
assay used is not sensitive enough to detect MRP activity changes. 
A similar study using daunorubicin (also a common substrate of Pgp, BCRP and 
MRPs), was unable to show MRP activity in 3 hours, but could after 24 hours, 
suggesting that MRP efflux is slow, and may require longer times to see its effects 
(Perriere et al., 2007). However, as some studies have shown suppression of 
endothelial MRP expression by astrocyte co-culture (Regina et al., 1998), the 
undetectable contribution of MRP activity in the PBECs in astrocyte co-culture systems 
could have reflected such suppression in the PBEC system (Figure 3.10). Early work 
by Seetharaman et al. (1998) indicated that MRP1 is weakly detected in human brain 
microvessels and only appears in culture, suggesting that its expression is suppressed 
in vivo. 
It is also clear that astrocytes from different species have different effects on the 
PBECs, with PBECs-hAS showing higher BCRP activity (Ko143-dependent efflux, 
Table 3.2) than PBECs-rAS. However, higher overall efflux was achieved by the 
PBECs-rAS (Figure 3.6) suggesting that other factors/transporters involved in efflux 
may be more active in the PBECs-rAS. It should be noted that the culture conditions 
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between the two systems were different. The PBECs-rAS were co-cultured for a total of 
four days, with the final day in serum-free PBEC medium with hydrocortisone, CPT-
cAMP and Ro-20-1724. By contrast, the PBECs-hAS were only in co-culture for two 
days, both days in serum-free PBEC medium with hydrocortisone, CPT-cAMP and Ro-
20-1724. The prolonged exposure of PBECs-rAS to the rat astrocytes could have led to 
the greater expression of more than one efflux transporter (indicated by the greater 
overall efflux). Moreover, the longer time spent in  hydrocortisone, CPT-cAMP and Ro-
20-1724 medium by the PBECS-hAS may have led to higher levels of BCRP 
specifically.  
Perriere et al. (2007) did show more significant elevation in BCRP mRNA than in Pgp 
mRNA as a result of hydrocortisone, CPT-cAMP and Ro-20-1724.  Increases in Pgp 
mRNA were inconclusive since a rodent model was used, where two genes control 
expression of Pgp (mdr1a and mdr1b) and the only significant increases in mRNA were 
for the mdr1b gene (Perriere et al., 2007). Interestingly, the pig and human MDR1 
genes (the sole genes responsible for Pgp expression in the porcine and human BBB) 
share more homology with the mrd1a gene (Smith et al., 1998). Furthermore, the 
regulation of human MDR1 has been shown to be similar to the mdr1a (and not 1b) 
gene via p53 (Thottassery et al., 1997). Therefore, is it not clear how hydrocortisone, 
CPT-cAMP and Ro-20-1724 would affect pig MDR1 expression, with the results 
obtained in this study also being inconclusive (showing either a decrease or no change 
in Pgp mRNA (Figure 3.13, Day 4). 
Finally, there is the question of the species-specificity of any astrocytic effects. Human 
astrocytes have been used in BBB co-culture models previously, but this was in co-
culture with human BBB models (Cucullo et al., 2007, Hatherell et al., 2011), and no 
comparison was made between the influence of rat and human astrocytes. It is clear 
that further work needs to be done to clarify the extent to which astrocyte-endothelial 
influences on ABC transporters in species-specific.   
 
4.2.3 PBECs as a tools for further study 
 
It should be mentioned that the polarity of Pgp and BCRP activity observed in all the 
cultures was apical (Figure 3.10), which is in agreement with the literature, where there 
is a consensus that these transporters are found on the luminal/apical blood-facing 
surface (Beaulieu et al., 1997, Eisenblatter et al., 2003, Begley, 2004, Roberts et al., 
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2008). In this respect, all the models used in the current study are good tools for the 
assessment of ABC transporter activity in vitro, although the co-culture models did 
show more consistent results. 
One of the aims of this phase of the current study was to establish the 
baseline/reference conditions before moving to examine co-culture of PBECs with 
glioma cells. Co-culture of PBECs with normal astrocytes did alter Pgp and BCRP 
activity. Hence, to distinguish glioma effects from normal astrocytic effects, glioma co-
culture cannot be compared with mono-culture, but must instead be compared with an 
astrocyte co-culture system. Therefore the choice of an appropriate ―normal‖ BBB 
condition depends on the type of glioma model used, and the control species will have 
to match as closely as possible the glioma model. 
Furthermore, since the results suggested that different species of astrocytes may have 
differential effect on PBECs, comparisons of glioma co-culture should be species-
specific, i.e. rat glioma compared with rat astrocytes and human glioma compared with 
a human astrocyte system. Therefore the choice of appropriate ‗normal‘ BBB condition 
depends on the type of glioma model used and the control species will have to match 
as closely as possible the glioma model. 
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5 The Effect of Glioma Co-culture on PBEC Efflux Transporter 
Activity 
 
5.1  Results 
 
In the previous chapter it was found that PBEC activity was differently affected by rat 
and human astrocyte co-culture. The aim in this part of the project was to assess the 
effect of glioma co-culture on PBEC efflux, primarily using rat C6 glioma cells (PBECs-
C6s) compared with rat astrocyte co-culture (PBECs-rAS). A limited stock of clonal 
human malignant glioma G7 cells (isolated from a glioblastoma multiform patient, from 
Dr Steven Pollard, UCL) were available and their effect on PBEC efflux (PBECs-G7s) 
was compared with human astrocyte co-culture (PBECs-hAS). 
Ideally, the time of co-culture with the C6s or G7s should be the same but unfortunately 
this was not possible since the G7s become senescent in the presence of serum, 
which is essential for PBEC growth. Conversely, serum-free conditions were 
detrimental to PBEC after 2 days.  Therefore, PBECs were co-cultured with human 
cells  for 2 days in serum-free conditions (compared with 4 days for the C6 co-culture in 
a combination of serum and serum-free conditions). In addition, attempts were made to 
replicate the longer C6-coculture, by moving the PBECs (in serum) to fresh G7s (in 
serum-free medium) every 12 hours for a total of 3 days and then changing the 
medium to serum-free for a further 24 hours (for a total of 4 days in culture) (PBECs-
G7.4). 
 
5.1.1 3H-MPP+ efflux by PBECs in glioma co-culture  
 
As described in Chapter 3, the rate of 3H-MPP+ efflux was measured to assess the 
effects of glioma co-culture on PBECs. Due to limited availability of G7 cells, the rate 
was only assessed for the PBECs-C6s (Figure 4.1). 
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efflux by PBECs in co-culture with C6 glioma cells.  





 efflux assays. 




. The loaded cells were then incubated with efflux 
buffer in both the apical and basal chambers of the Transwells for the times shown. The buffers 

















initially loaded into the cells. 
A)  Int racellular retention B) Apical efflux, C) basal -directed efflux, and D) Ln plot of the 
Intracellular retention. 
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The intracellular retention of 3H-MPP+ by PBECs-C6s decreased with time, indicating 
efflux of 3H-MPP+. As with the PBECs-rAS, intracellular retention began to plateau by 
35 minutes, while the profiles of the separated apical and basal efflux graphs were 
similar to those for PBECs-rAS suggesting  plateauing of basal efflux which may be 
due to an equilibrative process (Figure 4.1) 
The PBECs-C6 demonstrated similar rates of 3H-MPP+ efflux as the PBECs-rAS with 
similar t1/2s of 29 minutes and 32 minutes, respectively.  
As in Chapter 3 with the PBECs-rAS, the rates of apical and basal efflux from PBECs-
C6s were also estimated (Table 4.1). The results showed no significant difference 
between rates from PBECs-rAS and PBECS-C6s either apically or basally. However, 
both showed increased apical efflux compared to PBECs-M. 
Table 5.1 Rates of efflux by PBECs-C6s 
  Efflux rate constant K (min-1) 
  
Loss of total 
intracellular pool Apical Basal 
PBECs-M 0.013 ± 0.004 0.003± 0.001 0.010 ± 0.003 
PBECs-rAS 0.022 ± 0.003 * 0.011 ± 0.001 *** 0.011 ± 0.003 
PBECs-C6 0.024 ± 0.002 * 0.013 ± 0.001 *** 0.012 ± 0.002 
*p <0.05, *** p<0.001 difference in 1-tailed unpaired t-test between PBECs-M and indicated 
pair.  




To further asses any differences in 3H-MPP+ efflux between PBECs-C6s and the 
PBECs-rAS, 3H-MPP+ efflux by the PBECs at a single time point (35 minutes) was 
assessed. In addition, PBECs-G7s were compared with PBECs-hAS. 
For the rat co-cultures, no significant differences were noted in the apical and basal-
directed efflux of 3H-MPP+, with the PBECs-C6 showing similar overall efflux and 
intracellular retention of 3H-MPP+ to PBECs-rAS (Figure 4.2). This agreed with the 
previous observations concerning the rate of 3H-MPP+ efflux, which showed the 
PBECs-C6s had a similar efflux rate (Figure 3.4 and Figure 4.1).  
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Figure 5.2 3H-MPP+ efflux from PBECs in C6 glioma co-culture 
PBECs were grown in co-culture with either rat astrocytes (PBECs-rAS) or rat glioma C6s 




 efflux assays. 




. The loaded cells were then incubated with efflux 
buffer in both the apical and basal chambers of the Transwells for 35 minutes. The buffers were 
then collected and the cells were lysed. The buffers and lysate were analysed separately by 




















remaining int racellularly (from lysate analysis).
 
 
A) Apical efflux, B) basal-directed efflux, C) intracellular retention, D) overall efflux (the sum of 
the apical and basal efflux).  
Values are mean ± SEM of n=4-6 wells from 3 independent plates.  
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For the human co-culture, the PBECs-G7 after 2 days of co-culture showed 
significantly higher overall 3H-MPP+ efflux than their human astrocyte counterpart (also 
in 2 days of co-culture) (Figure 4.3). This was due to a significant increase in apical, but 
not basal-directed efflux under the G7 condition. However, in longer co-cultures with 
the G7s i.e. PBECs-G7.4 (where co-culture was maintained for 4 days), basal-directed 
efflux was lower than in the PBECs-G7 co-cultured for 2 days. However, no human 
astrocyte control was conducted for the longer 4 days co-culture, therefore it is not 
possible to distinguish whether the lower basal-directed efflux is due to a genuine 
decrease with time spent in co-culture with the G7s or results from changes during the 







 efflux from PBECs in G7 glioma co-culture 
PBECs were grown in co-culture with either human astrocytes (PBECs-hAS) or human glioma 





efflux assays. Alternatively, PBECs were grown in co -culture with G7s for a total of 4 days in a 
combination of serum and serum-free conditions (PBECs-G7.4) and then assayed.  
A B C 
D 
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. The loaded cells were then incubated with efflux buffer 
in both the apical and basal chambers of the Transwells for 35 mi nutes. The buffers were then 
collected and the cells were lysed. The buffers and lysate were analysed separately by liquid 




















remaining int racellularly (from lysate analysis).
 
 
A) Apical efflux, B) basal-directed efflux, C) intracellular retention, D) overall efflux (the sum of 
the apical and basal efflux).  
Values are mean ± SEM of n=4-7 wells from 3 independent plates.  
*p<0.05, difference in an unpaired 2 tailed t-test. 
 
All 3 glioma co-cultures, PBECs-C6, PBECs-G7 and PBECs-G7.4, showed similar 
levels of overall apical 3H-MPP+ efflux 27.2±0.7%, 23.7±0.9% and 24.4±1.6% 
respectively, irrespective of the species of the co-culture cells used. By contrast, 
previous results (Chapter 3, Figure 3.6) showed significant differences in apical efflux 
in PBECs in different astrocyte co-cultures (rat or human), with PBECs-rAS showing 
greater levels of 3H-MPP+ apically effluxed than PBECs-hAS (28.6±1.3% and 
19.8±0.6% respectively). This could indicate greater similarities between the influence 
of the different glioma cells, compared with their normal astrocyte counterparts. 
The integrity of the PBEC TJs was also assessed in the different glioma conditions. 
TEER measurements were taken before the start of the experiment and 14C-sucrose 
permeability was measured during the course of the 35 minute efflux assay (Figure 
4.4). 
Interestingly, the TEER and 14C-sucrose permeability of the PBECs in co-culture with 
the rat cells were different between the rat astrocyte and glioma co-cultures. The 
PBECs-C6s had higher TEERs and lower paracellular permeability of 14C-Sucorse, 
indicating ―tighter‖ TJs than their normal astrocyte counterparts. However, the TEER 
measurements and 14C-sucrose permeability were not different between the PBECs-
G7s and PBEC-hAS in the 2 day co-culture, indicating the TJ integrity of these PBECs 
were similar. There was no difference between the PBECs-G7 after 4 days compared 
with 2 days of co-culture, demonstrating that the different co-culture lengths or methods 
did not influence TJ integrity. 
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Figure 5.4 Tight junction integrity 
of PBECS in co-culture with 
glioma cells. 
The tight junction integrity of 
PBECs co-cultured with normal 
astrocytes or glioma cells was 
measured in two ways.  
Firstly, the transendothelial 
electrical resistance (TEER) of the 
PBEC monolayer was measured 





 efflux experiment (I). 
Secondly, the permeability of the 
paracellular marker  
14
C-sucrose 
(apical to basal direction) was 
measured over 35 minutes during 





efflux experiment (II). 
A) PBECs grown in co-culture with 
either normal rat astrocytes 
(PBECs-rAS) or rat C6 glioma 
cells (PBECs-C6s) for a total of 4 days.  
B) PBECs grown in co-culture with either human astrocytes (PBECs-hAS), human glioma G7s 
(PBECs-G7s) for a total of 2 days (serum-free) or for a total of 4 days in a combination of serum 
and serum-free conditions (PBECs-G7.4).  
Mean ± SEM, n=6-35 wells  
** p<0.01, unpaired 2-tailed t-test, # p<0.05 unpaired 1 tailed t-test  
No significant differences were found in unpaired t-tests between PBECs-hAS and PBECs-G7, 
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The amount of 3H-MPP+ loaded into the different PBECs was also assessed. Figure 4.5 
shows that co-culture of PBECs with C6s for 4 days or G7s for 2 days did not change 
3H-MPP+ loading when compared with their respective astrocyte co-culture controls, 
when compared with each other, or compared with the PBECs in G7 co-culture for 4 
days. This indicates that glioma cells have no additional effect(s) on uptake other than 
the ―normal‖ astrocytic effect(s), at least for 3H-MPP+ uptake, indicative of transporters 















 efflux was analysed by liquid scintillation 




 with correction for 
14
C-sucrose and expressed as fmol/Transwell.  
A) PBECs grown in co-culture with either normal rat astrocytes (PBECs-rAS) or rat C6 glioma 
cells (PBECs-C6s) for a total of 4 days.  
B) PBECs grown in co-culture with either human astrocytes (PBECs-hAS) or human glioma G7s 
(PBECs-G7s) for a total of 2 days under serum-free condition.  
C) PBECs grown in co-culture with  human glioma G7s for a total of 4 days in a combination of 
serum and serum-free conditions (PBECs -G7.4).  
Values are mean ± SEM of n=4-7 wells from 3 different plates. 
A    B      C 
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No significant differences were found in unpaired t-tests between PBECs-rAS and PBECs-C6, 
or PBECs-hAS and PBECs-G7, or PBECs-G7 and PBECs-G7.4, or PBECs-G7.4 and PBECs-
C6s. 
 
Together the results showed differences between the PBECs in co-culture with rat cells 
and the PBECs in co-culture with the human model. This could be due to differences 
between species, but also due to differences between the different co-culture methods 
or the times spent in co-culture.  
The PBECs were in co-culture with the rat cells for 4 days, while only 2 days were 
spent in co-culture with the human cells. Mimicking the 4 day co-culture process of the 
PBECs in rat co-culture using G7s (PBECs-G7.4) did result in different efflux activity 
than the PBECs in the 2 day co-culture, showing that the culture method or time-spent 
in co-culture does influence efflux activity. 
Therefore the human 2 day co-cultured may indicate earlier changes in efflux 
characteristics while the 4 day co-culture with rat cell or the human G7s may indicate 
later changes in efflux characteristics. Alternatively, the differences noted could arise if 
human-porcine cell interactions induce faster changes than rat-porcine cell interactions.  
 
5.1.2 ABC transporter activity in PBECs grown in glioma co-culture 
 
To determine whether the differences in 3H-MPP+ efflux noted above were due to 
differences in the activity of ABC transporter, a 3H-MPP+ efflux assay was conducted on 
the different PBECs in the presence of ABC transporter inhibitors.  
As previously, haloperidol (60 µM) and verapamil (50 µM) were used to assess Pgp 
activity, Ko143 (0.2 µM) and prazosin (35 µM) were used to assess BCRP activity and 
MK571 (10 µM) to asses MRP activity. Due to the scarce availability of human 
astrocytes and G7 cells, only the effect of Ko143 was tested on the PBECs with human 
cells after 2 days of co-culture and only haloperidol and Ko143 were tested for the 
PBECs in G7 co-culture for 4 days with results shown in Figure 4.6. 
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The previous chapter (Chapter 3, Figure 3.6) shows the inhibition of PBECs-rAS by 
both Pgp inhibitors and one BCRP inhibitor (prazosin) only on the apical surface, with 
no significant inhibition by the MRP inhibitor MK571. Here, the PBECs-C6s also 
showed Pgp and BCRP mediated efflux at the apical surface, however there were 
some differences compared with the PBECs-rAS. 
Firstly, the PBECs-C6s showed Pgp-dependent 3H-MPP+ efflux on the basal surface, 
with haloperidol significantly decreasing efflux (Figure 4.6). By contrast, the PBECs-
rAS did not show any inhibitable Pgp activity on the basal surface. In addition, apical 
Pgp-dependent efflux was significantly decreased during C6 co-culture, compared with 
PBECs-rAS (Figure 4.7 with Pgp inhibitors, haloperidol and verapamil). 
Secondly, both Ko143 and prazosin BCRP inhibitors showed significant effects on the 
apical 3H-MPP+ efflux from PBECs-C6s, while only prazosin showed significant effects 
in the PBECs-rAS (Figure 4.6). In addition, the BCRP-dependent component was 
shown to increase apically for both BCRP inhibitors in the C6 co-culture (Figure 4.7, 
with BCRP inhibitors, Ko143 and prazosin). 
Finally, the MRP inhibitor Mk571 significantly inhibited efflux at the apical surface of the 
PBECs-C6 in conjunction with increased intracellular retention (Figure 4.6), indicating 
the presence of MRP activity at the apical surface of PBECs-C6, which the PBECs-rAS 
did not show. 
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Figure 5.6 Efflux of 3H-MPP+ from PBECs in glioma co-culture  
PBECs were grown on Transwells in co-culture with either or C6 glioma cells (PBECs -C6s) for a 
total of 4 days or G7 glioma cells for either 2 days (PBECs-G7) or 4 days (PBECs-G7.4).  




. The loaded cells were then incubated with efflux buffer, 
without (vehicle) or with an inhibitor, in both the apical and basal chambers of the Transwells for 
35 minutes. The inhibitors used were the Pgp inhibitors haloperidol (60 µM) and verapamil (50 
µM), the BCRP inhibitors  Ko143 (0.2 µM) and prazosin (35 µM) and the non -specific MRP 
family inhibitor MK571 (10 µM).  





, along with the cell lysate. 
B I     B II      B III 
C I     C II      C III 
A I     A II      A III 
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initially loaded into the cells. 
A) Apical efflux, B) basal -directed efflux and C) intracellular retention.  
Values are mean ± SEM of n=3-6 wells from n=3 plates  
* p<0.05, ** p<0.01, ***p<0.001, p=0.05, p=0.09 difference in unpaired 2 tailed t -test between 
efflux in the presence or absence of the inhibitor.  
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Figure 5.7 ABC Transporter activity in PBECs grown in co-culture with rat glioma cells  
PBECs were grown on Transwells in co-culture with either rat astrocytes (PBECs-rAS) or C6 
glioma cells (PBECs-C6s) for a total of 4 days.  




. The loaded cells were then incubated with efflux 
buffer, without (vehicle) or with an inhibitor, in both the apical and basal chambers of the 
Transwells for 35 minutes. The inhibitors used were the Pgp inhibitors haloperidol (60 µM) and 
A I        A II               A III 
B I        B II               B III 
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verapamil (50 µM), the BCRP inhibitors Ko143 (0.2 µM) and prazosin (35 µM) and the non-
specific MRP family inhibitor MK571 (10 µM). 

















initially loaded into the cells.  
The inhibitable efflux was calculated for each inhibitor, as the efflux in the absence of inhibitor 
minus the efflux in the presence of inhibitor and expressed as a percentage of the efflux in the 
absence of inhibitor (% Control).  
A) Apical inhibition and B) inhibition at the basal surface, with I) showing Pgp inhibition, II) 
showing BCRP inhibition and III) showing MRP inhibition.  
Values are mean ± SEM of n=3-6 wells from n=3 plates  
* p<0.05, ** p<0.01 difference in unpaired 2 tailed t-test between efflux in the presence of the 
inhibitor and efflux in the absence of that inhibitor.  
$ p<0.05, difference in unpaired 2-tailed t-test between the indicted pairs  
# p<0.05 difference in unpaired 1-tailed t-test between the indicted pairs.  
 
In the PBECs co-cultured with human cells, only the Ko143 BCRP inhibitor was tested 
which inhibited apical (but not basal-directed) efflux (Figure 4.6). However, the Ko143-
inhibitable component on the apical surface changed from 26.7±2.3 % in PBECs-hAS 
to 32.8±1.5% in PBECs-G7 in the 2 days co-culture (Figure 4.8), indicating increased 
BCRP activity on the apical surface in agreement with the increased overall apical 
efflux shown in Figure 4.3. 
Interestingly, the PBECs-G7.4 (4 days of co-culture) showed similar levels of apical 
haloperidol-inhibitable efflux (19.5 ± 5.4%) as the PBECs-C6s (16.8 ± 1.7%) and 
similar levels of apical Ko143-inhibitable efflux (21.1 ± 3.4% and 20.9 ± 1.7 % 
respectively). This shows similar BCRP and Pgp transporter activities with the two 
systems yielding comparable results when co-cultured for 4 days. 
This also indicates that differences between the rat co-cultures and the 2 day co-
cultures with human cells are likely due to differences in the culturing process, either in 
the time of culture or the method. However, despite the differences between the rat 4 
day co-culture and human 2 days co-cultures, both showed increases in apical BCRP-
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dependent efflux in glioma co-culture when compared with their respective controls (i.e. 
astrocyte co-cultures), indicating that BCRP activity in PBECs is increased by co-
culture with glioma. 
 
Figure 5.8 ABC transporter activity in PBECs grown in co-culture human glioma cells. 
PBECs were grown in co-culture with human astrocytes (PBECs-hAS) or G7 glioma cells 
(PBECs-G7) for 2 days, under serum-free conditions or in co-culture with G7s for a total of 4 
days in a combination of serum and serum -free conditions (PBECs-G7.4) and then assayed. 




. The loaded cells were then incubated with efflux 
buffer, without (vehicle) or with an inhibitor, in both the apical and basal chambers of the 
Transwells for 35 minutes. The inhibitors used were the Pgp inhibitors haloperidol (60 µM) and 
verapamil (50 µM), the BCRP inhibitors Ko143 (0.2 µM) and prazosin (35 µM) and the non-
specific MRP family inhibitor MK571 (10 µM). 

















initially loaded into the cells. 
The inhibitable efflux was calculated for each inhibitor, as the efflux in the absence of inhibitor 
minus the efflux in the presence of inhibitor and expressed as a percentage of the efflux in the 
absence of inhibitor (% Control).  
A) Apical inhibition and B) inhibition at the basal surface.  
 Mean ± SEM of n=3-6 wells from n=3 plates  
A     B 
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* p<0.05, **p<0.01, difference in unpaired 2 tailed t-test between efflux in the presence of the 
indicated inhibitor and efflux in the absence of that inhibitor.  
$  p<0.05 difference in unpaired 2-tailed t-test between indicated pairs. 
5.1.3 Pgp and BCRP expression in PBECs during glioma co-culture 
 
To determine whether the differences in Pgp and BCRP activity noted above relate to 
their mRNA expression, comparisons were made between PBECs co-cultured with 
normal astrocytes and PBECs co-cultured with glioma cells.  
For the PBECs in rat co-cultures, mRNA expression was measured after the cells had 
been in co-culture for 3 days (when the PBECs reached confluence) or 4 days (after 24 
hour treatment with PBEC serum-free medium containing hydrocortisone, CPT-cAMP 
and Ro-20-1724). Two different C6 conditions were tested, one where the medium was 
changed on day two of co-culture and the other where the medium was not changed 
(the second is denoted by C6* in Figure 4.9 and Figure 4.10). Since C6 cells use up 
nutrients quickly and apoptose when nutrients are depleted, more cell death was 
expected when medium was not changed; apoptotic factors could influence the Pgp 
and BCRP mRNA expression in PBECs.  However, the results in Figure 4.9 and 4.10 
showed that frequency of medium change did not affect expression.  
For the PBECs in human co-cultures RNA was measured after only 2 days of co-
culture, due to the difficulties in co-culturing the cells for longer, as described 
previously.  
There was little change in Pgp or BCRP mRNA after 3 days in co-culture with C6s 
(Figure 4.9). However, after 4 days in co-culture there was ~3 fold greater BCRP 
mRNA expression under the C6 co-culture condition compared with rat astrocyte co-





The Effect of Glioma Co-culture on PBEC Efflux Transporter Activity




Figure 5.9 BCRP and Pgp mRNA in 
PBECs after 3 days in co-culture with 
rat glioma cells 
Total RNA was isolated from PBECs 
grown on Transwell filters in co-
culture with normal rat astrocytes 
(rAS) or C6 glioma cells (C6 or C6*) 
for 3 days in serum-containing media. 
The C6* denotes a condition where 
medium was not changed on day 2 of 
co-culture.  
The RNA underwent RT-QPCR using 
Pgp (A) or BCRP (B) primers. 
Ct values obtained per gene per 
sample were normalised against 
either β-actin (I) or GAPDH (II). Ct 
values obtained for the sample (to 
give the ΔCt) then further normalised 
against the average ΔCt of the rat 
astrocyte-cultured cells to give the 
ΔΔCt, which was then used to 
calculate the fold change 2
- ΔΔCt 
shown right.  
Mean ± SEM of n=3 samples per condition; PCR conducted in triplicate per plate on n=3 plates.  
* p<0.05, **p<0.01 difference from rAS control in unpaired 2 tailed t -test. 
 
The mRNA results after 4 days in co-culture agreed with the activity data for BCRP, 
with greater BCRP mRNA in the PBECs-C6s corresponding with greater BCRP activity 
results. However, mRNA levels for Pgp did not show any differences between PBECs-
rAS and PBECs-C6s, despite greater Pgp-dependent activity measured in the PBECs-
C6s than the PBECs-rAS.  
This suggests that BCRP activity is regulated at the transcriptional level in this co-
culture systems but that Pgp activity is not. It is possible that Pgp activity may be 
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Figure 5.10 BCRP and Pgp mRNA 
in PBECs after 4 days in co-culture 
with rat glioma cells 
Total RNA was isolated from 
PBECs grown on Transwell filters  
either in co-culture with normal rat  
astrocytes (rAS) or C6 glioma cells  
(C6 or C6*) for 3 day in serum-
containing media and for a further 
24 hours is serum-free medium, for 
a total of 4 days in co-culture. The 
C6* denotes a condition where 
media was not changed on day 2 
of co-culture.  
The RNA underwent RT-QPCR 
using Pgp (A) or BCRP (B) 
primers. 
Ct values obtained per gene per 
sample were normalised against  
either β-actin (I) or GAPDH (II). Ct  
values obtained for the sample (to 
give the ΔCt) then further 
normalised against the average ΔCt of the rat astrocyte-cultured cells to give the ΔΔCt, which 
was then used to calculate the fold change 2
- ΔΔCt 
shown right. 
Mean ± SEM of n=3 samples per condition; PCR conducted in triplicates per plate on n=3 
plates. 
**p<0.01, ***p<0.001 difference from rAS control in unpaired 2 tailed t-test from  
 
In the human co-cultures (Figure 4.11), no differences in Pgp or BCRP mRNA were 
seen when comparing the PBECs in human astrocyte co-culture with the PBECs in G7 
glioma co-culture. However, BCRP activity was shown to be significantly greater in 
PBECs-G7s, demonstrating greater levels of Ko143-inhibitable activity than PBECs-
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influenced by BCRP mRNA expression, indicating an mRNA-independent cause for the 
differences in BCRP activity, for example, possible post-transcriptional regulation. 
The differences in the rat and human BCRP expressions could be due to differences in 
the times the PBECs spent in co-culture. The rat model was co-cultured for 4 days and 
mRNA changes in BCRP were only consistently seen on the fourth day.  
 
Figure 5.11 Pgp and BCRP mRNA 
expression in PBECs co-cultured with 
human glioma cells for 2 days 
Total RNA was isolated from PBECs 
grown on Transwell filters either in co-
culture with normal human astrocytes 
(PBEC-hAS) or human G7 glioma cells 
(PBECs-G7) for 2 days in serum-free 
medium.  
The RNA underwent RT Q-PCR using 
Pgp (A) or BCRP (B) primers. 
Ct values obtained per gene per sample 
were normalised against either β-actin 
(I) or GAPDH (II). Ct values obtained for 
the sample (to give the ΔCt) then further 
normalised against the average ΔCt of 
the rat astrocyte-cultured cells to give 
the ΔΔCt, which was then used to 




Mean ± SEM of n=3 samples per condition; PCR was conducted in quadruplicate per plate.  
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5.2  Discussion 
 
This chapter focused on identifying the contribution of the major efflux transporters to 
apical efflux and how this is affected by normal astrocytes and glioma in co-culture. 
3H-MPP+ loading, the first step in the efflux assay used, showed that PBECs co-
cultured with glioma cells did not differ from co-culture with normal astrocytes. As 
described previous (Chapter 3), MPP
+
 uptake most likely occurs via OCT transporter 
(Martel et al., 2001). The lack of difference in loading, indicates that glioma cells have 
no glioma-specific effects on OCTs, beyond normal astrocytic effects. This could be a 
useful target for glioma therapy since intact OCT transporters could be a useful entry 
point for chemotherapeutic drugs to the brain. 
PBECs co-cultured with rat C6 cells showed lower apical Pgp activity than in PBECs-
rAS as well as some significant Pgp activity on the basal surface, which the PBECs-
rAS did not (Figure 4.7). No differences were seen between Pgp mRNA expression 
between the PBECs-C6s and PBECs-rAS (Figure 4.9 and Figure 4.10), which suggests 
that differences in Pgp activity between the PBECs-C6 and PBECs-rAS were not due 
to differences in mRNA levels. However, it is possible that Pgp activity was regulated 
post-transcriptionally (i.e. independent of mRNA levels). Further, since some Pgp-
dependant basal activity was detected, it may indicate that differences between the 
PBECs-C6s and the PBECs-rAS may involve differences in the regulation of Pgp 
apical:basal polarity and transporter localisation. 
BCRP showed greater apical activity in PBECs co-cultured with C6 than in PBECs co-
cultured with normal astrocytes (Figure 4.7). This correlated with increased mRNA 
expression of BCRP, indicating that increases in BCRP activity could be due to 
transcriptional changes. 
Comparisons between endothelial cells in astrocyte and C6 co-cultures have been 
conducted previously. Dohgu et al. (2004) showed that after 3 days in contact co-
culture mouse brain endothelial (MBEC4) cells in culture with C6 showed greater 
(paracellular) permeability to sodium fluorescein and decreased Pgp activity (measured 
via Rho 123 accumulation) compared with mono-cultured cells, whilst MBEC4 co-
cultured with astrocytes showed decreased permeability to sodium fluorescein and 
increased Pgp activity. This decrease in Pgp activity with C6 co-culture agrees with the 
current finding. By contrast, in the current study, the lower Pgp activity apically is 
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accompanied by increased barrier tightness (increased TEER and reduced 14C-
Sucrose Papp, Figure 4.4).  
Boveri et al. (2005) using bovine brain endothelial cells showed decreased Pgp protein 
expression and activity when co-cultured with C6s compared with normal astrocytes. 
Furthermore, the bovine brain endothelial cells did not differentiate as well as in the 
presence of C6 cells, with a less well developed pattern of TJ proteins (12 days in non-
contact co-culture).  
Taken together these studies suggest a link between the differentiation state of the 
BBB and Pgp expression, with a less differentiated BBB showing lower levels of Pgp.  
Interestingly, Boveri et al. (2005)  showed increased secretion of vascular endothelial 
growth factor (VEGF) by the C6 cells (with 40-fold higher levels detected in conditioned 
medium from C6s than from normal astrocytes), which was suggested to lead to  the 
lack of differentiation in their study. However, in the current shorter-term study, 
absence of BBB TJ breakdown suggests that the VEGF has not yet had such effects 
here. However, VEGF has been shown to decrease Pgp apical localisation/activity (see 
below). Therefore, in the current study VEGF secretion by the C6s could have led to 
Pgp activity decreases that were independent of BBB TJ breakdown. 
VEGF is a growth factor associated with angiogenesis and the growth and 
development of the BBB under normal condition (Ferrara et al., 2003). However, its 
over-expression by glioma cells has been implicated in tumour development and 
growth (Merrill & Oldfield, 2005), with the majority of gliomas showing increased 
expression of VEGF (Merrill & Oldfield, 2005). 
A direct link between BCRP activity or expression and VEGF has not been reported, 
but a link between Pgp activity and VEGF has been shown at the BBB. Hawkins et al. 
(2010b), showed both in vitro and in vivo (rat models) that VEGF decreases Pgp 
activity. Using rat capillaries and a fluorescent specific Pgp substrate ([N-ε(4-
nitrobenzofurazan-7-yl)-D-Lys(8)]-cyclosporin A), it was shown that the loss in Pgp 
activity after exposure to VEGF resulted from a loss of luminal expression  of Pgp. 
Overall protein expression was not altered, indicating that Pgp was not proteolytically 
degraded in response to VEGF. VEGF effects on Pgp were shown to be dependent on 
the activation of the VEGF receptor (flk-1) and scr kinase, the latter being involved in 
the caveolae phosphorylation pathway. 
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Jodoin et al. (2003) showed that around 70% of the Pgp in bovine brain capillary 
endothelial cells co-cultured with astrocyte, was found in isolated caveolae fractions. 
Similarly, 80% of the Pgp expressed in human capillaries was found co-localised with 
caveolin-1 and caveolin-2 within isolated caveolae fractions. In the caveolae fractions 
of the bovine brain endothelial cells Pgp was shown to interact with caveolin-1 and 
caveolin-2 and to be active within the caveolae, with disruption of caveolae decreasing 
Pgp activity (Jodoin et al., 2003).  
Barakat et al. (2007), showed that Pgp/caveolin-1 co-localised via direct interaction of 
the two proteins, where Pgp activity was suppressed by phosphorylated caveolin-1. 
Knock-down of caveolin-1 via siRNA resulted in increased Pgp activity in RBE4 cells 
(with Pgp substrate accumulation assay, showing decreased accumulation when 
caveolin-1 was silenced). The study further showed that src kinase and/or 
phosphorylation of tyrosine14 on caveolin-1 did not affect expression of Pgp, however 
did decrease Pgp activity. It was concluded that phosphorylation of tryosine14 on 
caveolin-1 increased its interactions with Pgp, resulting in down-regulation of Pgp 
activity, without altering expression. 
Caveolae have been shown to be largely expressed on the surface of plasma 
membranes with slow rates of endocytosis (Fagerholm et al., 2009). This maintenance 
at the plasma membrane has been suggested to be linked by caveolin-1 within the 
caveolae, which interacts with f-actin to maintain the caveolae at the plasma 
membrane. However, Fagerholm et al. (2009) showed  in adipocytes that 
phosphorylation of tyrosine14 on caveolin-1 can result in rapid internalisation of 
caveolae and endocytosis, with the phosphorylated caveolin-1 being internalised within 
an endosome. 
Hawkins et al. (2010b) showed that VEGF treatment resulted in the phosphorylation of 
caveolin-1 (via src kinases), therefore VEGF acts via activation of flk-1 and src to 
mediate phosphorylation of caveolin-1 resulting in internalisation of Pgp via caveolae 
vesicle endocytosis. In addition, Hawkins et al. (2010a) showed that VEGF could 
protect Pgp from protease kinase cleavage at the apical surface, by a mechanism 
consistent with internalisation via caveolae endocytosis.  
Together these studies indicates that Pgp activity can be regulated by VEGF without 
affecting Pgp expression, acting via src kinase phosphorylation of caveolin-1, leading 
to interaction of Pgp and phosphorylated calveolin-1, with the Pgp/phosphorylated 
caveolin-1 complex then internalised via caveolae endocytosis. 
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Early studies showed increases in the number of vesicles within brain microvasculature 
during tumour challenge (Dinda et al., 1993, Bertossi et al., 1997). Bertossi et al. 
(1997) showed no statistical difference in the number of vesicles between normal and 
peritumoural microvessels, however did show that in peritumoural vessels there were 
three times as many vesicles attached to the luminal surface. Regina et al. (2004) 
showed down-regulation of caveolin-1 and increases in phosphorylated caveolin-1 in 
glioma vasculature. In accordance with the above studies; increases in phosphorylation 
could then lead to increased internalisation of vesicles as well as decreases in Pgp 
activity. Similarly Zhao et al. (2011) showed that VEGF leads to increased caveolae 
endocytosis at the BBB.  
Taken together, these studies suggest that in the current study, Pgp differences under 
the influence of glioma co-culture (more particularly the lower apical Pgp activity of the 
PBECs in C6 co-culture) could have been (in part) due to altered Pgp/caveolae 
internalisation brought about by increased VEGF expression of glioma cells. 
Dinda et al. (1993), showed that in peritumoural microvasculature there were increased 
numbers of pinocytic vesicles and large vacuoles (mainly below the luminal surface), 
but also an increase in these at the abluminal/basal surface, where the number of 
abluminal vesicles increased with tumour grade/oedema. This indicates glioma can 
alter caveolae organisation at the plasma membrane of the BBB (shifting from 
luminal/apical to abluminal/basal surfaces). Furthermore, if Pgp is contained within the 
caveolin it could result in a reshuffling of Pgp from the luminal to the abluminal surface. 
This reshuffling contributes to the decreases apical Pgp activity but increased Pgp 
activity at the basal surface in this study. 
Together this suggests that one of the effects of glioma on the BBB is increased 
internalisation of caveolae/Pgp by endothelial cells, probably through VEGF/src/Cav-1-
P pathway, with potential reorganisation of Pgp/vesicles to the abluminal/basal surface.  
Pgp expression has been claimed at the basal surface under normal conditions 
(Bendayan et al., 2006). Here we showed that C6 cells induced Pgp activity at the 
basal surface, while rat astrocyte did not, demonstrating that any Pgp activity at the 
basal surface was increased due to the presence of C6 cells and did not occur under 
normal conditions. Hence, the Bendayan et al. (2006) needs to be treated with caution. 
The physiological implication of these finding is that under glioma challenge the BBB 
could have decreased Pgp activity at the apical surface and increased Pgp activity at 
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the basal surface, which could decrease the ability of the BBB to remove potentially 
dangerous chemicals but increase chemotherapeutic entry.   
Loss of Pgp in the BBB has been shown previously to result in BCRP upregulation 
(Cisternino et al., 2004), suggesting that endothelial cells can increase BCRP to 
compensate for a loss in Pgp. Here it was shown that BCRP activity was greater on the 
apical surface in the PBECs-C6 (as well as some evidence of greater MRP activity) 
where apical Pgp activity decreased (Figure 4.6 and Figure 4.7). Furthermore, in this 
study, there was no difference in overall efflux at the apical surface (Figure 4.2), 
demonstrating that increases in BCRP activity (and possibly MRP activity) did enough 
to compensate for the loss of apical Pgp activity.  
Concerning the changes in the PBEC BCRP expression under the normal and glioma 
co-culture, there was greater BCRP activity in rat glioma co-culture that correlated with 
the increased BCRP mRNA expression, suggesting BCRP activity may be regulated 
transcriptionally during glioma co-culture, with greater BCRP mRNA expression leading 
to greater protein expression and greater levels of BCRP activity. Furthermore, since 
BCRP mRNA was greater but Pgp mRNA was not, it suggests that BCRP is regulated 
by a different pathway to Pgp. Therefore joint pathways of regulation, such as 
glucocorticoid receptors (GRs), pregnane X receptor (PXR), glutamate/n-methyl-D-
aspartate (NMDA)/ cyclooxygenase 2 (COX-2) which have been shown to up-regulate 
both transporters together can be excluded (Lemmen et al., 2013, Narang et al., 2008, 
Yousif et al., 2012). 
Lemmen et al. (2013) used PBECs to show that  activation of PXR leads to increased 
BCRP and Pgp mRNA within 6 hours and increased protein/activity by 12 hours. 
Similarly, Narang et al. (2008), showed PXR expression correlated with increased 
BCRP and Pgp expression in response to dexamethasone (which occur quickly within 
6 hours) and inhibiting GRs prevented the increases, indicating that activation of both 
GR and PXR increased Pgp and BCRP mRNA/protein levels (using rat BBB model). 
Yousif et al. (2012) showed that morphine increased Pgp and BCRP mRNA and 
protein within 24 hours and that these effects were blocked by inhibiting NMDA 
receptors or COX-2, while activation of prostaglandin E2 receptors increased Pgp and 
BCRP mRNA. This implicated the glutamate NMDA/COX2 pathway in up-regulating 
Pgp and BCRP in response to morphine (using rat and human BBB models).  
Pathways which have opposing effects on Pgp and BCRP transporters have been 
identified. Liu et al. (2008) showed than insulin treatment of rat endothelia for 72 hours 
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increases Pgp mRNA and protein, while in another study Liu et al. (2011) showed that 
the same insulin treatment results in decreased BCRP mRNA and protein. Chernausek 
et al. (1993) did show that C6s secrete twice the amount of insulin-like growth factor-1 
(which acts on the same receptors as insulin) than normal glial cells. However, this 
cannot be the cause of the differences seen in the present study since this would lead 
to increased Pgp and decreased BCRP in accordance with the findings from Liu et al. 
(2008) and Liu et al. (2011). 
Poller et al. (2010) also showed opposite regulation of Pgp and BCRP (in human 
hCMEC/D3 BBB model). The study showed that pro-inflammatory cytokines affected 
transporter expression. Interleukin-1β (IL-1β) decreased BCRP mRNA but had no 
effect on Pgp mRNA, while interleukin 6 (IL-6) decreased both Pgp and BCRP mRNA 
and tumour necrosis factor-α (TNF-α) decreased BCRP and increased Pgp mRNA 
expression (72 hour treatments). Similarly, von Wedel-Parlow et al. (2009), showed 
TNF-α and IL-1β decreased BCRP mRNA expression of PBECs with no effect on Pgp 
mRNA (after just 6 hours of treatment). By 24 hours decreased protein levels of BCRP 
were noted with both treatments, while Pgp protein levels where only shown to 
decrease by 24 hours for IL-1β and 48 hours for TNF-α. Interestingly endothelin-1 
treatment (a upstream trigger of TNF-α) caused an increase in BCRP and a decrease 
in Pgp protein after 48 hours, implicating the endothelin-1 and TNF-α pathways, which 
according to Rigor et al. (2010) work via activation of endothelin B (ETB) receptor, nitric 
oxide signaling (NOS) and protein kinase C β1 (PKCβ1) to reduce Pgp. 
Conversely, von Wedel-Parlow et al. (2009) showed that treatment with an anti-
inflammatory glucocorticoid (hydrocortisone) (for 48 hours) increased BCRP mRNA (3 
fold)  and slightly decreased Pgp mRNA, more in agreement with the current study.  
This shows opposite regulation effects of inflammation on BCRP and Pgp. However in 
the current study in contrast to the above study with anti-inflammatory agents, although 
there was up-regulation of BCRP mRNA no effect on Pgp mRNA was noted. Therefore 
a truly independent pathway for BCRP mRNA is required to explain the results 
obtained here. However, very few individual pathways for BCRP mRNA regulation 
(independent of Pgp regulation) have been identified.  
One study by Hoque et al. (2012), showed that in hCMEC/D3 BBB cells, PPARα 
activation led to increased BCRP mRNA, protein and activity (in a time-dependent and 
ligand-concentration dependent manner) via PPARα binding to the BCRP promoter. 
Studies involving PPARα activation have shown either no effect or decreases in Pgp 
activity (Ehrhardt et al., 2004). Interestingly, Weiss et al. (2009), showed that  treatment 
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with PPARα/γ ligands resulted in increased BCRP mRNA  with no effect on Pgp 
mRNA. These studies are consistent with the findings of the current study, which may 
implicate the PPAR nuclear receptors in the effect seen here in C6 co-culture. 
Since the current study showed that BCRP mRNA expression increased on day 3 of 
co-culture prior to addition of CPT-cAMP and Ro-20-1724 (Figure 4.9), this indicates 
that the pathways responsible for BCRP mRNA increases can be independent of 
elevating cAMP. However, conclusive mRNA increases in BCRP (when using both 
reference genes) correlated with the addition of CPT-cAMP and Ro-20-1724 (Figure 
4.9), indicating that CPT-cAMP and Ro-20-1724 can enhance the C6 effects seen on 
day 3 of co-culture. Therefore, this indicates that BCRP mRNA is up-regulated by a 
pathway that can be influenced by, but is not dependent on, CPT-cAMP and Ro-20-
1724. Interestingly, cAMP can work via PKA to increase the phosphorylation of PPAR 
proteins, resulting in their activation/DNA binding capabilities, however 
phosphorylation/activation can also occur via other means (Diradourian et al., 2005). 
Therefore, this too implicates the PPAR pathway in the regulation of BCRP mRNA 
under C6 conditions. However, the way in which C6s could trigger PPAR responses in 
PBECs is unclear, with no studies conducted on the matter. Therefore, this is only a 
possibility, and other yet undiscovered pathways could be involved in BCRP regulation 
during glioma challenge. 
In the human co-cultures no notable changes in BCRP mRNA expression were seen in 
the glioma co-cultures (Figure 4.11), which was different to the greater BCRP mRNA 
expression shown in the rat glioma co-cultures by the PBECs-C6s, when compared to 
the PBECs-rAS. This difference could be due to the length of the co-culture or 
differences in the methods of co-culture.  
In the rat co-cultures, the rat cells were in co-culture for 4 days, while the human cells 
were in co-culture for only 2 days; the latter may not be enough time to induce mRNA 
changes. Similarly, Boveri et al. (2005), who used cells for 12 day co-culture with 
bovine endothelia,  could not replicate the results of Raub et al. (1992) who only 
conducted the co-culture for 2 days. However, even though there was no change in 
mRNA expression in the current study, increased BCRP activity was seen (Figure 4.8), 
suggesting that, like Pgp, BCRP can also be regulated post-transcriptionally. Although 
no post-transcriptional regulation of BCRP has yet been reported, regulation via 
dimerisation of BCRP (where a dimer is needed for BCRP activity) had been suggested 
as a means of regulating BCRP activity post-transcriptionally (Mo & Zhang, 2009, Ni et 
al., 2010), suggesting an expression-independent regulation of BCRP is possible. 
The Effect of Glioma Co-culture on PBEC Efflux Transporter Activity
   
136 
 
Furthermore, the co-cultures with the rat cells began while the PBECs were 
proliferating, but in the 2 day human co-cultures the PBECs were co-cultured after 
confluence had been reached. An early study could not induce BBB enzymes through 
astrocyte co-culture when using a non-proliferation confluent monolayer of  brain 
endothelial cells, but could when co-culturing the endothelial cells with the astrocytes 
during proliferation (Meyer et al., 1990). . 
This has implications for glioma development in vivo, indicating that new BBB formation 
is more vulnerable to the influence of glioma than an established BBB. Therefore in 
glioma, where VEGF has been shown to be commonly increased and be involved in 
promoting angiogenesis (Jain et al., 2012), the new BBB or blood-tumour barrier could 
be compromised. In addition this may have implications for repair of the BBB during 
glioma, where the new BBB formed after apoptosis, necrosis or hypoxia, may be 
compromised. This agrees with previous studies showing that the BBB in early tumour 
challenge is tight, while later stages of glioma show increased BBB permeability 
(Larsson et al., 1990) and also that the newly-formed vasculature of glioma is leaky 
(Jain et al., 2012 ). 
Understanding such differences in the BBB during tumour challenge may help in the 
development of pharmaceuticals that can more effectively treat glioma. Since in the 
current study, both the proliferating PBECs (4 day rat co-culture) and the confluent 
PBECs (2 day human co-cultures) showed glioma to increase BCRP activity, increases 
in BCRP activity may be a common feature of both the established and newly formed 
BBB, and its increased activity should be considered in pharmaceutical treatment of 
gliomas.   








Previous results (Chapter 4) indicated that PBEC BCRP is transcriptionally regulated in 
the presence of glioma cells, with mRNA expression in PBECs co-cultured with C6s 
increasing 3-4 fold when compared with PBECs in co-culture with normal rat 
astrocytes. However, no Pgp modulation in mRNA expression was observed. This 
suggested independent pathways exist for BCRP and Pgp regulation. 
Since the Wnt and Hedgehog signaling pathways are known to modulate BCRP and 
Pgp expression (Sims-Mourtada et al., 2007, Lim et al., 2008) and since the glioma 
secretome contains modulators of these systems (Zhou et al., 2010, Braun et al., 
2012), the effect of signaling agonist and antagonist were tested. 
PBECs were grown in either astrocyte-conditioned medium, C6-conditioned medium or 
human glioma-conditioned medium, to try and identify any pathways responsible for the 
effects noted previously. 
To assess differences in Pgp and BCRP activity between the PBECs in normal and 
glioma-conditioned media a modified Hoechst assay was used based on the cell 
accumulation of Hoechst 33342 dye which is both a Pgp and BCRP substrate (Shapiro 
et al., 1997, Tang et al., 2004, von Wedel-Parlow et al., 2009). This allowed rapid 
screening in a 96-well format, which the 3H-MPP+ assay did not. Hoechst 33342 is a 
nucleotide-binding dye that can freely diffuse through the plasma membrane and reach 
the nucleus and bind to DNA. Once bound to the DNA, Hoechst 33342 becomes 
fluorescent at a wavelength of ~460 nm (Zhang et al., 1999). Inhibition of efflux 
transporters reduces efflux of the dye, enhancing dye accumulation; thus transporter 
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6.1.1 PBECs grown in different media 
 
Since each co-culture cell type required different growth media, the effects of non-
conditioned media on PBECs efflux activity were compared. 
PBECs were grown in either 50% serum-free PBEC medium (sfPBEC), 50% Astrocyte 
Medium (AsM/sfPBEC) or 50% Neural Stem Cell medium (NsM). The growth was 
conducted as follows over a period of 4 days (Table 5.1):  
 
Table 6.1 PBEC media composition 
Medium 
Label 
Days After Passaging 
Day 1 Day 2 Day 3  Day 4 
sfPBEC 
a


























 50% PBEC Medium 50% PBEC Medium 50%PBEC Medium 50% PBEC Medium 
50% Neural Stem 
Cell Medium 
50% Neural Stem 
Cell Medium 
50% Neural Stem 
Cell Medium 




 sfPBEC replicates the condition of Mono-cultured PBECs (PBECs-M),  
b
 AsM/sfPBEC replicates the condition of  the rat astrocyte and C6 co-cultures (PBECs-rAS and 
PBECs-C6)   
c
 NsM replicates the condition of  the human astrocyte and G7 2 day co-cultures (PBECs-hAS 
and PBECs-G7).  
 
After four days the PBECs were then assayed using the Hoechst Uptake assay in the 
absence or presence of Ko143 (BCRP inhibitor) or haloperidol (Pgp inhibitor) (Figure 
5.1).  
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                  A 
 
                B          C
 
Figure 6.1 BCRP and Pgp activity of PBECs grown in standard media  
PBEC efflux activity was assayed using the Hoechst Uptake assay. Hoechst 33342 (10 µM) was 
incubated with the PBECs for 1 hour in the absence or presence of ABC transporter inhibitors 
Ko143 (0.2 µM) or haloperidol (60 µM) and Hoechst accumulation expressed as Relative 
Fluorescence Units (RFU) per µg protein.  
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A) The Hoechst uptake per µg protein by PBECs grown in different media compositions; 
sfPBEC = 100% serum-free PBEC medium; AsM/sfPBEC= 50% Astrocyte Medium and 50% 
serum-free PBEC medium; NsM = Neural Stem Cell Medium. 
The RFU/ µg protein data under the inhibitor conditions for a given medium type was then 
normalised against the control (no inhibitor, indicated by the dotted red lines) data for that same 
medium type to give the relative inhibition of BCRP (B) and Pgp (C) by the Ko143 and 
Haloperidol inhibitors respectively.   
The results are expressed as % control RFU/µg protein (with control uptake indicated by the red 
dotted line). Values are mean ± SEM of n=3 wells from 2-3 plates.  
* p<0.05 difference in unpaired 2-tailed t-test, between the indicated inhibitor and its own no 
inhibitor control.  
# p<0.05, ##p<0.01, ## p<0.001 difference in a paired 2-tailed t-test, between the indicated 
inhibitor and its own no inhibitor control on the same plate.  








N/A = not assessed 
 
The results (Figure 5.1 B and C) showed similar levels of Ko143 and of haloperidol 
inhibition between all the conditions, indicating similar levels of BCRP and Pgp activity 
respectively. 
PBECs were then grown for four days in conditioned medium from normal rat 
astrocytes (AsCM), rat C6 cells (C6CM), normal human neural stem cells (Cb660CM) 
or human malignant glioma cells with neural stem cell markers G15 (G15CM), G7 
(G7CM) or G26 (G26CM) (Table 5.2). However, due to low availability of the human 
cell-conditioned media only the BCRP activity was assessed. 
Conditioned medium (C6CM or AsCM) had no effect on Pgp activity compared with the 
non-conditioned medium equivalent (AsM/sfPBEC) (Figure 5.2A). However, growing 
PBECs in AsCM suppressed BCRP activity when compared with non-conditioned 
medium. BCRP activity was greater in C6CM than in than in AsCM (Figure 5.2A) but 
not significantly different from non-conditioned medium. 
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Similarly, G7- and G26-conditioned medium also showed increased BCRP activity 
when compared with Cb660CM (Figure 5.2C).  
This indicates that the glial cells supplement the medium with one or more factors that 
can influence PBEC ABC transporter activity. 
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Table 6.2 Conditioned media composition 
Medium 
Label 
Days After Pass aging 
Day 1 (Media 
Change) 





50% PBEC Medium 50%  PBEC Medium 50% PBEC Medium 50% PBEC Medium 
50% Astrocyte 
Medium B 
















50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 
50% Astrocyte 
Medium B 
condit ioned by C6s 
50% Astrocyte 
Medium B 
condit ioned by C6s 
50% serum-free 




condit ioned by C6s 
 50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 
Cb660CM 50% Neural Stem 
Cell Medium 
condit ioned by 
Cb660s  
50% Neural Stem 
Cell Medium 
condit ioned by 
Cb660s  
50% Neural Stem 
Cell Medium 
condit ioned by 
Cb660s  
50% Neural Stem 
Cell Medium 
condit ioned by 
Cb660s  
G15CM 
50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 
50% Neural Stem 
Cell Medium 
condit ioned by G15s 
50% Neural Stem 
Cell Medium 
condit ioned by G15s 
50% Neural Stem 
Cell Medium 
condit ioned by G15s 
50% Neural Stem 
Cell Medium 
condit ioned by G15s 
G7CM 
50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 50% PBEC Medium 
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Figure 6.2 BCRP and Pgp activity of PBECs grown in conditioned media  
PBECs were grown in media conditioned by rat or human cells and efflux  transporter activity 
was assessed using the Hoechst Uptake assay. Hoechst 33342 (10 µM) was inc ubated with the 
PBECs for 1 hour in the absence or presence of ABC transporter inhibitors Ko143 (0.2 µM) (A) 
or haloperidol (60 µM) (B) and Hoechst accumulation expressed as Relative Fluorescence Units 
(RFU) per µg protein. 
I) The Hoechst uptake per µg protein by PBECs grown in different media compositions; 
AsM/sfPBEC= 50% Astrocyte Medium and 50% serum-free PBEC medium; AsCM = rat 
astrocyte conditioned medium, C6CM = G6 glioma conditioned medium; NsM = Neural Stem 
Cell Medium, Cb660CM = conditioned medium from normal human neural stem cells, G15, G7 
and G26 CM = conditioned medium from different human glioma cell lines.  
The RFU/ µg protein data under the inhibitor conditions for a given medium type was then 
normalised against the control (no inhibitor, indicated by the red dotted lines) data for that same 
medium type to give the relative inhibition of BCRP (II) and Pgp (II) by the Ko143 and 
Haloperidol inhibitors respectively.   
A I     A II      A III 
B I            B II       
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The results are expressed as % control RFU/µg protein (with control uptake indicated by the red 
dotted line). Values are mean ± SEM of n=3 wells from 2-3 plates.  
* p<0.05 difference in unpaired 2-tailed t-test, between the indicated inhibitor and its own no 
inhibitor control.  
# p<0.05, ##p<0.01, ### p<0.001 difference in a paired 2 -tailed t-test, between the indicated 
inhibitor and its own no inhibitor control on the same plate.  
$ p<0.05, $$ p<0.01 statistically significant differences in 1-way ANOVA using Newman-Keuls 
Multiple Comparison post test 
£ p<0.05,  ££ p<0.01 statistically significant differences in 1-way ANOVA using Tukey's Multiple 
Comparison post test 







6.1.2 PBEC efflux transporter: Hedgehog and Wnt signaling 
 
To investigate whether the Hedgehog and Wnt signaling pathways could affect PBEC 
ABC transporter activity, PBECs were grown in AsCM or C6CM with agonists and 
antagonists of these systems for 48 hours (Table 5.3, Figure 5.3). PBECs grown in 
AsCM were used as the normal condition since AsCM influenced PBEC transporter 
activity and hence was deemed a more physiologically normal control than non-
conditioned medium.  
 
Table 6.3 Drug treatments 
Pathw ay Treatment Treatment Type Target Concentration Ref 
Hedgehog SHH Agonist Patch Receptor 1µg/ml Chen et al 2012 
 Cyclopamine Antagonist Smo membrane 
receptor 
30 µM Yauch et al 2008 
Wnt BIO Agonist GSK-3β 1 µM Lim JC 2008 
 Dkk-1 Antagonist Frizzled Receptor 0.1mg/ml Lim JC 2008 




Figure 6.3 Sonic Signaling (Modified from Comptom et al., 2007)  
a) Sonic hedgehog (SHH) secreted by a localised source (shown in green) creates a gradient of 
concentration that provides positional information to the cells in the gradient, dependent on the 
concentration and duration of the signal, and specifies distinct cell fates accordingly 
(represented by different shades of blue). The amount of SHH signal received by a cell affects 
the ratio of glioma-associated oncogene (GLI) activator form–GLI repressor form (GLIact–
GLIrep) protein content, with increased amount of GLIact in cells closer to the SHH secreting 
source and increased GLIrep in cells receiving low or no SHH. The ratio of GLIact:GLIrep 
proteins is instrumental in the interpretation of the SHH gradient.  
b) In the absence of SHH protein, patched (PTCH1) inhibits smoothened (SMO) activity 
allowing the protein kinase A (PKA)-mediated phosphorylation and truncation of GLI2 and GLI3. 
GLI2rep and GLI3rep are transported to the nucleus where they negatively regulate gene 
transcription. In the presence of SHH, interaction of SHH with PTCH1 relieves the inhibi tion of 
SMO. Activated SMO protects the GLI proteins from PKA-mediated modification and activates 
them. GLI1act–GLI3act are translocated to the nucleus where they activate target gene 
transcription. 
Cyclopamine inhibits SMO activity inducing an inactive state, while SHH treatment alleviates 
SMO inhibition activating the pathway. 
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The results (Figure 5.4) show that for PBECs in AsCM, the sonic pathway agonist, 
SHH, increased BCRP activity, but inhibition of the sonic downstream receptor Smo 
alone had no effect. Conversely, for PBECs in C6CM, treatment with SHH decreased 
both BCRP and Pgp activity, while treatment with the sonic receptor antagonist 
(cyclopamine) increased BCRP activity, indicating that the response to sonic signaling 
is altered by C6CM.  
 
Figure 6.4 Sonic Hedgehog and ABC transporter activity  
PBECs grown in either rat astrocyte-condition medium (AsCM, light bars) or C6-conditioned 
medium (C6CM, dark bars) and treated for 48 hours with either recombinant sonic hedgehog 
A       B  
C I      D I 
C II               C III   D II            D III 
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(SHH, 1µg/ml),  cyclopamine (Cyc, 30 µM) or vehicle control (-), were assayed using a Hoechst 
Uptake assay.  
Hoechst 33342 (10 µM) was incubated with the PBECs for 1 hour in the absence or presence of 
ABC transporter inhibitors Ko143 (0.2 µM, BCRP inhibitor, K) or haloperidol (60 µM, Pgp 
inhibitor, H)  and Hoechst accumulation is expressed as Relative Fluorescence Units (RFU) per 
µg protein. 
The inhibition effect of the transporters was calculated as the increase in RFU/µg protein in the 
presence of inhibitor when compared to the RFU/µg protein in the absence of that inhibitor on 
the same plate. The inhibition effect was then normalised to baseline Hoechst uptake on the 
same plate (i.e. the uptake in the absence of any treatment or inhibitors) (indicated by the red 
dotted lines in A and B), with normalised inhibition data given in C I and D I for Ko143 and 
Haloperidol respectively.  
Ko143 inhibition was used to determine BCRP activity (C) and Haloperidol was used to 
determine Pgp activity (D).  
The normalised inhibition data in the SHH or cyclopamine treated PBECs were then expressed 
as a percentage of the normalised Ko143 and haloperidol inhibitions measured in untreated 
PBECs (as shown in CII-CIII and DII- DIII). 
Mean ± SEM of n=4-10 wells from 3-5 plates.  
#p<0.05, ##p<0.01, ###p<0.001 statistically significant differences in a 2-tailed paired t-test 
between the indicated inhibitor condition and its respective no inhibitor control from the same 
plate.  
*p<0.05, **p<0.01 statistically significant differences in a paired t -test between the indicated 
condition and its respective untreated control from the same plate.   
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To investigate the Wnt pathway, PBECs were treated with BIO to upregulate signaling, 
and Dkk-1 to inhibit signaling (see Table 5.3, Figure 5.5).  
The data (Figure 5.6) show that for PBECs in AsCM, activation of the Wnt pathway 
increased both BCRP and Pgp activity, while inhibition of Wnt signaling using Dkk-1 
alone decreased BCRP activity, demonstrating endogenous Wnt activity in PBEC in 
AsCM. By contrast, for PBECs in C6CM neither intervention had any significant effect.  




Figure 6.5Wnt Signaling (Modified from Staal et al., 2008) 
a) In the absence of WNT signalling, β-catenin levels in the cytoplasm and nucleus are low as a 
result of continuous phosphorylation by the serine/threonine kinases CK1 (casein kinase 1) and 
GSK3β (glycogen synthase kinase 3β), leading to binding of -transducin-repeat-containing 
protein (TRCP) and to ubiquitylation and degradation by the proteasome. The destruction 
complex is composed of CK1 and GSK3β, as well as the anchor proteins AXIN1 (axis inhibition 
protein 1) and APC (adenomatous polyposis coli). In the nucleus, TCF (T-cell factor) molecules 
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are bound by co-repressors such as GRG/TLE (Groucho/transducin -like enhancer) proteins that 
shut off expression of WNT target genes. Other components of the repressor complex include 
CTbP (C-terminal binding protein) and HDACs (histone deacetylases). β-catenin in the nucleus 
is inhibited from binding TCF by ICAT (cell autonomous inhibitor of β-catenin and TCF) . The 
Frizzled receptor complex — composed of Frizzled and LRP5 (LDL-receptor-related protein 5) 
or LRP6 — can also be actively inhibited by receptor-bound soluble inhibitors such as DKK1 
(Dickkopf homologue 1).  
b) Upon binding of a lipid-modified WNT protein to the receptor complex, a signaling cascade is 
initiated. LRP is phosphorylated by CK1 and GSK 3β, and AXIN1 is recruited to the plasma 
membrane. The kinases in the β-catenin destruction complex are inactivated and β-catenin 
translocates to the nucleus to form an active transcription factor complex with TCF, leading to 
transcription of a large set o f target genes. In the nucleus, β-catenin binds to TCF and LEF 
factors and recruits co-factors such as legless (LGS; also known as BCL9) and Pygopus 
(PYGO), CBP/p300, Brahma and MED12 to initiate transcription
 
DVL, mammalian homologue of 
Drosophila Dishevelled; PP2A, protein phosphatase 2A.  
Dkk-1 treatment acts to inactivate the Wnt pathway, while BIO inhibits GSK3β acting to promote 
the active Wnt state. 
 




Figure 6.6 Wnt and ABC transporter activity 
PBECs grown in either rat astrocyte-condition medium (AsCM, light bars) or C6-conditioned 
medium (C6CM, dark bars) and treated for 48 hours with either BIO (1 µM), recombinant Dkk -1 
(0.1mg/ml) or vehicle control (-), were assayed using a Hoechst Uptake assay.  
Hoechst 33342 (10 µM) was incubated with the PBECs for 1 hour in the absence or presence of 
ABC transporter inhibitors Ko143 (0.2 µM, BCRP inhibitor, K) or haloperidol (60 µM, Pgp 
inhibitor, H) and Hoechst accumulation is expressed as Relative Fluorescence Units (RFU) per 
µg protein. 
The inhibition effect of the transporters was calculated as the increase in RFU/µg protein in the 
presence of inhibitor when compared to the RFU/µg protein in the absence of that inhibitor on 
the same plate. The inhibition effect was then normalised to baseline Hoechst uptake on the 
A       B  
C I      D I 
C II         C III                          D II     D III  
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same plate (i.e. the uptake in the absence of any treatment or inhibitors) (indicated by the red 
dotted line in A and B), with normalised inhibition data given in CI and D I for Ko143 and  
Haloperidol respectively.  
Ko143 inhibition was used to determine BCRP activity (C) and Haloperidol was used to 
determine Pgp activity (D).  
The normalised inhibition data in the SHH or cyclopamine treated PBECs were then expressed 
as a percentage of the normalised Ko143 and haloperidol inhibitions measured in untreated 
PBECs (as shown in CII-CIII and DII- DIII). 
Mean ± SEM of n=4 from 2 plates.  
$ p<0.05, statistically significant differences in a 2-tailed unpaired t-test between the indicated 
inhibitor condition and its respective no inhibitor control.  
#p<0.05, ##p<0.01, ###p<0.001 statistically significant differences in a 2-tailed paired t-test 
between the indicated inhibitor condition and its respective no inhibitor control from the same 
plate.  
*p<0.05, **p<0.01 statistically significant differences in a paired t -test between the indicated 




The current study aimed to investigate Wnt and Hedgehog signaling in PBECs grown 
in AsCM and glioma CM. 
The results showed that in PBECs in AsCM, activation of the canonical Wnt/β-catenin 
pathway (by inhibiting GSK-3β with BIO) led to increased BCRP and Pgp activity in 
PBECs. Conversely, inhibition of Wnt (by inhibitor of the Wnt Frizzled receptor, Dkk-1) 
decreased BCRP activity (Figure 5.4). This showed not only that Wnt can increase 
BCRP and Pgp activity in PBECs, but that for PBECs in AsCM medium, the Wnt 
pathway is constitutively active, since the inhibitor did have an effect.  
The constitutive activity of Wnt in the PBECs is not necessarily derived from the AsCM. 
Similar results of Wnt activation and inhibition in both primary rat and human 
endothelial cells in non-conditioned medium, have been shown by Lim et al. (2008). In 
that study, Wnt activation using BIO led to increased mdr1a (rat endothelial cells) and 
MDR1 (human endothelial cells) mRNA and Pgp protein expression. ABCG2 mRNA 
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and BCRP protein expression also increased. The increases correlated with increased 
β-catenin translocation to the nucleus, implicating β-catenin/TCF/LEF in the 
transcriptional regulation of the ABCs. Conversely, the addition of Wnt inhibitors to the 
endothelial cells, caused decreased Pgp and BCRP mRNA and protein expression. 
This together demonstrates that Wnt in constitutively active within brain endothelial 
cells and that this is partly responsible for the basal expression levels/activity of BCRP 
and Pgp.  
Harati et al. (2013) also investigated the link between the Wnt/β-catenin pathway and 
Pgp/BCRP expression. Harati et al. (2013) examined capillaries isolated from rats at 
different stages of development and showed that Pgp and BCRP mRNA expression 
increased with rat maturation. Pgp protein expression also increased with rat 
maturation, however, BCRP protein expression did not, with BCRP protein expression 
stabilising early in the development process. Furthermore, neither Pgp nor BCRP 
activity changed throughout development, showing that despite changes in the protein 
and/or mRNA expression of Pgp and BCRP, activity was constant. 
Interestingly, β-catenin expression (both mRNA and protein expression) was shown to 
decrease with rat brain development. There was  an inversely correlation between with 
the mRNA expression of Pgp and BCRP and β-catenin expression, showing that 
despite decreases in Wnt signaling, BCRP and Pgp mRNA expression continued to 
increase (Harati et al., 2013). This indicates that factors other than Wnt are also 
involved in the regulation of BCRP and Pgp expression. However, as with the Lim et al. 
(2008) study, Harati et al. (2013) did show that, activation of Wnt (with BIO) increased 
β-catenin mRNA and protein expression.  Wnt activation in vivo also resulted in higher 
nuclear levels of β-catenin that correlated with increased BCRP and Pgp mRNA/protein 
and activity. In addition, Harati et al. (2013) further showed the endothelin-1 (ET-1) 
mRNA and protein were increased in response to BIO in vivo and that the BIO effect on 
BCRP could be countered by simultaneous administration of an ETA receptor (receptor 
for ET-1) inhibitor. This demonstrates that Wnt effects on the ABC transporters could 
be ET-1 dependent. 
In the current study, the involvement of the Hedgehog pathway was also investigated. 
Although the role of the Hedgehog pathway has been investigated in the BBB 
previously, no effects of Hedgehog on the BBB ABC transporters has been reported.  
Alvarez et al. (2011) did show that the Sonic hedgehog pathway can be activated in 
endothelial cells, with activation promoting BBB integrity. In this study, Alvarez et al. 
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(2011) showed that the SHH protein precursor is  made and secreted by astrocytes; 
human foetal astrocytes (but not human brain endothelial cells) demonstrated the 
expression of the SHH precursor and cleaved SHH protein was detected in astrocyte-
conditioned medium. Similarly SHH was found in human and mouse astrocytes in vivo, 
but not in endothelial cells or pericytes (Alvarez et al., 2011). Furthermore, brain 
endothelial cells were shown to express the Hedgehog receptor and respond to SHH 
signals. 
Treatment of brain endothelial cells in vitro with either astrocyte-conditioned media 
(ACM) or recombinant SHH was shown to have similar effects, which included 
increased Hop, Gli1 and SOX-18 transcription. Furthermore, SHH and ACM treatment 
of endothelial cells increased occludin and claudin-5 mRNA and protein expression in 
the endothelial cells, increased TEER and decreased 14C-Sucrose permeability across 
the endothelial cells. Conversely, inhibiting the hedgehog pathway with cyclopamine 
(Smo inhibitor) reduced the effects of ACM on human brain endothelial cells. These 
findings demonstrate that astrocytes can secrete SHH that can in turn affect endothelial 
cells. 
In the current study, cyclopamine had no effect on the PBECs in AsCM (either on 
BCRP or Pgp activity), suggesting that for the PBECs in AsCM no Hedgehog activity 
was present to be inhibited. This therefore indicates that the rat astrocytes did not 
secrete SHH into the medium or did not secrete sufficient SHH, to elicit an effect that 
could be significantly inhibited by cyclopamine.  
Interestingly, the use of AsCM combined with SHH treatment of PBECs increased the 
activity of BCRP, when compared with the use of AsCM alone. However no effect on 
Pgp activity was noted. This indicates that the pathway (although not constitutively 
active) can be activated, with effects leading to increased BCRP activity. 
Similar effects of SHH on BCRP have been reported in non-BBB cells. In cancer cell 
lines, Sims-Mourtada et al. (2007) showed SHH increased chemotherapeutic 
resistance of cells by increasing efflux of the chemotherapeutics from the cells, which 
was attributed to the increased expression of ABC efflux transporters in response to 
SHH. SHH treatment resulted in increased Gli-1 (sonic transcription factor), BCRP and 
Pgp protein expression and activity. Furthermore, siRNA against Gli-1 and inhibition by 
cyclopamine decreased BCRP and Pgp protein expression and activity, implicating 
SHH, Gli-1 and Smo (cyclopamine target) in the regulation of both efflux transporters. 
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Singh et al. (2011) showed the presence of a Gli-1 binding site in the BCRP promoter 
region. SHH treatment of lymphoma cells resulted in a concentration-dependent 
increase in the expression of BCRP mRNA and protein, while Smo inhibition by 
cyclopamine led to decreased Gli-1 and BCRP mRNA and protein expression. siRNA 
against Gli-1 also decreased BCRP mRNA and protein expression, showing BCRP is 
downstream of Gli-1 and that regulation of BCRP involves SHH, Smo and Gli-1. 
The current results concerning BCRP are consistent with these earlier studies, which 
together demonstrate that active sonic hedgehog pathway increases BCRP mRNA and 
protein expression, leading to increased activity of BCRP. However, the current study 
diverges from these previous studies concerning Pgp activity, where PBECs treated 
with SHH in AsCM did not show increased Pgp activity, while the older studies showed 
that as for BCRP, sonic activation leads to increased Pgp mRNA and protein, and 
increased activity.  
In ovarian cancer cells normally resistant to paclitaxel (a Pgp substrate), resistance 
was decreased by knocking down or inhibiting Smo (using siRNA or cyclopamine). 
Decreased drug resistance to the Pgp substrates again implicated the Hedgehog 
pathway in Pgp regulation (Steg et al., 2012) 
Chen et al. (2012) showed that in MCF-7 cancer cells the addition of SHH increased 
Pgp expression in MCF-7 sensitive cells, making them resistant to Pgp substrates. 
Conversely, siRNA against mdr1a had no effect on SHH or Smo expression, showing 
Pgp to be downstream of SHH/Smo and not upstream. 
The differences between the current studies and earlier studies concerning Pgp and 
sonic signaling could be due to differences between BBB and non-BBB cells in Pgp 
regulation or to other factors influencing Pgp activity in the BBB but not in the other cell 
types. 
Teng et al. (2012) showed a link between SHH and VEGF in the BBB, with SHH shown 
to increase VEGF expression (both mRNA and protein) in mouse brain endothelial 
cells. Furthermore, Hawkins et al. (2010) showed that VEGF could decrease Pgp 
activity without changes in overall Pgp expression, by causing Pgp internalisation. 
Therefore, in the current study SHH treatment could have resulted in the activation of 
VEGF pathway leading to Pgp internalisation, where any increases in Pgp expression 
(in response to SHH) could be masked by loss of Pgp activity in response to VEGF.  
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Concerning the effects of SHH on the PBECs in C6CM in the current study combined, 
C6CM and SHH treatment of PBECs resulted in decrease in both BCRP and Pgp 
activity (when compared with the effect of C6CM alone). This indicates that as a result 
of glioma-secreted factors the sonic pathway in these BBB endothelial cells is altered. 
Similarly, Wnt pathway regulation of BCRP and Pgp was altered in PBECs in C6CM, 
as neither BIO (increased BCRP and Pgp activity in AsCM) nor Dkk-1 (decreased 
BCRP activity in AsCM) had any effect on the activity of BCRP or Pgp in the PBECs 
under C6CM conditions. 
Interestingly, sonic hedgehog and the Wnt/β-catenin pathways do interact. Meng et al. 
(2001) showed that SUFU, a negative regulator of Hedgehog that controls the nuclear-
cytoplasmic distribution of Gli transcription factors by binding Glis and prevent ing them 
from reaching their nuclear targets, also complexes with β-catenin, preventing it from 
acting in the nucleus as a transcription factor (with TCF/LEF protein) (Meng et al., 
2001).  
In Xenopus development, SUFU was shown to integrate Wnt and Hedgehog signals 
(Min et al., 2011). SUFU was shown to suppress both pathways by binding to β-catenin 
and Gli-1 respectively. Interestingly, Gli1 was shown to inhibit Wnt under β-catenin 
over-expression (preventing TCF-transcription), while β-catenin was shown to stimulate 
Hedgehog pathway when Gli-1 was over-expressed (increased Gli-1 transcription); 
these effects where both SUFU dependent.  
In addition, GSK-3β, the same protein involved in phosphorylation and subsequent 
ubiquination of β-catenin (in Wnt inactive state), is involved in the sonic signaling 
pathway (Kise et al., 2009, Chen et al., 2011). Chen et al. (2011) showed that SUFU is 
also phosphorylated by GSK-3β at Ser 342, which stabilises the SUFU against SHH 
signaling-induced degradation via ubiquination. In addition, Kise et al. (2009) showed 
that SUFU (known to suppress Gli-dependent transcription) mediated the processing of 
Gli3 Repressor (acts as a repressor of Gli-1 and Gli-2 transcription) by GSK-3β. SUFU 
mediates processing of Gli3 by acting as a bridge between GSK-3β and the 
unprocessed form of Gli3, facilitating the phosphorylation processing of Gli3 by GSK-3β 
by bringing the two proteins into close contact. It was shown that SUFU is essential for 
Gli3 phosphorylation via GSK-3β to occur, as GSK-3β could not interact with Gli3 in the 
absence of SUFU. Activation of the sonic pathway by SHH was shown to stimulate the 
dissociation of SUFU/GSK-3β complex from Gli-3, preventing Gli3 repressor 
processing. 
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Together this shows that the Sonic and Wnt pathways are linked by at least three 
proteins SUFU, GSK3B and β-catenin. Therefore, incorrect regulation of one pathway 
may influence the other pathways. Furthermore, the active Hedgehog pathway has 
been shown able to negatively regulate Wnt, while active Wnt pathway has been 
shown to act as a positive regulator of the Hedgehog pathway (Min et al., 2011)  
Since the two pathways are interlinked and do influence each other, it is not possible to 
completely differentiate between the two in the current study. Therefore it is not 
possible to determine whether the alterations in the pathway responses that were seen 
in the PBECs in C6CM exist within one or both pathways, nor whether alteration in one 
pathway may be influenced by the other pathway. 
Research into gliomas has given some insight into Wnt signaling under glioma 
conditions. Zhou et al. (2010)  investigated the expression of Dkk-1 in normal and 
glioma cell lines as well as in normal and glioma tissue samples. The culture medium 
of all 12 glioblastoma cell lines tested positive for expression of Dkk-1 while normal and 
medulloblastoma cell line media were negative. Similarly, in human tissues, in normal 
tissues 9/11 samples tested negative for Dkk-1 while the remaining two only showed 
weak expression. Conversely, in glioma tissues 28/47 showed strong staining for Dkk-
1, 15 tissues showed weak staining and only 4 tissues were negative. In addition, Dkk-
1 expression was shown to positively correlate with tumour grade, with more Dkk-1 
expressed in higher grade tumours. Zhou et al. (2010) concluded that Dkk-1 was a 
good marker of gliomas. 
In the current study, conditioned medium was also obtained from a glioblastoma cell 
line, the C6 cells, where Dkk-1 secretion is possible although not confirmed. 
The presence of Dkk-1 in the medium could explain why BIO could not elicit an 
increase in the BCRP and Pgp activity of PBECs in C6CM. Similarly, if Dkk-1 were 
already present in the medium, the Wnt-dependent expression of BCRP and Pgp 
would already have been suppressed and so the addition of more Dkk-1 would have no 
effect. Due to the common pathways shared by the Sonic and Wnt pathways, Dkk-1 
may also influence the sonic pathway, however how that might happen is still unknown. 
Interaction between the two pathways needs to be further explored in PBECs both in 
AsCM and C6CM. 
Other research into gliomas has shown high expression of SHH in glioma cells as well 
as high expression of members of the signaling pathway (Patch-1, Smo and Gli1) 
(Braun et al., 2012). If, like their astrocyte counterparts, the glioma cells can secrete 
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the SHH protein, then gliomas would be able to influence nearby endothelial cells via 
activation of the Hedgehog pathway, promoting the expression of the ABC 
transporters. However, in the current study SHH treatment of PBECs in C6CM resulted 
in PBECs with decreased BCRP and Pgp activity, while cyclopamine increased BCRP 
activity (opposite effects to those seen under AsCM condition and in previous studies), 
implying some alterations of the Hedgehog pathway caused by the C6CM.  
As detailed above, the presence of Dkk-1 in the C6CM is a candidate, which could 
have caused a change in Wnt, which may have in turn interfered with the hedgehog 
pathway. However, other factors may also be acting on the PBECs in C6CM, for 
example Boveri et al. (2005) showed C6s to secrete 40 times more VEGF than 
astrocytes, and VEGF has been shown to decrease Pgp activity without affecting 
expression, via caveolae internalisation of Pgp (Hawkins et al., 2010b). Therefore, 
activity levels of Pgp in the PBECs could have been influences by high levels of VEGF 
in the C6CM.  
Other yet undetermined glioma factors may also have influenced any of the other 
signaling pathways involved in ABC transporter regulation. Therefore due to the 
complexity of signaling cascades (e.g. the involvement of Wnt in Hedgehog signaling, 
as well as the effect of ET-1 signaling on Wnt and the possible influence of the VEGF 
pathway on Pgp), definitive conclusions concerning the influence of the Hedgehog 
pathway on the ABC transporters, in endothelial cells in glioma-conditioned media 
cannot be reached. However, alterations of normal Wnt and Sonic Hedgehog pathways 
are apparent. 
Further work is needed on brain endothelial cells concerning the composition of C6CM 
as well as work dissecting the influences of sonic on Wnt and vice versa. 




7 ABCs in Human Brain 
7.1 Results 
 
In order to assess changes in ABC efflux transporter in human brain, an 
immunohistochemical study was conducted on brain tissue samples from control, 
Grade I and Grade II astrocytoma patients (Table 6.1).  
Table 7.1 Tissue descriptions  
Tissues 1-4,9-12 and15-18, were all contained on a single slide as a tissue array, with all other samples 
obtained as 1 tissue per slide. 
a Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly. 
a Grade 2 or moderately-differentiated: Cells appear slightly different from normal. 
b TNM grading: 
T - Primary tumour 
Tx - Primary tumour cannot be 
assessed 
T0 - No evidence of primary 
tumour 
Tis - Carcinoma in situ; 
intraepithelial or invasion of 
lamina propria 
T1 - Tumour invades submucosa 
T2 - Tumor invades muscularis 
propria 
 
N - Regional lymph nodes 
Nx - Regional lymph nodes 
cannot be assessed 
N0 - No regional lymph node 
metastasis 





M - Distant metastasis 
Mx - Distant metastasis cannot 
be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
No  Sex Age  Organ    Pathology diagnosis    Grade
a
  Stage  TNM
b
  Sample Type 
1  F 28 Cerebrum Normal cerebral tissue – – – 
Control 
 
2  F 20 Cerebrum Normal cerebral tissue – – – Control 
3  M 26 Cerebrum Normal cerebral tissue – – – Control 
4  F 24 Cerebrum Normal cerebral tissue – – – Control 
5 F 24 
 
Normal cerebral tissue 
   
Control 
6 M 32 
 
Normal cerebral tissue 
   
Control 
7 M 54 Brain Normal brain 
   
Control 
8 M 50‘s Brain Normal brain 
   
Control 
9 M 30 Cerebrum Astrocytoma 1 IIA T1M0 Grade I 
10  M 33 Cerebrum Astrocytoma 1 I T1M0 Grade I 
11 F 37 Cerebrum Astrocytoma 1 I T1M0 Grade I 
12 M 39 Cerebrum Astrocytoma 1 I T1M0 Grade I 
13 F 15 Left Frontal Lobe Astrocytoma 1 
  
Grade I 






15 M 62 Cerebrum Astrocytoma 2 II T1M0 Grade II 
16  M 31 Cerebrum Astrocytoma 2 IIB T2M0 Grade II 
17  F 47 Cerebrum Astrocytoma 2 II T2M0 Grade II 
18  F 48 Cerebrum Astrocytoma 2 II T1M0 Grade II 
19 M 25 Left Frontal Lobe Astrocytoma 2 
  
Grade II 
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BCRP and Pgp staining intensity was determined using  antibodies BXP-21 and JSB-1 
respectively,  which have been used to identify BCRP and Pgp in human brain 
capillaries/tissue (Sawada et al., 1999, Lee et al., 2007). 
For each tissue, once a capillary was identified and the image captured, the image 
pixels staining for endothelial marker CD34 were specifically analysed further for BCRP 
and Pgp staining. This procedure therefore excluded as far as possible any 
background or other non-specific staining from the analysis. Tissue No.3 was 
eliminated from analysis since no capillaries were identified within the tissue. 
 
7.1.1 Identifying capillaries 
 
Two different endothelial markers were tested, von Willebrand Factor (VWF) and 
glycoprotein CD34, both of which are established endothelial cell markers (Muller et al., 
2002) used on human brain samples previously (Zhang et al., 2011, Wang et al., 
2013).  
Antibodies against both markers positively stained blood vessels in the tissues tested. 
However, more background (non-specific staining) was observed with the anti-VWF 
antibody (Figure 6.1), hence, the anti-CD34 antibody was used for the next stage of 
analysis.  
 
Three criteria were used to select capillary images for analysis:  
a) CD34 positive staining 
b) The CD34 marker was used in conjunction with DAPI staining of nuclei within the 
same z-stack to confirm the presence of live cells. 
c) Diameter of vessels used was measured using ImageJ software from the z-stacks 
and only vessels < 7μm were selected for analysis since capillary diameters in human 
brain have been reported as 4-7 μm (Patel et al., 2008).  
  





Figure 7.1 CD34 and VWF staining in astrocytoma Grade I tissue (No. 14)  
The images show CD34 stained tissue (A, B, C) and VWF stained images (D, E, F), from the 
same patient (No.14). 
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7.1.2 BCRP and Pgp Quantification 
 
Tissues sections, 5 µm thick (control, Grades I and II astrocytoma) were stained with 
anti-BCRP antibody (BXP-21, 1:200), anti-Pgp antibody (JSB-1, 1:40), anti-CD34 
antibody (1:100) and DAPI to detect nuclei. The tissues were then counterstained with 
secondary antibodies coupled to AlexaFluor 488 (Pgp), 562 (BCRP) and Cy5 (CD34) 
respectively.  
Examples of the staining are shown in Figure 6.2.  
The results showed BCRP and Pgp to co-localise with the CD34 endothelial cell 
marker, showing the ABC transporters to be expressed on brain microvessels. In 
addition areas of co-localisation of Pgp and BCRP were also noted (indicated by the 
arrows in Figure 6.2).  
The BCRP and Pgp staining intensity was semi-quantified based on intensity for each 
pixel also showing staining for the endothelial marker CD34.  
The data from all images in one z-stack of a capillary were combined to obtain data 
that reflected expression over the whole thickness of the slide. Intensity was 
represented by a number from 0 (no staining) to 1 (maximum intensity). Since all 
samples underwent simultaneous staining and imaging with the same parameters, the 
maximum staining intensity found throughout all the samples tested became 1. The 
intensity was plotted as a histogram against the frequency with which it occurred (i.e. 
the number of pixels of a given intensity) as shown in Figure 6.3.  
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CONTROL (Sample No.1) 
 
GRADE I (Sample No.12) 
 
GRADE II (Sample No.18) 
 
Figure 7.2 Immunohistological staining of human tissue sample from Control, Grade I and 
Grade II glioma brains. 
All tissues were from a single slide containing multiple patient samples. Consequently all 
staining and imaging was conducted simultaneously for all patients. Imaging was conducted 
using the SP8 Confocal microscope with the same basic parameters used for all images, where 
false colour was added by the SP8 software. 
A) CD34 , B) Pgp C) BCRP, D) DAPI, E) CD34+Pgp, F) Pgp+BCRP, G)DAPI+BCRP  
Areas of co-localisation are highlighted by arrows. 
A B C D 
G F E 
A B C D 
G F E 
A B C D 
G F E 





Figure 7.3 The frequencies of different staining intensities for Pgp and BCRP throughout a z -
stack imaged from a Grade I astrocytoma (Sample No. 9)  
Tissue was stained with BXP-21 (BCRP), JSB-1 (Pgp) and CD34 antibody. The CD34-positive 
pixels were mapped and the intensity of the BXP -21 and JSB-1 signals within the CD34-positive 
pixels was then measured through a z-stack of images (0.5μm per step). A histogram of the 
intensities (normalised between 0 minimum and 1 maximum) against frequency is shown. Data 


















































































To quantify BCRP and Pgp, the area under the curve (AUC) for each patient was 
calculated and normalised against the total number of CD34-positive pixels analysed 
for that patient. The fold change from control is shown in Figure 6.4.  
 
 
Figure 7.4 Relative BCRP and Pgp expression in astrocytoma microvessels  
The expression of BCRP (A) and Pgp (B) was measured within human brain capillaries of 
Control, Grade I and Grade II astrocytoma tissues.  
Capillaries were initially identified by staining positi ve for CD34 with nuclei present as indicated 
by DAPI and with diameters of < 7 µm. The CD34-postive pixels were then isolated and the 
intensity of Pgp and BCRP within the CD34-positive pixels were expressed as histograms. 
Transporter expression was then quantified as the area under the curve (AUC) of the 
histograms divided by the number of CD34-positive pixels. The results are expressed as fold 
change compared with control.  
The values are mean ± SEM of n=3, n=4 and n=4 patient of Control, Grade I and Grade II 
astrocytomas, respectively.   
**p<0.01 in 1-way ANOVA analysis using Newman-Keuls Multiple Comparison post test.  
1 way ANOVA analysis of Pgp data showed unequal variances in Barlette‘s test (Barlette‘s 
statistic 12.15, P=0.0023) so data was analysed with unpaired 2 tailed t-test using Welch‘s 
correction for unequal variances. # p<0.05 difference in the t -test analysis. 
A       B 
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The results showed a significant increase (1.6 fold) in BCRP expression in Grade I 
astrocytomas when compared with Control. Conversely, BCRP expression decreased 
in Grade II astrocytomas where the decrease resulted in the same amount of 
expression as in Control. Pgp expression decreased in Grade II astrocytomas when 
compared with Grade I astrocytoma. 
Concerning the relative expression of Pgp and BCRP, the ratio of the expression of 
BCRP to Pgp showed an increase in Grade I astrocytomas but a decrease in Grade II 
astrocytoma (Table 6.2) indicating alterations in the relative expression of one or both 
of these transporters. The ratio mirrored the changes in BCRP expression (Figure 6.4) 
indicating changes in the ratio were largely due to changes in BCRP expression. 
 
Table 7.2 The ratio of BCRP to Pgp expression in astrocytoma microvessels  
8  BCRP/Pgp Ratio 
Mean ± SEM 
Control 0.48±0.10 
Grade I 0.66±0.13* 
Grade II 0.56±0.04 




An initial observation of this study was the heterogeneity of efflux transporter staining 
within a single patient, especially for Pgp. Normal distributions of Pgp staining have 
been previously reported in rat brain vasculature (Saubamea et al., 2012) showing that 
Pgp staining intensity varies. However, no similar information for BCRP or comparisons 
between BCRP and Pgp staining in human brain have been reported as far as is 
known. In the current study, Pgp intensity range (maximum intensity minus minimum 
intensity) was ~0.7 in control brain samples, with a more narrow range of BCRP 
intensities (~0.5), although there was some between-sample variation (e.g. similar 
intensity ranges for BCRP and Pgp in control  Patient No.4). However, caution is 
needed with these control tissues since full details of their origin are unknown.  
Typically normal tissue is obtained from patients with neurological disorders (e.g. 
glioblastoma or epilepsy), from the periphery of the diseased area (Warren et al., 2009, 
Shawahna et al., 2011). Although attempts can be made to then select normal tissue 
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by using sections taken from as far away as possible from any diseased region 
(Shawahna et al., 2011), there is no guarantee that the tissue has not been influenced 
by the disease (e.g. by secreted factors).   
BCRP expression was shown to be greater in Grade I astrocytoma when compared 
with control samples or with Grade II astrocytomas, indicating an increase in BCRP 
expression in Grade I astrocytomas that decreases back to basal/control levels by 
Grade II astrocytomas. Pgp showed no differences between control and Grade I 
astrocytomas, but showed significantly lower expression in Grade II astrocytoma 
samples, indicating that in microvessels of Grade I gliomas little change in Pgp protein 
expression occurs, however in later stages i.e. Grade II gliomas Pgp decreases. This is 
in some agreement with previous results by Sawada et al. (1999). Sawada et al. (1999) 
examined Pgp expression in capillaries isolated from 30 human brain tumour samples 
and showed a trend towards decreased Pgp expression with tumour grade. They found 
weaker Pgp staining in new tumour blood vessels compared with normal cerebral blood 
vessels, although Pgp was shown to be retained luminally expressed.  An inverse 
correlation between Pgp expression and proliferation was noted, with Pgp expression 
reduced/absent in proliferating cells (Sawada et al., 1999). 
Similarly, Toth et al. (1996), found that in Grade I and II tumours, Pgp staining of 
microvessels was as strong as in normal brain. Conversely, Grade IV glioblastoma 
vessels showed more heterogeneous staining, with both weak and strong Pgp staining 
observed, and 4 of the 18 samples tested being completely negative.  
Disruption in Pgp staining was only noted in the vasculature of high grade tumours by 
Henson et al. (1992). This study showed that Pgp was expressed in the vasculature of 
low grade gliomas in all but 1 sample (17 samples total) although staining was quite 
variable, while in high grade gliomas 5/22 samples did not show positive and 10 
samples only had weak staining 
Together these observations indicate that large alterations to Pgp expression may not 
be seen until later stage gliomas, with the current study indicating changes begin at 
Grade II. Furthermore, if Pgp expression is linked to the proliferative state of the 
endothelial cells (as suggested by Sawada 1999), this could explain why lower grade 
tumours do not show large changes, since only in Grade IV gliomas are capillary 
endothelial cells proliferating (Grier & Batchelor, 2006). 
Little research has been conducted concerning BCRP expression in glioma 
microvessels. Sakata et al. (2011) examined both Pgp and BCRP and found BCRP to 
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behave like Pgp; in low grade gliomas all samples showed stronger BCRP and Pgp 
staining of capillaries than the staining found in normal brains. Conversely, in high 
grade gliomas (28 samples) 77% showed strong BCRP and Pgp staining, with the rest 
showing weaker staining relative to normal brain. This suggests that both Pgp and 
BCRP may first increase in low grade tumours (hence showing stronger expression 
than normal brain vessels), but then decrease in higher grade tumours (hence showing 
weaker expression than normal brain vessels). Zhang et al. (2003) used laser capture 
microscopy to isolate tumour vessels from non-malignant tumours and glioblastoma 
tumours for QPCR, with results showing significantly higher BCRP mRNA in 
glioblastoma when compared with non-malignant vessels; this could indicate increase 
in BCRP mRNA in higher grade tumours. However, the mRNA expression of Pgp was 
not assessed and so relative expression of Pgp and BCRP in glioblastoma is unknown. 
The fluctuations in BCRP expression found in the current study mirrors the expression 
pattern of BCRP in the Sakata et al. (2011) study, however does not fully agree for 
Pgp. In the current study expression BCRP and Pgp showed different changes in 
transporter expression in Grade I astrocytoma, which could indicate different and 
independent regulation of these efflux transporters during low stage glioma challenge. 
However, both transporters were shown to decrease in Grade II glioma, more in 
agreement with Sakata et al. (2011), indicative of common changes of the expression 
of the efflux transporters during higher grade glioma challenge. However, more 
research is needed to reach more decisive conclusions. A greater number of samples 
need to be analysed with a greater range of grades examined. Analysis of Grade III 
and Grade IV tumours is also needed to better compare the current results with 
previous studies.  
Summary of the Project, General Discussion and Future Directions




9 Summary of the Project, General Discussion and Future 
Directions 
 
The aim of the project was to investigate changes in the ABC transporters of the BBB 
during glioma challenge. Investigations are reported in Chapters 3-6 and the findings 
summarised here.  
PBECs were used as an in vitro BBB model to study the ABC efflux transporters during 
glioma challenge.  Chapter 3 showed that co-culture of PBECs with normal astrocytes 
alters their efflux capabilities, indicating that astrocyte co-culture provides a more 
physiological comparison for glioma co-culture. Comparisons of glioma co-cultures to 
mono-culture may be misleading since glioma cells can induce some of the same 
changes as normal glial cells (i.e. astrocytes) (e.g. increases in the overall rate of 
efflux). 
By comparing PBECs in astrocyte co-culture with PBECs in glioma co-culture (Chapter 
4), greater BCRP activity was demonstrated on the PBEC apical surface in the glioma 
co-cultures. This greater activity was shown when using PBECs in co-culture with rat 
cells and the ‗humanised‘ PBEC co-culture with human astrocytes or human glioma. 
The greater BCRP activity in the rat glioma co-culture correlated with greater BCRP 
mRNA expression, indicating that the increased BCRP activity could be a result of 
increased BCRP transporter expression. 
Since this was a non-contact co-culture system, the results further indicated that the 
changes induced by the glioma cells resulted from factors secreted by the glioma cells. 
This was confirmed by the use of conditioned medium from normal rat astrocyte or rat 
glioma cells, since PBECs grown in the rat glioma-conditioned medium showed higher 
levels of BCRP activity than the PBECs grown in normal rat astrocyte-conditioned 
medium (Chapter 5).  
Concerning Pgp activity/expression, the results indicated that overall Pgp mRNA 
expression is not altered by glioma co-culture. However, alterations to the cellular 
polarity of Pgp were noted in the rat glioma co-culture, with significant Pgp activity on 
the basal surface not noted in rat astrocyte co-culture. 
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The BCRP and Pgp mRNA expression measured in the PBECs co-cultured with rat 
glioma cell (Chapter 4) agreed with the BCRP and Pgp protein expression measured in 
human glioma tissues (Chapter 6). Grade I glioma tissue showed increased BCRP 
expression, but no change in Pgp expression in the capillaries of the tumour tissue 
when compared with control brain capillaries. This indicates that PBECs co-cultured 
with rat glioma cells (after 4 days of co-culture) are a good model for Grade I glioma 
challenge in vivo. However, BCRP expression was shown to decrease back to basal 
levels (i.e. the levels seen in control tissue) in Grade II glioma samples (Chapter 6), 
showing that more work needs to be conducted to understand the longer-term changes 
in BCRP activity in vivo. Longer co-cultures (greater than four days) could be tried to 
replicate the higher grade glioma conditions. 
Concerning possible signaling mechanism involved in inducing the changes in BCRP 
expression in the glioma co-culture, Chapter 5 investigated the affects of the Sonic 
Hedgehog and Wnt signaling pathways in vitro using PBECs grown in astrocyte-
conditioned media or glioma-conditioned medium. Both signaling pathways were 
shown able to modulate BCRP and Pgp activity in vitro, with the Wnt pathways 
showing constitutive activity within the PBECs. This indicated that the Wnt pathway 
was at least partly responsible for the constitutive expression of the BCRP and Pgp 
efflux transporters within the PBECs. In addition, de-regulation of both pathways was 
shown in the PBECs treated with glioma-conditioned medium when compared with 
astrocyte-conditioned medium. Furthermore, since this was shown with the use of 
conditioned medium, it indicated that factors in the medium secreted by the glioma 
cells caused the changes in Sonic and Wnt signaling in the PBECs. However, since 
these two signaling pathways are interlinked it was not possible to distinguish whether 
both pathways were truly influenced by the secreted factors or whether de-regulation in 
one pathway led to alterations in the other. Dkk-1 was identified as a potential factor 
that might be secreted into the medium by glioma cells. This in an inhibitor of the Wnt 
pathway, and may have led to the changes in the Wnt pathway. However further work 
is needed to establish whether Dkk-1 is present in the glioma-conditioned medium, and 
if so, whether and how the sonic pathway could also be influenced.  
In Chapter 5, the Sonic and Wnt pathways were shown to co-regulate both BCRP and 
Pgp activity. The literature suggested that this regulation is via inducing mRNA and 
protein changes. However, in the PBECs co-cultured with rat glioma cells, BCRP 
mRNA was increased but Pgp mRNA was not, indicating different regulation of the two 
transporters. Therefore the Sonic and Wnt pathways cannot be solely responsible for 
the changes noted in the PBEC-rat co-culture, as the presence of a BCRP-independent 
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regulator pathway is suggested by the work in Chapter 4. The involvement of a BCRP-
independent pathway in modulating BCRP activity in cancer challenge is supported by 
the work in Chapter 6; BCRP expression increased in microvessels of Grade I glioma 
patients but Pgp showed no change in expression. More research needs to be 
conducted to identify which pathway(s) are responsible for the changes observed. In 
addition, the effects of Wnt and Sonic signaling molecules should also be tested on the 
PBECs in co-culture (as opposed to conditioned media) since in this model the polarity 
changes of the transporters (e.g. Pgp) can also be monitored. Furthermore, both Pgp 
and BCRP post-transcriptional regulation needs to be investigated, as some results in 
Chapter 4 indicated that transporter activity can be altered by glioma co-culture without 
alteration of transporter mRNA levels. Further work is also needed on the protein 
expression of the BCRP and Pgp transporters in the PBECs in co-culture with the 
glioma cells, to establish whether the increased BCRP mRNA does lead to increased 
BCRP protein expression and consequently increased activity.  
Overall the project indicated that increased BCRP expression and activity occur as a 
result of early stage glioma challenge, which has implications in chemotherapeutic 
treatment of early stage gliomas since many chemotherapeutics are substrates of 
BCRP. However, more work is needed to identify the mechanism of BCRP increases 
and its implications for glioma treatment. 
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11.1 Binding properties of 3H-MPP+ 
To determine whether the positive charge of MPP+ resulted in its binding to either 
plastics or cells, the binding properties of 3H-MPP+ were assessed. 
 
11.1.1 Binding to plastic 
 
To assess whether 3H-MPP+ significantly binds to plastics, the recovery of 3H-MPP+ 
from a standard 96-well plate was determined. The recovery of 3H-MPP+ into PBS and 
acid washes is shown in Table 9.1.1. PBS washes were used as standard since this is 
a common step in radioactive assay procedures. An acid wash was then used (after 
the PBS washes) to specifically target binding between the 3H-MPP+ and the plastic 
plate, where a strong acid, 1M HCl, would displace any 3H-MPP+ bound to the plastic.  
The results showed that only 0.1% of the 3H-MPP+ was collected in the acid wash, with 
the majority recovered in the assay buffer (96%) and with 2.7% recovered in the PBS 
















In the Removed 
Assay Buffer 
In the Pooled 
PBS Washes 
In the Acid 
Wash Total 
 
133029 ± 717 127749 ± 1695 3541 ± 1159 150 ± 54 131440± 593 
 
      B 
 





In the Removed 
Assay Buffer 
In the Pooled 
PBS Washes 
In the Acid 
Wash Total 
133029 ± 717 96.0 ± 1.27 2.7 ± 0.87 0.1 ± 0.04 98.8 ± 0.45 1.2 ± 0.45 
      
    










 was then 
removed and kept (Removed Buffer) and the wells were washed with PBS three times with all  
the washes kept and pooled into a single sample (Pooled PBS Washes). The wells were then 
incubated with 1M HCl acid for 10 minutes. The acid wash was then collected (Acid wash 
sample).  
The DPMs within each of the collected samples was measured using liquid scintillation counting 




 recovery was then calculated as given in B.  
Results are mean ± SEM of n=3.  
 
11.1.2 Binding to the glycocalyx 
 
To assess whether MPP+ was binding to the glycocalyx of the PBECs, alternative acid 
wash experiments were conducted. PBECs were incubated with 3H-MPP+ for 1 hour, 
the cells were then washed with PBS three times, followed by a fourth wash with either 
PBS or Glycocalyx Acid wash (28mM Sodium Acetate, 20mM Barbitone sodium and 
117mM NaCl) (Olefsky and Kao 1982) with the fourth wash kept  for analysis. The cells 
were then lysed and the lysates were also analysed. If the MPP+ was binding to the 
glycocalyx, the acid wash would displace the MPP+ from cells, so more MPP+ would 
be found in the acid wash than in the PBS wash, and consequently less MPP+ would 
be found in the lysate when an acid wash was used. 
The results show a trend towards greater amounts of 3H-MPP+ within the acid wash 
and lower 3H-MPP+ within the lysate when an acid wash had been used. However no 
significant differences between the percentage of 3H-MPP+ measured within the PBS or 
acid wash, or within the cell lysates of the two conditions were observed,  
demonstrating that glycocalyx binding does not play a significant role in the 
assessment of 3H-MPP+ uptake or efflux.    
 


















removed and the cells were washed three times with PBS. The cells were then incubated with 
either PBS or Glycocalyx Acid Wash for 6 minutes at 4⁰C for a final 4
th
 wash. The fourth wash 
was kept and the cells were lysed with the lysate also kept. The 4
th
 wash (Extracellular sample, 




 by scintillation counting with data corrected against 
14






 measured within the 4
th
 Wash or within the lysate was then expressed as a 




 loaded into the cells (prior to the start of the 4
th
 wash).  
Values are mean ± SEM of n=3. 
No significant differences were noted in unpaired t-tests between PBS and Acid wash 
conditions in the 4
th
 wash or the lysates. 
  




11.2 Dose-response raw data 
 
As detailed in 3.1.5 dose-response analysis of the ability of Pgp and BCRP inhibitors to 
inhibit 3H-MPP+ efflux was assessed, using 3H-MPP+ efflux assay in the presence of 
different concentrations of each inhibitor. The raw data (i.e. prior to normalisation) is 
shown below.  
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Figure B. Raw dose-response data 




. The loaded cells were then 
incubated with efflux buffer with or without ABC inhibitors (0 – 300 µM) for 35 minutes. The 
inhibitors used were the Pgp inhibitors haloperidol (I) and verapamil (II), and the BCRP 
inhibitors Ko143 (III) and prazosin (IV).  The data is shown on a normal scale (A) and on a log 
scale (B). 
















 initially loaded into 
the cells. 
The values are shown as mean ± SEM of 3-5 wells where possible, or as single mean point 
when less than 3 wells were tested at the same concentration. Values are pooled from 3 -5 
plates. 
11.3 Effect of OCT inhibitor amantadine on 3H-MPP+ uptake and efflux 
To assess the involvement of OCT transporters in the uptake of 3H-MPP+ into PBECs a 
3H-MPP+ uptake assay was conducted on PBECs grown in 96-well plates. Uptake was 
measured in the absence (Control) and presence of the OCT1/2 transporter 
amantadine. The concentration of amantadine used was 1mM, which has been 
previously shown to effectively inhibit OCT transporter activity (Shimomura et al., 
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2013). In addition, 2mM amantadine was also used to assess whether a greater 
inhibition could be achieved with a higher concentration of amantadine.  
The results (Figure C) showed that amantadine significantly decreased 3H-MPP+ 
uptake by ~65% when 1mM or 2mM amantadine concentrations were used, indicating 
that uptake of 3H-MPP+ into PBECs was OCT-dependent. No increase in inhibition was 
observed upon using 2mM as opposed to 1mM amantadine, indicating that 1mM 
amantadine was sufficient to maximally inhibit OCT-dependent 3H-MPP+ uptake. 
 
















) for 1 hour, with
14
C-sucrose as a marker for extracellular space. The cells were 






C-sucrose and the 
other half of used for protein content measurement using a BCA assay.  
Results are expressed as volume of distribution (Vd) in µl.mg
-1




Values are mean ± SEM of n=5-6 wells from 2 different batches of PBECs. 
**p<0.01 significant difference indicated conditions and control using an unpaired 2 -tailed t-test. 
 
To determine the involvement of the OCT transporters in the efflux of 3H-MPP+ from 
PBECs, an 3H-MPP+ efflux assay was conducted on PBECs-P (PBECs in 24 well 
plates) in the absence (Control) or presence of the OCT1/2 inhibitor amantadine 
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The results showed no significant difference in efflux or intracellular retention of  3H-
MPP+ in the absence or presence of amantadine, indicating that the OCT1/2 
transporters were not significantly involved in the efflux of  3H-MPP+. 
These results were compared to other results involving inhibition of Pgp by Haloperidol, 
where Haloperidol did significantly inhibit 3H-MPP+ efflux, demonstrating that inhibition 













 and then incubated with efflux 
buffer without (Control) or with the OCT 1/2 inhibitor Amantadine (1mM) for 35 minutes.  
The buffer was then collected and the cells were lysed. The buffer and lysate samples were 




 with correction for 
14
C-sucrose.  
A I) The DPMs measured extracellularly (Extra, in the buffer) and intracellularly (Intra, in the 




 effluxed  extracellullarly or maintained int racellularly was then 




 initially loaded into the cells. 
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B) The amantadine inhibition results were then compared to Haloperidol Inhibition results (Pgp 
inhibitor), where Haloperidol inhibition was conducted exactly as Amantadine inhibition 
experiment had been conducted, only using Haloperidol (60 µM) instead of Amantadine.  
The values are shown as mean ± SEM of n=3-6.  
 
 
11.4 RT-QPCR: Additional information 
Additional information regarding the RT-PCR work conducted is given below. 
 
11.4.1 RT-QPCT probe details 
 
The details regarding the TaqMan Assay used are shown below (from Life Technology 
website). The exact probe sequences are not provided by the company, however the 
details of the target sequences are given. 
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11.4.2 Pgp and BCRP Ct values 
 






Figure E. Pgp and BCRP Ct values  
The charts show the Ct values for Pgp (A) and BCRP (B) RNA from RT-QPCR experiments 
conducted on RNA collected from PBECs at different stages of the cell culture process.  
Day 0 represents the primary isolated porcine capillaries. The PBECs were grown out  from the 
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after the 3 days of puromycin treatment (Day 3) and on day 6 when the cells were passaged to 
Transwells (Day 6).  
Once on Transwells (TW), the PBECs were either grown alone (i.e. in mono-culture, M) or in co-
culture with primary rat astrocytes (rAS) or C6 glioma cells (C6). The PBECs, in either mono-
culture or in co-culture were grown on the Transwells for 3 days in serum -containing medium 
after which RNA was isolated (3 Days on TW). Alternatively, the PBECs, in either mono-culture 
or in co-culture were grown on the Transwells for 3 days in serum -containing medium, followed 
by 24 hours in serum-free medium containing 550 nM hydrocortisone, 250 µM CPT-cAMP and 
17.5 µM Ro-20-1724, before RNA isolation (4 Days on TW). Two different C6 conditions were 
tested, one where the medium was changed on day two of co-culture and the other where the 
medium was not changed (the second is denoted by C6*).  
Values are mean ± SEM of n=3 samples per condition, where PCR was conducted on triplicates 
per plate and n=3 plates were run.  
 
11.5 Western Blotting Optimisations 
 
Dot blot analysis was initially conducted to determine appropriate antibody 
concentrations for the anti-Pgp (C219) and the anti-BCRP (BXP-21) antibodies (Figure 
A), which showed positive staining of PBEC proteins by both antibodies. 
 
Figure F. Dot Blot for BCRP and Pgp 
1:20             1:50               1:200       BXP-21 (BCRP)   
10µg/ml     1µg/ml        0.25µg/ml      C219 (Pgp)   
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PBEC cell lysates obtained from mono-cultured cells was placed on a PVDF, using 2µl per dot. 
The blot was incubated with either mouse BXP -21 or mouse C219 antibody at the indicated 
concentration for 1 hour (room temp) washed then incubated with 1:1000 anti mouse IgG, HRP 
secondary antibody for 1 hour. HRP activity was then visualised with Syngene imager and 
Software. 
 
Western Blots were then conducted of PBEC lysates using a standard blotting protocol, 
10% Gels, 12-Wells 1mm thick, Tris-Glysine Transfer Buffer, Semi-Dry Transfer for 30 
minutes at 20V, using 1:200 BXP-21 and/or 0.25µl/ml C219. BCRP was successfully 
deselected in PBEC cell lysates, lysed with 1% Triton-X 100 containing protease 
inhibitors for 1 hour (Figure B). However Pgp was not detected, either in samples or in 




Figure G. Protein expression in PBECs grown in conditioned medium  
PBECs were grown in rat astrocyte conditioned media (Astro Media) or C6 conditioned media 
(C6 Media). The cells were lysed and 20µg of protein lysates were loaded onto a 10% gel. The 
gels was transferred onto a PVDF membrane and incubated with anti-BCRP antibody (BXP-21, 
1:200), anti-Pgp antibody (C219, 0.25µl/ml) and anti-βactin antibody (C-11, 1:1000) and 
respective secondary antibodies at 1:1000 dilutions. 
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The detected signals within the samples are shown in the image alongside a positive control 
from a pooled sample of PBEC cell lysates obtained from mono -cultured cells. 
 
 
The lack of Pgp signal within the blot correlated with incomplete transfer of higher 
molecular proteins (including Pgp 170kDa). Therefore, thinner gels were run (0.75mm) 
in attempt to improve the transfer of Pgp and other higher molecular weight protein. In 
addition, different acrylamide percentages were also tested (6%, 8%, 10% and 12% 
gels). Transfer of higher molecular weight proteins improved with decreasing 
acrylamide concentrations. However, the 6% gels consistently melted during 
electrophoresis. Therefore 8% was decided on for western blotting experiments (data 
not shown). Furthermore, different transfer buffers were tested for different lengths of 
transfer times. The high pH Dunn‘s buffer with the addition of methanol and SDS, 
showed the best result with a transfer time of 75 minutes, where Pgp could be detected 
in rat liver positive control protein lysates (Figure C). 
 
Figure H. Western Blotting for Pgp 
Decreasing amounts of protein from a rat liver lysate underwent western blotting with anti -Pgp 
antibody (C219, 0.25µl/ml) and anti-βactin antibody (C-11, 1:1000) antibody A) 15 µg, B) 12.5 
µg C) 10 µg D) 7.5 µg.   
 
Using the optimised conditions, 0.75mm 8% Gel, Dunn‘s transfer buffer with methanol 
in bottom of the sandwich and SDS in the top of the sandwich, protein from PBECs-M, 
Pgp  
~170kDa 
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PBECs-rAS, PBECs-C6 from after 3 days in co-culture was analysed by Western 
blotting (Figure D).  
In attempt to correlate mRNA levels with protein levels, TRI isolation of RNA and 
protein from the same cells was conducted. TRI isolation was conducted from PBECs-
M, PBECs-rAS and PBECs-C6. Due to phenol contamination from the TRI isolation 
process, accurate protein measurements of the protein samples isolated could not be 
obtained. Purification via TCA precipitation was attempted, but protein could not then 
be fully resuspendent into solution. Therefore, TCA purified protein was not appropriate 
for quantitative comparisons between the different PBEC conditions. 
Instead, the equivalent of 1 Transwell of protein (i.e. the total protein isolated from a 
single Transwell) was loaded onto a 8%, 5-Well Gel without quantification. Western 
blotting was conducted using the optimised protocol, with antibodies against Pgp, 
BCRP and β-actin. The blot showed positive BCRP and Pgp within all the samples. 
However, due to insufficient time the western could not be repeated to achieve 
accurate quantification nor could western blots for other samples (e.g. samples from 4 
days in co-culture) be conducted.  
 
 
Figure I. BCRP and Pgp expression in PBECs after 3 days on Transwells 
PBECs were grown on Transwells in mono-culture (PBECs-M) or in co-culture with rat 
astrocytes (PBECs-rAS) or C6 rat glioblastoma cells (PBCs-C6s) for a total of 3 days. The 
protein was isolated via TRI isolation and the equivalent of 1 Transwell of protein was loaded 
per well onto a 8%, 0.75mm gel. The gel underwent SDS -PAGE and transfer onto a PVDF 
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membrane, where blotting for Pgp, BCRP and actin was conduted using anti -Pgp antibody 
(C219, 0.25µl/ml), anti-BCRP antibody (BXP-21, 1:200), and anti-β-actin antibody (C-11, 
1:1000) and respective secondary antibodies at 1:1000 for Pgp and BCRP and 1 in 25000 for β-
actin. 
The detected signals within the samples are shown after 5 minutes of imaging with Syngene 
imager and software.  
11.6 Application of the PBECs-G7 as a Model of BBB Glioma 
Challenge 
 
In collaboration with Steven Pollard‘s group (UCL) the following publication was 
achieved, where the extract shows the application of the humanised 2 day PBEC co-
culture with G7s in drug screening process for glioblastoma. 
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